



EMORY UNIVERSITY AND ITS SUBSIDIARIES

Independent Auditors' Reports as Required by the Uniform
Guidance and State of Georgia and Related Information

Year Ended August 31, 2025

EMORY UNIVERSITY AND ITS SUBSIDIARIES

Table of Contents

	Page
Independent Auditors' Report	1
Consolidated Financial Statements – Years ended August 31, 2025 and 2024	3
Notes to Consolidated Financial Statements	8
Independent Auditors' Report on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance With <i>Government Auditing Standards</i>	38
Supplementary Schedules	
Supplementary Schedule of Expenditures of Federal Awards	40
Supplementary Schedule of Cash Receipts and Expenditures of State of Georgia Awards	107
Notes to Supplementary Schedules of Expenditures of Federal Awards and Cash Receipts and Expenditures of State of Georgia Awards	108
Uniform Guidance Reports	
Independent Auditors' Report on Compliance for the Major Federal Program; Report on Internal Control Over Compliance; and Report on Supplementary Schedules of Expenditures of Federal Awards Required by the Uniform Guidance and Cash Receipts and Expenditures of State of Georgia Awards	111
Schedule of Findings and Questioned Costs	114



KPMG LLP
Suite 2000
303 Peachtree Street, N.E.
Atlanta, GA 30308-3210

Independent Auditors' Report

The Board of Trustees
Emory University:

Report on the Audit of the Consolidated Financial Statements

Opinion

We have audited the consolidated financial statements of Emory University and its subsidiaries (the University) which comprise the consolidated statements of financial position as of August 31, 2025 and 2024, and the related consolidated statements of activities, and cash flows for the years then ended, and the related notes to the consolidated financial statements.

In our opinion, the accompanying consolidated financial statements present fairly, in all material respects, the consolidated financial position of the University as of August 31, 2025 and 2024, and the changes in its net assets and its cash flows for the years then ended in accordance with U.S. generally accepted accounting principles.

Basis for Opinion

We conducted our audit in accordance with auditing standards generally accepted in the United States of America (GAAS) and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States. Our responsibilities under those standards are further described in the Auditors' Responsibilities for the Audit of the Consolidated Financial Statements section of our report. We are required to be independent of the University and to meet our other ethical responsibilities, in accordance with the relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Responsibilities of Management for the Consolidated Financial Statements

Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with U.S. generally accepted accounting principles, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the University's ability to continue as a going concern for one year after the date the consolidated financial statements are issued.

Auditors' Responsibilities for the Audit of the Consolidated Financial Statements

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with GAAS and *Government Auditing Standards* will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are



considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the consolidated financial statements.

In performing an audit in accordance with GAAS and *Government Auditing Standards*, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the University's internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the consolidated financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about the University's ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control related matters that we identified during the audit.

Other Reporting Required by *Government Auditing Standards*

In accordance with *Government Auditing Standards*, we have also issued our report dated December 12, 2025 on our consideration of the University's internal control over financial reporting and on our tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements and other matters. The purpose of that report is solely to describe the scope of our testing of internal control over financial reporting and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the University's internal control over financial reporting or on compliance. That report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the University's internal control over financial reporting and compliance.

KPMG LLP

Atlanta, Georgia
December 12, 2025

EMORY UNIVERSITY
CONSOLIDATED STATEMENTS OF FINANCIAL POSITION

AUGUST 31, 2025 AND 2024 (Dollars in thousands)

	August 31, 2025	August 31, 2024
ASSETS:		
Cash and cash equivalents	\$ 1,638,560	\$ 845,459
Patient accounts receivable, net	959,306	769,299
Student accounts receivable, net	20,682	19,886
Loans receivable, net	16,904	14,524
Contributions receivable, net	122,642	150,498
Other receivables, net	484,274	389,184
Prepaid expenses, deferred charges, and other assets	628,510	517,116
Investments	12,946,696	11,678,888
Interests in perpetual funds held by others	2,050,386	2,013,211
Operating lease right-of-use assets	174,480	180,933
Property and equipment, net	4,777,813	4,707,332
Total assets	\$ 23,820,253	\$ 21,286,330
LIABILITIES AND NET ASSETS:		
Accounts payable and accrued liabilities	\$ 1,467,809	\$ 1,211,079
Deferred revenue	367,595	360,164
Interest payable	59,759	53,624
Liability for derivative instruments	22,682	32,604
Bonds and notes payable	4,168,013	3,304,279
Accrued liabilities for benefit obligations and professional liabilities	929,194	791,494
Operating lease liabilities	199,063	206,925
Finance lease liabilities	16,559	16,498
Funds held in trust for others	1,269,348	1,183,408
Annuities payable	13,889	13,737
Government advances for federal loan programs	12,554	13,281
Asset retirement obligations	98,743	97,167
Total liabilities	8,625,208	7,284,260
Net assets without donor restrictions, controlled by Emory	6,932,118	6,171,010
Net assets without donor restrictions related to noncontrolling interests	11,577	119,822
Net assets without donor restrictions	6,943,695	6,290,832
Net assets with donor restrictions	8,251,350	7,711,238
Total net assets	15,195,045	14,002,070
TOTAL LIABILITIES AND NET ASSETS	\$ 23,820,253	\$ 21,286,330

See accompanying notes to consolidated financial statements.

EMORY UNIVERSITY

CONSOLIDATED STATEMENTS OF ACTIVITIES

YEAR ENDED AUGUST 31, 2025 (WITH SUMMARIZED COMPARATIVE INFORMATION FOR AUGUST 31, 2024) (Dollars in thousands)

	Net Assets without Donor Restrictions	Net Assets with Donor Restrictions	Total August 31, 2025	Total August 31, 2024
OPERATING REVENUE				
Tuition and fees, net of scholarship allowance	\$ 567,217	-	\$ 567,217	\$ 532,165
Sales and services of auxiliary enterprises, net of scholarship allowance	75,598	-	75,598	83,169
Endowment spending distribution	300,466	-	300,466	280,141
Distribution from perpetual funds	66,700	-	66,700	49,094
Other investment income designated for current operations	112,732	-	112,732	112,778
Gifts and contributions for current use	49,938	19,433	69,371	62,152
Grants and contracts	804,058	-	804,058	793,137
Indirect cost recoveries	241,537	-	241,537	235,529
Net patient service revenue	7,330,173	-	7,330,173	6,258,326
Medical services	409,399	-	409,399	359,413
Independent operations	21,584	-	21,584	23,695
Other revenue	836,639	-	836,639	676,976
Net assets released from restrictions	45,123	(17,218)	27,905	30,045
Total operating revenue	10,861,164	2,215	10,863,379	9,496,620
OPERATING EXPENSES				
Salaries	5,265,449	-	5,265,449	4,672,130
Fringe benefits	1,259,151	-	1,259,151	1,080,649
Student financial aid	26,697	-	26,697	24,248
Other operating expenses	3,533,612	-	3,533,612	3,213,549
Interest on indebtedness	113,892	-	113,892	110,286
Depreciation and amortization	379,158	-	379,158	398,179
Total operating expenses	10,577,959	-	10,577,959	9,499,041
NET OPERATING ACTIVITIES	283,205	2,215	285,420	(2,421)
NONOPERATING ACTIVITIES, NET				
Investment return	427,841	413,712	841,553	555,687
Change in undistributed income from perpetual funds held by others	-	41,400	41,400	285,135
Gifts and contributions for capital and long-term investment	16,694	98,992	115,686	113,314
Other losses	(1,210)	-	(1,210)	(2,844)
Gain on retirement of debt	-	-	-	5,982
Change in fair value of derivative instruments	9,922	-	9,922	(12,361)
Net periodic benefit cost other than service cost	(1,976)	-	(1,976)	(5,443)
Changes in pension and other postretirement obligations	6,512	-	6,512	5,808
Inherent contribution received in business combination	195,609	-	195,609	-
Other nonoperating items, net	5,180	22,784	27,964	55,677
Net assets released from restrictions	11,086	(38,991)	(27,905)	(30,045)
Total nonoperating activities, net	669,658	537,897	1,207,555	970,910
OTHER ACTIVITY				
Purchase of membership interests from noncontrolling interests	(300,000)	-	(300,000)	-
CHANGE IN NET ASSETS	652,863	540,112	1,192,975	968,489
BEGINNING NET ASSETS	6,290,832	7,711,238	14,002,070	13,033,581
ENDING NET ASSETS	\$ 6,943,695	8,251,350	\$ 15,195,045	\$ 14,002,070

See accompanying notes to consolidated financial statements.

EMORY UNIVERSITY

CONSOLIDATED STATEMENT OF ACTIVITIES

YEAR ENDED AUGUST 31, 2024 (Dollars in thousands)

	Net Assets without Donor Restrictions	Net Assets with Donor Restrictions	Total August 31, 2024
OPERATING REVENUE			
Tuition and fees, net of scholarship allowance	\$ 532,165	-	\$ 532,165
Sales and services of auxiliary enterprises, net of scholarship allowance	83,169	-	83,169
Endowment spending distribution	280,141	-	280,141
Distribution from perpetual funds	49,094	-	49,094
Other investment income designated for current operations	112,778	-	112,778
Gifts and contributions for current use	51,402	10,750	62,152
Grants and contracts	793,137	-	793,137
Indirect cost recoveries	235,529	-	235,529
Net patient service revenue	6,258,326	-	6,258,326
Medical services	359,413	-	359,413
Independent operations	23,695	-	23,695
Other revenue	676,976	-	676,976
Net assets released from restrictions	46,178	(16,133)	30,045
Total operating revenue	9,502,003	(5,383)	9,496,620
OPERATING EXPENSES			
Salaries	4,672,130	-	4,672,130
Fringe benefits	1,080,649	-	1,080,649
Student financial aid	24,248	-	24,248
Other operating expenses	3,213,549	-	3,213,549
Interest on indebtedness	110,286	-	110,286
Depreciation and amortization	398,179	-	398,179
Total operating expenses	9,499,041	-	9,499,041
NET OPERATING ACTIVITIES	2,962	(5,383)	(2,421)
NONOPERATING ACTIVITIES, NET			
Investment return	276,743	278,944	555,687
Change in undistributed income from perpetual funds held by others	-	285,135	285,135
Gifts and contributions for capital and long-term investment	9,127	104,187	113,314
Other losses	(2,844)	-	(2,844)
Gain on defeasance of debt	5,982	-	5,982
Change in fair value of derivative instruments	(12,361)	-	(12,361)
Net periodic benefit cost other than service cost	(5,443)	-	(5,443)
Changes in pension and other postretirement obligations	5,808	-	5,808
Other nonoperating items, net	50,105	5,572	55,677
Net assets released from restrictions	19,200	(49,245)	(30,045)
Total nonoperating activities, net	346,317	624,593	970,910
CHANGE IN NET ASSETS	349,279	619,210	968,489
Less change in net assets related to noncontrolling interests	2,944	-	2,944
CHANGE IN NET ASSETS CONTROLLED BY EMORY	346,335	619,210	965,545
BEGINNING NET ASSETS	5,941,553	7,092,028	13,033,581
ENDING NET ASSETS	\$ 6,290,832	7,711,238	\$ 14,002,070

See accompanying notes to consolidated financial statements.

EMORY UNIVERSITY
CONSOLIDATED STATEMENTS OF CASH FLOWS

YEARS ENDED AUGUST 31, 2025 AND 2024 (Dollars in thousands)

	August 31, 2025	August 31, 2024
CASH FLOWS FROM OPERATING ACTIVITIES:		
Change in net assets	\$ 1,192,975	\$ 968,489
Adjustments to reconcile change in net assets to net cash provided by operating activities:		
Contributions and pledge payments restricted for long-term investment and capital projects	(91,326)	(96,173)
Contributions of donated securities	(60,226)	(37,991)
Proceeds from sale of donated securities	6,279	5,051
Equity in gains of joint ventures	(1,930)	(1,535)
Net realized and unrealized gain on investments	(1,127,219)	(817,537)
Inherent contribution received in business combination	(195,609)	-
Purchase of noncontrolling interest	300,000	-
Loss on disposal of property and equipment	5,786	2,844
Change in undistributed income from perpetual funds held by others	(41,400)	(285,135)
Depreciation and amortization	375,552	395,537
Amortization of bond premiums and issuance costs	(28,068)	(27,110)
Amortization of right-of-use assets	33,526	37,062
Change in pension and other postretirement	(3,736)	448
Change in fair value of derivative instruments	(9,922)	(7,060)
Change in operating assets:		
Accounts and other receivables, net	(263,870)	(110,132)
Contributions receivable for operations	28,924	12,133
Prepaid expenses, deferred charges, and other assets	(87,910)	(88,618)
Interests in perpetual funds	4,225	6,000
Change in operating liabilities:		
Accounts payable, accrued liabilities, and interest payable	81,629	102,511
Asset retirement obligations	1,576	3,647
Accrued liabilities for benefit obligations and professional liabilities	126,245	128,544
Lease liabilities, net	(33,385)	(36,840)
Deferred revenue	7,431	(98,346)
Net cash provided by operating activities	219,547	55,789
CASH FLOWS FROM INVESTING ACTIVITIES:		
Cash received from acquisition	70,761	-
Distributions from partnerships	1,000	500
Disbursements for loans to students	(4,668)	(1,874)
Repayment of loans from students	2,288	2,493
Proceeds from sales and maturities of investments	3,286,297	11,665,594
Purchases of investments	(3,392,753)	(11,349,851)
Purchases of property, plant, and equipment	(308,038)	(412,389)
Decrease in funds held in trust for others	(51,836)	(28,921)
Net cash used in investing activities	\$ (396,949)	\$ (124,448)

EMORY UNIVERSITY
CONSOLIDATED STATEMENTS OF CASH FLOWS

YEARS ENDED AUGUST 31, 2025 AND 2024 (Dollars in thousands)

	August 31, 2025	August 31, 2024
CASH FLOWS FROM FINANCING ACTIVITIES:		
Contributions and pledge payments restricted for long-term investment and capital projects	\$ 90,258	\$ 94,743
Proceeds from sale of donated securities restricted for long-term investment and capital projects	53,947	32,940
Proceeds from bonds payable, including commercial paper	1,184,430	350,000
Principal repayments of bonds payable, including commercial paper	(289,410)	(361,450)
Payments on finance lease obligations	(1,240)	(1,194)
Change in annuities payable	152	492
Debt issuance costs	(3,218)	(442)
Change in government advances for federal loan programs	(727)	(553)
Purchase of noncontrolling interest	(167,945)	-
Net cash provided by financing activities	866,247	114,536
Net change in cash, cash equivalents, and restricted cash	688,845	45,877
Cash, cash equivalents, and restricted cash at beginning of year	1,011,522	965,645
Cash, cash equivalents, and restricted cash at end of year (Note 2a)	\$ 1,700,367	\$ 1,011,522
Supplemental disclosures:		
Cash paid for interest	\$ 136,830	\$ 112,703
Accrued liabilities for property, plant, and equipment purchases	4,273	11,765
Accrued acquisition of noncontrolling interest	132,055	-

See accompanying notes to consolidated financial statements.

EMORY UNIVERSITY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2025 AND 2024

(1) Organization

Emory University (the University or Emory) is a private, coeducational, not-for-profit institution, located in Atlanta, Georgia. Founded in 1836, Emory owns and operates educational, research, and healthcare facilities to support its mission. Emory provides educational services to approximately 8,300 undergraduate students and 8,200 graduate and professional students within its nine schools and colleges. Included within the University are the Emory Healthcare System (Emory Healthcare), Emory Medical Care Foundation, and Emory Innovations, LLC.

Emory Healthcare consists of Emory Healthcare, Inc. (EHC) and its controlled operating companies, including Emory University Hospital Midtown (EUHM), Emory University Hospital (EUH), Emory Saint Joseph's Hospital (ESJH), EHCA Johns Creek Hospital, LLC (EJCH), Emory Rehabilitation Hospital (ERH), DeKalb Medical Center, Inc. (DMC), Decatur Health Resources, Inc. (DHR), DeKalb Medical Center Foundation (DMCF), The Emory Clinic, Inc. (TEC), Emory Specialty Associates, LLC (ESA), Emory Specialty Associates, LLC (ESA), The Medical Group of Saint Joseph's LLC (ESA-JOC), Wesley Woods Center of Emory University, Inc. (WWC), Clifton Casualty Insurance Company, Ltd. (CCIC), and Houston Healthcare System, Inc. (HHSI). EUHM, EUH, ESJH, EJCH, ERH, DMC, DHR, EHP, and EHW are sometimes referred to herein, collectively, as "the Hospitals."

In fiscal year 2025, Emory Healthcare purchased CHE Trinity Health's 49% membership interest in Emory/Saint Joseph's Inc. (JOC) for \$300.0 million. As of August 31, 2025, \$132.1 million was recognized as an accrued liability and will be paid in increments ending in March 2027.

Changes in net assets without donor restrictions for fiscal years 2025 and 2024, are summarized below:

	Controlled by Emory	Noncontrolling Interest	Total
Balance as of August 31, 2023	\$ 5,824,675	116,878	5,941,553
Change in net assets from operating and non-operating activities	346,335	2,944	349,279
Balance as of August 31, 2024	\$ 6,171,010	119,822	6,290,832
Change in net assets from operating and non-operating activities	912,345	40,518	952,863
Redemption of Trinity's membership interest	(151,237)	(148,763)	(300,000)
Balance as of August 31, 2025	\$ 6,932,118	11,577	6,943,695

On June 1, 2025, Emory Healthcare became the sole and controlling member of Houston Healthcare System, Inc. (HHSI) and its affiliates, which is comprised of two hospitals: Emory Hospital Perry (EHP), operating a 45-bed acute care hospital in Perry, Georgia and Emory Hospital Warner Robins (EHW), operating a 237-bed acute care hospital in Warner Robins, Georgia, and multiple outpatient facilities, and physicians. This acquisition integrates the innovation of Emory's academic medical center within the Central Georgia community (note 10).

The consolidated financial statements include the University and all other entities in which Emory has a significant financial interest and control. All significant inter-entity accounts and transactions have been eliminated in consolidation.

(2) Summary of Significant Accounting Policies

The consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (GAAP).

Net assets and revenue, gains, and losses are classified based on the existence or absence of externally imposed restrictions. Accordingly, net assets of the University are classified and reported as follows:

Net assets without donor restrictions – Net assets that are not subject to donor-imposed stipulations.

Noncontrolling interests in net assets are reported in the accompanying consolidated statements of financial position as a separate component of net assets without donor restrictions.

Net assets with donor restrictions – Net assets that are subject to donor-imposed stipulations that will or may be met either by actions of the University and/or the passage of time. These net assets include donor-restricted endowments, unconditional pledges, split-interest agreements, and interests in perpetual trusts held by others. Generally, the donors of these assets permit the University to use all, or part, of the income earned and net appreciation on related investments for general or specific purposes.

Revenue is reported as an increase in net assets without donor restrictions unless its use is limited by donor-imposed restrictions. Expenses are reported as decreases in net assets without donor restrictions. Gains and losses on investments and other assets or liabilities are reported as increases or decreases in net assets without donor restrictions unless restricted by explicit donor stipulation or by law. Expirations of restrictions on net assets (i.e., the donor-stipulated purpose has been fulfilled and/or

EMORY UNIVERSITY
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2025 AND 2024

the stipulated time period has elapsed) are reported as net assets released from restrictions and shown as reclassifications among the applicable classes of net assets.

The University considers the following items to be nonoperating activities: gifts and contributions for capital and long-term investment and the related net assets released from restrictions, investment return, change in fair value of derivative instruments, pension and postretirement related changes and net periodic benefit cost other than service cost, and other activities, net.

(a) Cash, Cash Equivalents, and Restricted Cash

Cash and cash equivalents consist primarily of bank balances and short-term money market mutual funds and treasury bills with original maturities generally three months or less that are not invested as part of the long-term investments. These amounts are carried at cost, which approximates fair value. Cash and cash equivalents that are part of the long-term pool are shown within investments as those funds generally are not used for daily operating purposes. For purposes of the statements of cash flows, activity related to liabilities with original maturities of three months or less is presented net.

Restricted cash consists of cash on hand that is restricted for a specific purpose under various capital financing arrangements or cash held for others and, therefore, not available to Emory for immediate or general business use. Restricted cash appears separately from the cash and cash equivalents on the University's accompanying consolidated statements of financial position.

The following table is a reconciliation of cash, cash equivalents, and restricted cash reported within the accompanying consolidated statements of financial position to the amounts shown in the accompanying consolidated statements of cash flows as of August 31 (in thousands):

	2025	2024
Cash and cash equivalents	\$ 1,638,560	\$ 845,459
Restricted cash included in investments	61,807	166,063
Total cash, cash equivalents, and restricted cash	\$ 1,700,367	\$ 1,011,522

Included within the 2025 and 2024 cash and cash equivalents balance is \$432.6 million and \$52.3 million of bond proceeds, respectively (note 12).

(b) Contributions Receivable, Net

Contributions to be received after one year, net of an allowance for uncollectible amounts, are discounted to their present value at credit-adjusted rates. Amortization of discounts is recorded as additional contribution revenue. An allowance for uncollectible contributions receivable is recorded to reduce the contributions receivable balance to the amount reasonably expected to be collected and is based on management's judgment, considering such factors as prior collection history, type of contribution, relationship with donor, and other relevant factors.

(c) Loans Receivable, Net

Loans receivable represent the outstanding loan balance due under Emory-funded and various federal government loan programs offered to graduate and undergraduate students less allowances for bad debt. Loans to students are carried at the estimated net realizable value. Interest earned on these loan programs is recognized as operating revenue in the accompanying consolidated statements of activities. Loans receivable from students under certain government loan programs, carried at cost, can only be assigned to the federal government or its designees. In addition to federal direct loans (which are not reported in the accompanying consolidated financial statements), loans to qualified students are funded principally with government advances to Emory under the Perkins, Nursing, and Health Professions Student Loan Programs.

(d) Student Accounts and Other Receivables, Net

Student accounts and other receivables are recorded at net realizable value and include receivables from students, sponsors, other organizations, and reinsurers. Allowances for uncollectible amounts are recorded based on management's assessment of expected net collections considering historical trends and current economic factors.

(e) Investments

Investments are reported at fair value. Investments in securities and listed funds are valued using quoted prices in active markets if available; otherwise, if the market is inactive, fair value is determined by the University in accordance with its valuation policy.

Investments in alternative investment fund structures are valued using the net asset value (NAV) per share of the investment (or its equivalent), as a practical expedient, if (a) the underlying investment manager's calculation of NAV is fair value based and

EMORY UNIVERSITY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2025 AND 2024

(b) the University does not currently have plans to sell the investment for an amount different from NAV. Valuations provided by the general partners and investment managers are evaluated by Emory Investment Management as of August 31, 2025 and 2024.

Investments are exposed to several risks, which may include (but are not limited to) interest rate, liquidity, tax, regulatory, currency, market, and credit risks. The University attempts to manage these risks through diversification, ongoing due diligence of fund managers, and monitoring of economic conditions, though it is at least reasonably possible that changes in the values of investments will occur in the near term and that such changes could materially affect the amounts reported in the University's consolidated financial statements.

Investment transactions are accounted for on a trade-date basis. Dividend income is recognized on the ex-dividend date, and interest income is recognized on an accrual basis. Investment return, including realized and unrealized gains and losses, is recognized when earned and reported in the accompanying consolidated statements of activities, net of external and direct internal investment expenses. Investment return, if restricted, is reported in the accompanying consolidated statements of activities as increases or decreases in net assets with donor restrictions until amounts have been appropriated and the donor-imposed or statutory time restrictions have been satisfied.

(f) Fair Value Measurements

The University uses valuation approaches that maximize the use of observable inputs and minimize the use of unobservable input to the extent possible. The University determines fair value based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels:

Level 1 – Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date.

Level 2 – Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability.

Level 3 – Unobservable inputs for the asset and liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little,

if any, market activity for the asset or liability at the measurement date.

(g) Split-Interest Agreements

The University's split-interest agreements with donors consist primarily of gift annuity agreements and irrevocable charitable remainder trusts for which the University serves as trustee. Assets held in the trusts are included in investments. Contribution revenue is recognized when trusts (or annuity agreements) are established, after recording liabilities for the present value of the estimated future payments to be made to beneficiaries. The liabilities are adjusted annually for changes in the value of assets, accretion of the discount, and other changes in the estimates of future benefits.

(h) Interests in Perpetual Funds Held by Others

The University is also the beneficiary of certain perpetual funds held and administered by others. The value of the funds' net assets (or Emory's share when there are other beneficiaries) is considered a reasonable estimate of the present value of the estimated future cash flows from these funds and is recognized in change in undistributed income from perpetual funds held by others and as contribution revenue at the date such funds are established. The carrying value of Emory's interest in such perpetual funds is adjusted for changes in fair value.

(i) Property and Equipment, Net

Land, buildings, and equipment are recorded at cost at the date of acquisition or fair value at the date of gift to the University. Depreciation expense is based on the straight-line method over the estimated useful lives of the assets. Useful lives are as follows: buildings – 10 to 60 years, land improvements and infrastructure – 5 to 40 years, movable equipment – 3 to 20 years, fixed equipment – 3 to 30 years, software and enterprise systems – 3 to 10 years, leasehold improvements – term of the lease, and library books – 10 years. Certain assets totaling \$131.6 million and \$128.6 million, such as art, museum assets, and rare books, are included in property and equipment, net, as of August 31, 2025 and 2024, respectively, but are not depreciated.

If circumstances require property and equipment to be tested for impairment, the University compares undiscounted cash flows expected to be generated by the property and equipment to its carrying amount. If the carrying amount exceeds the undiscounted cash flows, an impairment is recognized to the extent that the carrying amount exceeds its fair value. There were no asset impairments for fiscal years 2025 or 2024.

EMORY UNIVERSITY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2025 AND 2024

(j) Health Insurance Plan

The University is self-insured for employee and student health insurance costs, with losses insured in excess of a maximum amount on both a per claim and annual aggregate claim amount. The self-insurance liability is based on claims filed and an estimate of claims incurred but not yet reported. Self-insurance claims are reported as net of insurance premiums collected from employees and students.

(k) Patient Accounts Receivable and Concentrations

Patient accounts receivable are reported at the estimated net realizable amounts due from patients, third-party payors, and others for services rendered, including estimated retroactive adjustments due to future audits, reviews, and investigations. Retroactive adjustments are considered in the recognition of revenue on an estimated basis in the period the related services are rendered, and such amounts are adjusted in future periods as adjustments become known or as years are no longer subject to such audits, reviews, and investigations.

Emory Healthcare analyzes contractually due amounts and provides an allowance for implicit price concessions. Accounts receivable are written off after collection efforts have been undertaken in accordance with Emory's policies.

The mix of net receivables from patients and third-party payors for the years ended August 31 is as follows:

	2025	2024
Managed care and other third-party payors	67%	62%
Medicare	27	30
Medicaid	2	4
Patients	4	4
	100%	100%

(l) Leases

The University determines whether an arrangement is a lease (operating or finance) at inception by evaluating whether the contract conveys the right to use an identified asset and whether Emory obtains substantially all of the economic benefits from and has the right to control the asset. Right-of-use (ROU) assets represent the University's right to use an underlying asset for the lease term and lease liabilities represent the University's obligation to make lease payments arising from the lease. Operating and finance lease ROU assets and liabilities are recognized at the lease commencement date based on the present value of the lease payments over the lease term discounted using the interest rate implicit in the lease agreement or Emory's

relevant incremental borrowing rate. The University's current discount rates range from 1.0% to 5.6% depending on the term of the arrangement.

(m) Income Taxes

The University is recognized as a tax-exempt organization as defined in Section 501(c)(3) of the U.S. Internal Revenue Code of 1986, as amended (the Code), and is generally exempt from federal income taxes on related income pursuant to Section 501(a) of the Code. The University is, however, subject to federal and state income tax on unrelated business income and provision for such taxes is included in the accompanying consolidated statements of activities.

The University is subject to an excise tax on net investment income and excess compensation as well as unrelated business income taxes. In July 2025, Congress enacted spending legislation which included changes to the net investment income and excess compensation taxes. Emory has reflected the tax assets and liabilities in the accompanying consolidated financial statements based on reasonable estimates and based on the expected tax rates upon realization of these tax liabilities. The University also has a net operating loss carryforward related to unrelated business income aggregating \$140.0 million, for which a valuation allowance of \$58.5 million is recorded as of August 31, 2025. As of August 31, 2024, the University had a net operating loss carryforward of \$170.9 million, with a valuation allowance of \$117.0 million.

The University regularly evaluates its tax positions and as of August 31, 2025 and 2024, does not believe it has any material uncertain tax positions that require disclosure or adjustment to the accompanying consolidated financial statements.

(n) Derivative Instruments

Certain investment strategies used by the University and its investment managers incorporate various derivative financial instruments to reduce volatility, manage market risk, and enhance investment returns. Such instruments are reflected at fair value and included in either investments or liability for derivative instruments within the accompanying consolidated statements of financial position. Changes in the fair value of investment-related derivative instruments are included in investment return on the accompanying consolidated statements of activities. The University also utilizes interest rate swap agreements to hedge interest rate market exposure of variable rate debt. The difference between amounts paid and received under such agreements is reported in interest expense. Changes in the fair value of these

EMORY UNIVERSITY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2025 AND 2024

swap agreements or any gains or losses that result from the termination of these swap agreements are recognized as nonoperating activities in the accompanying consolidated statements of activities.

(o) Pension and Postretirement Benefit Plans

The University recognizes the funded status of its defined-benefit pension and postretirement benefit plans as an asset or liability and recognizes changes in funded status during the year in which the changes occur as changes in net assets without donor restrictions.

(p) Use of Estimates

The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions affecting the reported amounts of assets, liabilities, revenue, and expenses, as well as disclosure of contingent assets and liabilities. Actual results could differ from those estimates.

Significant items in the University's consolidated financial statements subject to such estimates and assumptions include valuations for certain investments without readily determinable fair values, the determination of the allowances for price concessions for medical services, reserves for employee and student healthcare and workers' compensation claims, accrued professional and general liability costs, estimated third-party settlements, and actuarially determined benefit liabilities.

(q) Conflict of Interest Policies (Related Parties)

University trustees, directors, principal officers, and key employees may periodically be directly or indirectly associated with companies doing business with the University. The University requires annual disclosure of significant financial interests in, or employment or board service with, entities doing business with the University. The annual disclosures cover these key officials and their immediate family members.

When such relationships exist, measures are taken to appropriately manage the actual or perceived conflict. The written conflict of interest policy for the University requires, among other things, that no member of a governing board may participate in any decision in which he or she (or an immediate family member) has a material financial interest.

(r) Investments in Joint Ventures

Emory accounts for certain operating investments in joint ventures over which it has significant influence but not a

controlling interest, using the equity method. Investments in joint ventures are generally included in investments in the accompanying consolidated statements of financial position and equity income/loss is recorded within other nonoperating activities in the accompanying consolidated statements of activities. One of these joint ventures owns a medical office tower that was funded by an \$83.0 million loan, which is secured by the constructed building. Emory, which owns a 50% investment, and its joint venture partner, jointly and severally fully guarantee the loan obligations of the company in the event of the company's bankruptcy, insolvency, or related circumstances. The loan is due June 1, 2032.

(3) Contributions Receivable

Contributions receivable as of August 31 consist of the following (in thousands):

	2025	2024
UNCONDITIONAL PROMISES EXPECTED TO BE COLLECTED IN:		
Less than one year	\$ 71,818	\$ 67,999
One year to five years	60,732	94,816
Over five years	1,145	3,563
Gross contributions receivable	133,695	166,378
Less:		
Allowance for uncollectible amounts	(4,544)	(5,638)
Discount to present value	(6,509)	(10,242)
Contributions receivable, net	\$ 122,642	\$ 150,498

At August 31, 2025 and 2024, the five largest outstanding donor pledge balances represented 41.0% and 37.0%, respectively, of Emory's total contributions receivable, net. Contribution receivables are discounted at rates ranging from 4.15% to 4.25%.

As of August 31, 2025, the University had received bequest intentions and conditional promises of approximately \$67.0 million. These intentions to give are not recognized as assets or revenue and, if received, will generally be restricted for purposes stipulated by the donor.

(4) Revenue Recognition

(a) Net Tuition and Fees

Tuition and fees revenue is derived from degree programs and continuing education programs. Tuition and fees are recognized in the fiscal year in which the academic programs are provided. Revenue is reflected in the accompanying consolidated statements of activities for the portion of the program or service that is completed by the end of the fiscal year. The remaining

EMORY UNIVERSITY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2025 AND 2024

performance obligation that will be completed in the following fiscal year remains a liability and is recorded within deferred revenue on the accompanying consolidated statements of financial position.

Most undergraduate students receive institutional financial aid based upon academic promise and demonstrated financial need. Graduate students often receive tuition support in connection with research assistant, teaching assistant, and fellowship appointments. Student financial aid provided by the University for tuition and fees is reflected as a reduction of tuition and fees revenue from published rates. Institutional resources provided in excess of amounts owed by the students to Emory are recorded as scholarship expenses.

(b) Sales and Services of Auxiliary Enterprises

An auxiliary enterprise is a nonacademic entity that exists predominantly to furnish goods and services to students, faculty, and staff. Auxiliary enterprises revenue primarily includes residential services, parking, and the bookstore. Residential services and parking revenue are recognized over time, as the services are performed. Sales of goods occur as a point-of-sale transaction, and the revenue is recognized as the sale occurs. Any discounts are factored into the selling price at the point of sale.

The following table provides the components of tuition and fees and student-related auxiliary enterprises revenue for the year ended August 31, 2025 (in thousands):

	Tuition and Fees	Auxiliary Enterprises	Total
Undergraduate programs	\$ 544,255	59,985	604,240
Graduate and professional programs	404,533	1,637	406,170
Total at published rates	948,788	61,622	1,010,410
Less institutional aid for undergraduate programs	(194,947)	(12,773)	(207,720)
Less institutional aid for graduate and professional programs	(195,463)	(385)	(195,848)
Tuition and fees and auxiliary enterprises, net of institutional aid	558,378	48,464	606,842
Other academic programs	8,839	-	8,839
Total tuition and fees and auxiliary enterprises	\$ 567,217	48,464	615,681

The following table provides the components of tuition and fees and student-related auxiliary enterprises revenue for the year ended August 31, 2024 (in thousands):

	Tuition and Fees	Auxiliary Enterprises	Total
Undergraduate programs	\$ 515,423	56,986	572,409
Graduate and professional programs	373,749	1,418	375,167
Total at published rates	889,172	58,404	947,576
Less institutional aid for undergraduate programs	(181,101)	(10,262)	(191,363)
Less institutional aid for graduate and professional programs	(184,688)	(298)	(184,986)
Tuition and fees and auxiliary enterprises, net of institutional aid	523,383	47,844	571,227
Other academic programs	8,782	-	8,782
Total tuition and fees and auxiliary enterprises	\$ 532,165	47,844	580,009

(c) Gifts and Contributions Revenue

Contributions, including unconditional promises to give, are recognized as revenue in the period the contribution is received, or in the period in which the unconditional promise was made. Unconditional promises to give, with payments due in future periods, are recorded as increases in net assets with donor restrictions at the estimated present value of future cash flows, net of an allowance for uncollectible pledges. Contributions of assets other than cash are recorded at their estimated fair value at the date of the gift.

Donor-restricted contributions are reported as revenue with donor restrictions, which increases this net asset class. If the donor stipulation is met in the year of the gift, the contribution is reflected in net assets without donor restrictions. Restrictions on gifts to acquire long-lived assets are considered met in the period when the asset is placed in service. Conditional promises to give are not recognized until they become unconditional.

EMORY UNIVERSITY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2025 AND 2024

(d) Grants and Contracts Revenue

Emory receives funding from federal, state, corporate, and private foundations (sponsors). The agreement with the sponsor may take the form of a contract, grant, or cooperative agreement. If resource providers do not receive commensurate benefit (only indirect benefit because the research findings serve the general public), such grants and contracts are considered contributions.

Most Emory nonexchange, sponsored research agreements are conditional contributions as the agreements include both a right of return or release of assets and a barrier that Emory must overcome to be entitled to the consideration. The University recognizes revenue associated with these sponsored agreements as qualifying allowable expenses are incurred or a measurable performance-related barrier is achieved in accordance with the terms and conditions of the agreements. Conditional agreements with sponsor-imposed restrictions that expire simultaneously with the satisfaction of the specified conditions are reported as net assets without donor restrictions. Deferred revenue is recognized when cash is received from sponsors in advance of revenue being earned. Amounts recorded in other receivable, net are for services rendered or expenditures incurred in advance of the receipt of funds.

Emory considers revenue from most clinical trial agreements to be exchange transactions where revenue is recognized as services are performed, billed, and the University has contractual right to consideration. Revenue related to clinical trial agreements included in grants and contracts revenue in the accompanying consolidated statements of activities for the years ended August 31, 2025 and 2024 totaled \$82.6 million and \$71.6 million, respectively.

Indirect cost recoveries are based on negotiated rates with grantor agencies and represent recoveries of facilities and administrative costs incurred under grant and contract agreements.

The following table presents Emory's sources of grants and contracts revenue (including indirect cost recoveries) for the years ended August 31 (in thousands):

	2025		2024	
	Grants	Contracts	Grants	Contracts
Federal government	\$ 807,106	3,878	\$ 784,397	2,829
Other government	2,109	–	2,967	–
Corporate	16,780	69,199	23,984	59,634
Private institutions	136,982	9,541	145,761	9,094
Total	\$ 962,977	82,618	\$ 957,109	71,557

As of August 31, 2025 and 2024, Emory had unexpended grant awards of \$956.9 million and \$1.0 billion, respectively, for which revenue will be recognized when conditions have been met, or performance obligations have been satisfied.

(e) Royalties Revenue

The University recognizes revenue from nonrefundable, up-front fees allocated to a license at a point in time when the license is transferred to the licensee and the licensee is able to use and benefit from the license. Sales-based royalties revenue, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, is recognized over the licensing agreement.

(f) Medical Services and Other Revenue

Medical services revenue is recognized as services are performed, and the customer receives and uses the benefits of the services. The University has contractual agreements with Grady Memorial Hospital where practicing interns and medical residents of the Emory School of Medicine receive clinical training and faculty provide teaching, medical care, and hospitalization services. The School of Medicine is reimbursed for expenses incurred for interns and medical residents based on the costs for labor and reimbursed for the faculty teaching, administrative, and clinical services based on the number of interns and residents trained and time spent performing clinical and administrative services.

The University also has affiliation and administrative services agreements with Children's Healthcare of Atlanta and the Emory + Children's Pediatric Institute, where it provides various administrative services. Revenue is recognized over time and is recorded as other revenue in the accompanying consolidated statements of activities.

Retail pharmaceutical sales are recognized at a point in time when the customer receives the product.

The major components of other sources of operating revenue for the years ended August 31 are as follows (in thousands):

	2025	2024
Retail pharmaceutical sales	\$ 489,480	\$ 360,145
Royalties	48,625	64,785
Other	298,534	252,046
Other revenue	\$ 836,639	\$ 676,976

EMORY UNIVERSITY
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2025 AND 2024

(g) Independent Operations Revenue

Independent operations are activities independent of its mission, including an externally managed conference center, hotel, and fitness center. Fee charges are based on market rates for the services provided and revenue is recognized at a point in time or over time as the services are rendered.

(h) Net Patient Service Revenue

Emory Healthcare has agreements with government and other third-party payors that provide for reimbursement to Emory Healthcare at amounts different from established rates.

Revenue is recognized as performance obligations are satisfied. Performance obligations are determined based on the nature of the services provided. Revenue for performance obligations satisfied over time is recognized based on actual charges incurred in relation to total expected (or actual) charges. Emory Healthcare believes that this method provides a faithful depiction of the transfer of services over the term of the performance obligation based on the inputs needed to satisfy the obligation. Generally, performance obligations satisfied over time relate to patients in Emory Healthcare’s hospitals receiving inpatient, outpatient, or emergency services. Emory Healthcare measures the performance obligation from admission, or the commencement of an outpatient service, to the point when it is no longer required to provide services to that patient, which is generally at the time of discharge or completion of the outpatient services. Revenue for performance obligations satisfied at a point in time is generally recognized when services are provided to Emory Healthcare’s patients.

Emory Healthcare determines the transaction price based on standard charges for goods and services provided, reduced by contractual adjustments provided to third-party payors, discounts provided to uninsured patients in accordance with Emory Healthcare policy, and implicit price concessions provided to patients. Emory Healthcare determines its estimates of contractual adjustments and discounts based on contractual agreements, its discount policies, and historical experience.

Emory Healthcare provides care to patients regardless of their ability to pay. Emory Healthcare has determined it has provided implicit price concessions to uninsured patients and patients with other uninsured balances (e.g., co-pays and deductibles).

The implicit price concessions included in estimating the transaction price represent the difference between amounts billed to patients and the amounts Emory Healthcare expects to collect based on its collection history with those patients considering

business and economic conditions, trends in healthcare coverage, and other collection indicators. Periodically, management assesses the adequacy of the allowance for implicit price concessions based upon historical write-off experience by payor category and adjusts the allowance as appropriate.

Patient service revenues, net of contractual adjustments, implicit price concessions, and other discounts recognized from major payor sources for the years ended August 31 are as follows (in thousands):

	2025	2024
Medicare	\$ 2,259,529	\$ 2,070,112
Medicaid	321,990	250,520
Managed care and other third-party payors	4,663,307	3,848,254
Patients	85,347	89,440
Net patient service revenue	\$ 7,330,173	\$ 6,258,326

Included within Medicare revenue in fiscal year 2024 is a \$75.4 million payment from the Centers for Medicare and Medicaid Services to compensate for an invalid payment rate utilized during the period from 2018 to 2022 for drugs acquired under Section 340B of the Public Health Service Act.

The composition of net patient service revenue based on the Emory Healthcare lines of business for the years ended August 31 is as follows (in thousands):

	2025	2024
Services lines:		
Hospital – inpatient	\$ 3,001,929	\$ 2,571,358
Hospital – outpatient	2,925,120	2,404,706
Physician services	1,403,124	1,282,262
Net patient service revenue	\$ 7,330,173	\$ 6,258,326

Emory Healthcare provides care to patients who meet certain criteria under its financial assistance policy without charge or at amounts less than their established rates and such amounts are not included in net patient service revenue.

Data is maintained to identify and monitor the level of charity care provided, including the amount of charges foregone and actual costs for services furnished under its charity and indigent care policies.

The cost of charity care provided totaled \$163.0 million and \$160.9 million for the years ended August 31, 2025 and 2024, respectively. Emory Healthcare estimated these costs by applying

EMORY UNIVERSITY
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2025 AND 2024

a ratio of cost to gross charges to the gross uncompensated charges associated with providing care to the charity patients.

(5) Liquidity and Availability

Emory regularly monitors the liquidity required to meet its operating needs and other contractual commitments, while also maximizing the investment of its available funds.

For purposes of analyzing resources available to meet general expenditures over a 12-month period, the University considers all expenditures related to its ongoing mission-related activities as well as the conduct of services undertaken to support those activities to be general expenditures.

In addition to financial assets available to meet general expenditures over the next 12 months, the University operates with a balanced budget and anticipates collecting sufficient revenue to cover general expenditures not covered by donor-restricted resources.

As of August 31, 2025 and 2024, the following financial assets could readily be made available within one year of the statements of financial position date to meet cash needs for general expenditures (in thousands):

	2025	2024
TOTAL ASSETS	\$ 23,820,253	\$ 21,286,330
Less:		
Property and equipment, net	(4,777,813)	(4,707,332)
Interest in perpetual trusts held by others	(2,050,386)	(2,013,211)
Donor-restricted and board-designated endowment funds	(8,926,229)	(8,088,842)
Other investments	(3,681,770)	(3,290,671)
Prepaid expenses, deferred charges, and other assets	(628,510)	(517,116)
Operating lease right-of-use assets	(174,480)	(180,933)
Contributions receivable, net	(122,642)	(150,498)
Loans receivable, net	(16,904)	(14,524)
Add:		
Endowment payout in following year	272,454	257,306
Contributions receivable due within one year for operations	71,818	67,999
Financial assets	\$ 3,785,791	\$ 2,648,508

The University has \$3.8 billion of financial assets as of August 31, 2025 to meet cash needs for general expenditures, consisting of cash and cash equivalents of \$1.6 billion, accounts receivable of \$1.5 billion, contributions receivable, less than one year of \$71.8 million, unrestricted payout on endowment funds of \$272.5 million, and other operating investments of \$338.7 million.

EMORY UNIVERSITY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2025 AND 2024

(6) Investments

The following table summarizes investments as of August 31 (in thousands):

	2025	2024
Short-term investments and cash equivalents ^(a)	\$ 578,579	\$ 458,413
Public equity ^(b)	4,208,594	3,903,838
Absolute return/fixed income ^(c)	2,980,135	2,691,485
Private equity/venture capital ^(d)	4,280,074	3,714,144
Real assets ^(e)	899,824	911,097
Derivative instruments ^(f)	(2,319)	(898)
Total investments at fair value	12,944,887	11,678,079
Joint ventures (equity method)	1,809	809
Total investments	\$ 12,946,696	\$ 11,678,888

a) Includes short-term U.S. and non-U.S. Treasury securities with original maturities of less than one year, as well as funds that invest in these types of investments.

b) Includes domestic and international stocks, as well as interests in funds that invest in both long only and long/short equity-based strategies; certain investments in funds may be subject to restrictions that limit the University's ability to withdraw capital until (i) a certain "lock-up period" has expired or (ii) until certain underlying investments designated as "illiquid" or "side pockets" are sold. In addition, fund investments in this category may be subject to restrictions limiting the amount the University is able to withdraw as of a given redemption date. Certain fund investments in this category may not be eligible for redemption and instead issue distributions received through liquidation of the funds' underlying assets, which is expected to occur over the next seven years.

c) Includes directly-held actively traded global fixed-income securities (such as government bonds and corporate bonds) or commingled funds holding such securities of \$1.8 billion and \$1.8 billion and investments in multistrategy or credit funds, as well as opportunistic absolute return funds intended to enhance diversification and reduce correlation to public equity of \$1.2 billion and \$881.0 million as of August 31, 2025 and 2024, respectively; certain fund investments included in this category may hold marketable securities and be subject to redemption terms governed by the respective fund agreement or may contain illiquid investments and, therefore, offer no liquidity over the fund life. Such funds holding illiquid investments are expected to yield liquidating distributions over the next 10 years.

d) Includes illiquid investments in private and public companies, both domestically and internationally; the majority of these investments are held through funds and also include buyout, venture capital, private debt, high yield, and subordinated debt strategies. The nature of the investments in this category is such that distributions are received through liquidation of the funds' underlying assets, which are expected to occur over the next 14 years.

e) Includes investments in oil and gas, commodities, timber, and real estate, the majority of which are held through funds. The nature of the investments in this category is such that distributions are received through liquidation of the underlying assets of the funds, which are expected to occur over the next 10 years.

f) Includes investments in foreign exchange contracts valued at fair value of each underlying investment.

As of August 31, 2025, the related unfunded commitments of the University's alternative investments valued using the practical expedient and limitations and restrictions on the University's ability to redeem or sell are summarized as follows (in thousands):

	Unfunded Commitments	Redemption Frequency (if currently eligible)	Redemption Notice Period
Absolute return	\$ 448,046	0 - 90 days or not eligible	45 - 92 days
Private equity/ venture capital	1,304,576	180-360 days or not eligible	90-120 days
Public equity	7,498	0-720 days or not eligible	0-180 days
Real assets	454,000	not eligible	not eligible
	\$ 2,214,120		

Unfunded commitments are generally expected to be called by funds within five years of fund inception.

EMORY UNIVERSITY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2025 AND 2024

(7) Endowment Net Assets

The University's endowed assets (the Endowment) consist of approximately 2,500 individual funds established for various purposes, including with donor restriction endowment funds and without donor restrictions funds designated by the Board of Trustees to function as endowments. The Endowment provides stable financial support to a wide variety of programs and activities in perpetuity, playing a critical role in enabling the University to achieve its mission. Net assets associated with these endowment funds are classified and reported based on the existence or absence of donor-imposed restrictions.

(a) Interpretation of Relevant Law

The University follows the State of Georgia's Uniform Prudent Management of Institutional Funds Act (UPMIFA), which provides standards for managing investments of institutional funds and spending from endowments. The University classifies as donor-restricted historical value net assets (a) the original value of gifts donated to the permanent endowment, (b) the original value of subsequent gifts to the permanent endowment,

and (c) accumulations to the permanent endowment made under the direction of the applicable donor gift instrument at the time the accumulation is added to the fund.

The remaining portion of the donor-restricted endowment fund is classified as restricted appreciation until those amounts are appropriated for expenditures by the University in a manner consistent with the standard of prudence prescribed by UPMIFA. Per UPMIFA, the University considers several factors in deciding to appropriate or accumulate donor-restricted endowment funds, including the duration and preservation of the fund, the purposes of the fund, general economic conditions, the possible effect of inflation and deflation, the expected total return from income and the appreciation of investments, other resources of the University, and the investment policies of the University. The endowment funds subject to UPMIFA are true endowments and do not include perpetual funds held by others, long-term investments, annuity funds, funds held in trust for others, and miscellaneous investments. As of August 31, 2025, 72.9% of the investments described in note 6 are classified as endowed net assets.

EMORY UNIVERSITY
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2025 AND 2024

Endowment funds are categorized in the following net asset classes as of August 31 (in thousands):

	2025			2024		
	Without Donor Restrictions	With Donor Restrictions	Total	Without Donor Restrictions	With Donor Restrictions	Total
Donor-restricted endowment funds						
Appreciation	\$ –	4,495,711	4,495,711	\$ –	4,089,078	4,089,078
Historical value	–	1,488,818	1,488,818	–	1,389,120	1,389,120
Total donor restricted	–	5,984,529	5,984,529	–	5,478,198	5,478,198
Funds functioning as endowments or board-designated	2,941,700	–	2,941,700	2,610,644	–	2,610,644
Total endowment net assets	\$ 2,941,700	5,984,529	8,926,229	\$ 2,610,644	5,478,198	8,088,842

The following table represents endowment net asset composition by purpose as of August 31 (in thousands):

	2025			2024		
	Without Donor Restrictions	With Donor Restrictions	Total	Without Donor Restrictions	With Donor Restrictions	Total
Academic and research ⁽¹⁾	\$ 1,889,956	5,858,092	7,748,048	\$ 1,719,946	5,366,490	7,086,436
Capital maintenance, infrastructure, and real estate	1,051,744	126,437	1,178,181	890,698	111,708	1,002,406
Total endowment net assets	\$ 2,941,700	5,984,529	8,926,229	\$ 2,610,644	5,478,198	8,088,842

⁽¹⁾ Academic and research includes endowment net assets for student financial aid of \$2.4 billion as of August 31, 2025 as well as program support.

Changes in endowment funds by net asset classification for the years ended August 31 are summarized as follows (in thousands):

	Without Donor Restrictions	With Donor Restrictions	Total
Balance as of August 31, 2023	\$ 2,367,757	5,126,203	7,493,960
Endowment investment return, net	231,168	502,217	733,385
Gifts and additions to endowment, net	124,382	82,312	206,694
Withdrawal of board-designated funds for strategic initiatives	(10,504)	–	(10,504)
Endowment spending distributions	(102,159)	(232,534)	(334,693)
Balance as of August 31, 2024	\$ 2,610,644	5,478,198	8,088,842
Endowment investment return, net	313,513	655,092	968,605
Gifts and additions to endowment, net	142,015	99,698	241,713
Withdrawal of board-designated funds for strategic initiatives	(11,357)	–	(11,357)
Endowment spending distributions	(113,115)	(248,459)	(361,574)
Balance as of August 31, 2025	\$ 2,941,700	5,984,529	8,926,229

EMORY UNIVERSITY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2025 AND 2024

(b) Funds with Deficiencies

From time to time, the fair value of assets associated with individual donor-restricted endowment funds may fall below the level of the donor's original contribution. Deficiencies of this nature were \$0.0 million and \$1.6 million as of August 31, 2025 and 2024, respectively.

(c) Return Objectives and Risk Parameters

The University has adopted investment and spending policies for endowment assets that attempt to provide a predictable stream of funding to programs supported by its endowment and seek to maintain the purchasing power of the endowment assets. Under this policy, as approved by the Board of Trustees, the endowment assets are invested within the risk tolerances of the University to provide an expected total return and inflation over the long term.

(d) Strategies Employed for Achieving Objectives

To satisfy its long-term return objectives, the University relies on a total return strategy in which investment returns are achieved through both capital appreciation (realized and unrealized) and current yield (interest and dividends). The University employs a diversified asset allocation strategy across public equity, absolute return/fixed income, private equity/venture capital, and real

assets to achieve its long-term return objectives within a prudent risk framework. The Endowment's long-term target asset allocation is approved by the Investment Committee of the Board of Trustees. The portfolio is periodically rebalanced to the target weightings for each asset class.

(e) Relationship between Investment Objectives and Spending Policy

The University's Board of Trustees has established a spending policy that determines how endowment distributions are made. The University employs a total return endowment spending policy that establishes the amount of endowment investment return available to support current operating and capital needs while preserving the purchasing power of the endowment over the long term. The distribution of endowment investment return was based on 5.0% of the average fair value of the endowment over the previous 60 months. The University considers the historical average market value in setting the annual appropriation amount. Accordingly, the University expects the current spending policy to allow its endowment to maintain its purchasing power if projected growth rates are achieved. Additional real growth will be provided through new gifts and any excess investment return. The payout rate is approved annually by the Board of Trustees as part of the budget process.

EMORY UNIVERSITY
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2025 AND 2024

(8) Fair Values of Assets and Liabilities

The following table summarizes the valuation of the University's assets and liabilities according to the fair value hierarchy levels as of August 31, 2025 (in thousands):

	Investments Measured at NAV ⁽¹⁾	Fair Value Hierarchy			Total Fair Value
		Level 1	Level 2	Level 3	
FINANCIAL ASSETS:					
Short-term investments and cash equivalents	\$ –	483,867	94,712	–	578,579
Public equity	2,937,723	1,142,074	128,579	218	4,208,594
Absolute return/fixed income	1,200,404	1,321,377	458,354	–	2,980,135
Private equity/venture capital	4,238,679	100	–	41,295	4,280,074
Real assets	894,141	2,667	1,375	1,641	899,824
Derivative instruments	–	(1,542)	(777)	–	(2,319)
Total investments at fair value	9,270,947	2,948,543	682,243	43,154	12,944,887
Interests in perpetual funds held by others	–	–	–	2,050,386	2,050,386
Total assets at fair value	9,270,947	2,948,543	682,243	2,093,540	14,995,273
FINANCIAL LIABILITIES:					
Derivative instruments – interest rate swaps	–	–	(22,682)	–	(22,682)
Funds held in trust for others ⁽²⁾	(1,269,348)	–	–	–	(1,269,348)
Total liabilities at fair value	\$ (1,269,348)	–	(22,682)	–	(1,292,030)

EMORY UNIVERSITY
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2025 AND 2024

The following table summarizes the valuation of the University's assets and liabilities according to the fair value hierarchy levels as of August 31, 2024 (in thousands):

	Investments Measured at NAV ⁽¹⁾	Fair Value Hierarchy			Total Fair Value
		Level 1	Level 2	Level 3	
FINANCIAL ASSETS:					
Short-term investments and cash equivalents	\$ –	306,155	152,258	–	458,413
Public equity	3,016,609	887,226	–	3	3,903,838
Absolute return/fixed income	881,389	1,486,413	323,683	–	2,691,485
Private equity/venture capital	3,676,543	82	–	37,519	3,714,144
Real assets	904,317	3,639	1,500	1,641	911,097
Derivative instruments	–	(898)	–	–	(898)
Total investments at fair value	8,478,858	2,682,617	477,441	39,163	11,678,079
Interests in perpetual funds held by others	–	–	–	2,013,211	2,013,211
Total assets at fair value	8,478,858	2,682,617	477,441	2,052,374	13,691,290
FINANCIAL LIABILITIES:					
Derivative instruments – interest rate swaps	–	–	(32,604)	–	(32,604)
Funds held in trust for others ⁽²⁾	(1,183,408)	–	–	–	(1,183,408)
Total liabilities at fair value	\$ (1,183,408)	–	(32,604)	–	(1,216,012)

⁽¹⁾ Certain investments that are measured at fair value using the net asset value (NAV) per share (or its equivalent) practical expedient have not been categorized in the fair value hierarchy. The fair value amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the amounts presented in the accompanying consolidated statements of financial position.

⁽²⁾ Emory uses net asset value of units held in endowment pool as an estimate for fair value.

EMORY UNIVERSITY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2025 AND 2024

The following tables present a summary of the University's activity for investments categorized as Level 3 for the years ended August 31, 2025 and 2024 (in thousands):

	2025		
	Purchases	Sales	Transfers out ⁽¹⁾
Private equity/venture capital	\$ 40	(1)	–
Real assets	–	–	–
Total Investments	40	(1)	–
Interests in perpetual funds held by others	–	–	(4,225)
Total assets	\$ 40	(1)	(4,225)

	2024		
	Purchases	Sales	Transfers out ⁽¹⁾
Private equity/venture capital	\$ 93	(37)	–
Real assets	1	(207)	–
Total Investments	94	(244)	–
Interests in perpetual funds held by others	17,500	–	(6,000)
Total assets	\$ 17,594	(244)	(6,000)

⁽¹⁾ Transfers of interests in perpetual funds held by others is due to funds released from operations.

(9) Derivative Instruments and Hedging Activities

(a) Debt

Historically, as a component of the debt portfolio, the University entered into interest rate swap agreements that effectively convert a portion of variable rate debt to fixed rates and are used to manage interest rate risk. Since the inception of the interest rate swap agreements, the debt portfolio has changed to incorporate

fixed rate debt not associated with derivatives. The University's exchange arrangements are exposed to credit loss in the event of nonperformance by the counterparty and to interest rate risk driven by any potential basis risk with variable rate debt. Certain of the University's derivative instruments contain provisions requiring long-term, unsecured debt to be maintained at specified credit ratings from Moody's Investors Service and Standard and Poor's Ratings Service. If the ratings of the University's debt were to fall below certain benchmarks, the counterparty could request immediate payment on derivative instruments in net liability positions. As of August 31, 2025, the University's long-term debt ratings exceeded these benchmarks.

At August 31, 2025, Emory had four interest rate swap agreements expiring on various dates ranging from September 1, 2035 through December 1, 2042. These agreements require Emory to pay fixed interest rates to the counterparties varying from 3.2% to 3.6% in exchange for variable rate payments from the counterparties based on a percentage of Term Secured Overnight Financing Rate (SOFR) plus a spread.

Net settlement transactions related to the agreements described above resulted in interest expense of \$0.4 million and interest revenue of \$2.0 million in fiscal year 2025 and 2024, respectively. During fiscal year 2024 the University terminated four interest rate swap agreements resulting in a gain of \$6.0 million recorded within non-operating activities, net on the accompanying consolidated statements of activities. The fair value of each of the remaining exchange agreements is estimated based on pricing models that utilize significant observable inputs, such as relevant current interest rates, which reflect assumptions on the amount the University would receive or pay to terminate the agreement at the reporting date. As such, the University's exchange agreements are categorized as Level 2 in the fair value hierarchy.

EMORY UNIVERSITY
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2025 AND 2024

The following table summarizes the debt-related derivative instruments as of and for the years ended August 31 (in thousands):

Interest Rate Swaps			2025		2024	
Inception	Maturity	Notional Amount ⁽¹⁾	Liability Fair Value	Unrealized Gain	Liability Fair Value	Unrealized Loss
December 1, 2007	September 1, 2035	75,000	(5,405)	1,589	(6,994)	(1,553)
May 1, 2008	September 1, 2038	75,000	(6,460)	2,252	(8,712)	(1,400)
December 1, 2008	December 1, 2042	100,000	(5,197)	4,474	(9,671)	(2,408)
December 1, 2009	September 1, 2035	75,000	(5,620)	1,607	(7,227)	(1,546)
Total		\$ 325,000	(22,682)	9,922	\$ (32,604)	(6,907)

⁽¹⁾ The notional amount is the predetermined dollar amount on which the exchanged interest payments are based.

Emory is exposed to financial loss in the event of nonperformance by a counterparty to any of the financial instruments described above. General market conditions could impact the credit standing of the counterparties and therefore, potentially impact the value of the instruments. Emory management, with consultation from third-party financial advisers, controls this counterparty credit risk by considering the credit rating, business risk, and reputation of any counterparty before entering into a transaction, monitoring for any change in the credit standing of its counterparty during the life of the transaction, and requiring collateral be posted when predetermined thresholds are crossed.

(10) Property and Equipment, Net

Property and equipment, net as of August 31 is summarized as follows (in thousands):

	2025	2024
Land and improvements	\$ 291,127	\$ 253,178
Buildings and improvements	5,613,825	5,397,810
Equipment	4,153,429	3,678,621
Finance lease ROU assets (note 11)	26,588	25,248
Library and museum assets	604,815	579,064
Construction in progress	149,408	249,121
	10,839,192	10,183,042
Less: accumulated depreciation	(6,046,571)	(5,462,688)
Less: accumulated amortization of finance leases	(14,808)	(13,022)
Total property, plant, and equipment, net	\$ 4,777,813	\$ 4,707,332

In June 2025, Emory Healthcare acquired 100% of the membership interests in the Houston Healthcare system and its affiliates (note 1). At the acquisition date, Emory Healthcare

recorded \$138.2 million of property and equipment (estimated fair value), within the accompanying consolidated statements of financial position.

No cash consideration was paid for the assets and liabilities and a gain of approximately \$195.6 million, representing the fair value of the net assets acquired and liabilities assumed, was recognized by Emory Healthcare in other non-operating activities, net, within the accompanying consolidated statements of activities.

A depreciation study was completed in fiscal year 2025 and the applicable remaining useful lives for certain Emory Healthcare buildings, improvements and equipment were revised beginning as of September 1, 2024. This change in estimate was due to revised useful life assumptions for assets in service. These changes generally increased the remaining useful lives and reduced depreciation expenses by \$27.1 million for fiscal year 2025.

The University has identified asset retirement obligations predominantly from commitments to remove asbestos and lead paint in the University's facilities at the time of major renovation or demolition. The liability was estimated using an inflation rate of 5.0% and a discount rate of 4.25%.

(11) Leases

The University has operating and finance leases for office buildings, research and development facilities, hospital and educational buildings, and certain equipment. Leases have remaining lease terms of 1 year to 25 years, some of which include purchase options or options to extend the leases.

Operating leases except for leases with an initial term of less than 12 months for which the University made the short-term election are included in operating lease right-of-use assets and operating

EMORY UNIVERSITY
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2025 AND 2024

lease liabilities in the accompanying consolidated statements of financial position. Finance leases are included in property, plant, and equipment, net, and finance lease liabilities in the accompanying consolidated statements of financial position.

Operating lease liabilities represent the remaining fixed lease payments discounted to present value, while the right-of-use (ROU) assets include any lease payments made, lease incentives received and are amortized over the term of the lease. Renewal options are excluded from the calculation of lease liabilities unless it is reasonably assured that the renewal option will be exercised. Lease costs associated with operating lease assets are recognized on a straight-line basis within operating expenses over the term of the lease.

Finance lease ROU assets are amortized within operating expenses on a straight-line basis over the shorter of the estimated useful lives of the assets or the lease term. The interest component of a finance lease is included in interest expense and recognized using the effective interest-method over the lease term. Variable lease costs, such as common area maintenance, property taxes, and insurance are expensed as incurred.

Emory has lease agreements with lease and nonlease components. The University elected a practical expedient, primarily for its copier leases, whereby nonlease components are not separated from the lease component. This results in all of the lease and nonlease components being combined, and accounted for, as a single lease component and included in the measurement of the ROU assets and lease liabilities.

The components of lease expense for the year ended August 31 are as follows (in thousands):

	2025	2024
Finance lease cost	\$ 2,444	\$ 2,368
Amortization of ROU assets	1,786	1,686
Interest on lease liabilities	658	682
Operating lease cost	36,688	41,201
Short-term lease cost	26,342	25,518
Total lease expense	\$ 65,474	\$ 69,087

Aggregate future payments under noncancelable operating and finance leases as of August 31, 2025 are as follows (in thousands):

	Operating Leases	Finance Leases
2026	\$ 34,214	1,990
2027	29,195	1,429
2028	24,254	1,214
2029	22,335	1,120
2030	21,221	1,110
Thereafter	91,262	16,138
Total lease payments	222,481	23,001
Less: amounts representing interest	(23,418)	(6,442)
Total obligation	\$ 199,063	16,559

Supplemental cash flow information related to leases for the year ended August 31 is as follows (in thousands):

	2025	2024
Other information		
Cash paid for amounts included in the measurement of lease liabilities		
Operating cash flows from operating leases	\$ 33,926	\$ 35,376
Operating cash flows from finance leases	1,786	1,686
Financing cash flows from finance leases	1,240	1,194
Right-of-use assets obtained in exchange for new lease obligations		
Operating leases	26,658	1,407
Finance leases	1,341	407
Weighted-average remaining lease term -- finance lease	18 years	19 years
Weighted-average remaining lease term -- operating lease	9 years	10 years
Weighted-average discount rate -- finance lease	3.95%	3.93%
Weighted-average discount rate -- operating lease	2.43%	2.21%

Emory is the lessor in a long-term noncancelable operating sublease for space to serve as an expanded point of entry for imaging and surgical cases for Emory Healthcare at its Executive Park property. The lease agreement's underlying asset will continue to be classified as the original lessor's fixed asset.

EMORY UNIVERSITY
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2025 AND 2024

(12) Bonds and Notes Payable

Bonds and notes payable, including unamortized premiums, discounts, and issuance costs, consisted of the following as of August 31 (dollars in thousands):

	Average Interest Rate	Final Maturity	Outstanding Principal	
			2025	2024
Tax-exempt, fixed-rate revenue bonds:				
2025 Series A	5.10%	September 1, 2045	\$ 862,700	\$ –
2023 Series A	5.00	September 1, 2033	142,500	142,500
2023 Series B	5.00	September 1, 2033	234,750	234,750
2022 Series A	5.00	September 1, 2032	212,055	212,055
2020 Series B	4.49	September 1, 2041	351,090	486,470
2019 Series A	5.00	September 1, 2039	181,225	187,085
2019 Series B	5.00	September 1, 2048	39,725	39,725
2016 Series A	4.62	October 1, 2046	130,030	130,030
2016 Series B	4.14	October 1, 2043	183,465	186,770
2013 Series A	5.00	October 1, 2043	177,850	177,850
Total tax-exempt, fixed-rate revenue bonds			2,515,390	1,797,235
Tax-exempt, variable-rate revenue bonds:				
2022 Series B	2.92	September 1, 2052	110,380	110,380
Total tax-exempt, variable-rate revenue bonds			110,380	110,380
Taxable, fixed-rate revenue bonds:				
2020 Series A	2.56	September 1, 2050	799,710	943,750
1994 Series C	0.00	October 1, 2024	–	825
Total taxable, fixed-rate revenue bonds			799,710	944,575
Taxable, variable-rate revenue bonds:				
2022 Series C-1 ⁽¹⁾	4.85	September 1, 2052	110,450	110,450
2022 Series C-2 ⁽¹⁾	4.82	September 1, 2052	110,445	110,445
Total taxable, variable-rate revenue bonds			220,895	220,895
Commercial papers:				
2008 Program 1 - Taxable	4.38	April 1, 2047	250,000	–
Total commercial papers			250,000	–
Unamortized bond premiums			284,513	241,856
Bond issuance costs			(12,875)	(10,662)
Total bonds and notes payable			\$ 4,168,013	\$ 3,304,279

⁽¹⁾ Average reset rates taken from Electronic Municipal Market Access (EMMA), plus credit facility and remarketing fees.

EMORY UNIVERSITY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2025 AND 2024

The University incurred interest expenses of \$113.9 million and \$110.3 million in 2025 and 2024, respectively, net of capitalized interest of \$0.0 million and \$17.5 million in 2025 and 2024, respectively. During 2025, the average interest rate on the University's tax-exempt variable demand bonds, including fees, was 2.92% and the average interest rate on taxable variable bonds, including fees, was 4.84%. Related indices for this period were 2.88% for tax-exempt debt Securities Industry and Financial Markets Association Index (SIFMA), and 4.35% for taxable debt.

As of August 31, 2025 the aggregate annual maturities of bonds and notes payable for the next five years and thereafter are as follows (in thousands):

	2025
PAYABLE IN FISCAL YEAR:	
2026	\$ 11,190
2027	11,825
2028	12,185
2029	12,845
2030	360,290
Thereafter	3,488,040
	3,896,375
Unamortized net premium	284,513
Unamortized net bond issuance costs	(12,875)
	\$ 4,168,013

In June 2025, the University issued \$862.7 million in par value of 2025 Series A bonds and received \$934.4 million in proceeds from the issuance. From the proceeds, \$279.4 million was used to refund par value on the 2020 Series A and 2020 Series B bonds.

The 2008 taxable Commercial Paper program of \$350.0 million had an outstanding balance of \$250.0 million and \$0.0 million as of August 31, 2025 and 2024, respectively, under this program.

The University has three credit facilities to enable the University to purchase tendered variable rate debt in the event of a failed remarketing. It has a direct-pay letter of credit of \$112.0 million supporting the 2022 C-1 bonds of \$110.5 million, a standby bond purchase agreement supporting 2022 C-2 bonds totaling \$110.5 million, and a revolving credit agreement supporting any self-liquidity debt totaling \$175.0 million. These credit facilities are committed for the sole purpose of supporting these debt instruments and cannot be used for operating needs of the University. There were no draws against any of these facilities in 2025 or 2024.

The University has a syndicated line of credit of \$750.0 million that expires in April 2026. During fiscal year 2025, the University borrowed \$575.0 million against the line of credit, which was paid back in full prior to year-end. There is no outstanding balance as of August 31, 2025, and 2024.

The University has a letter of credit with a commercial bank totaling \$1.1 million. There were no outstanding balances as of August 31, 2025 or 2024. The letter of credit agreement expires in March 2026.

The terms of the University's long-term debt provide for certain financial and nonfinancial covenants, including provisions as to the use of the proceeds, limits as to arbitrage and bond issuance costs, and various other administrative requirements.

EMORY UNIVERSITY
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2025 AND 2024

(13) Net Assets

The following is a summary of net assets as of August 31 (in thousands):

	2025			2024		
	Without Donor Restrictions	With Donor Restrictions	Total	Without Donor Restrictions	With Donor Restrictions	Total
Emory undesignated funds	\$ 3,094,577	–	3,094,577	\$ 2,418,671	–	2,418,671
Endowment funds	2,941,700	5,984,529	8,926,229	2,610,644	5,478,198	8,088,842
Investment in plant	907,418	–	907,418	1,261,517	–	1,261,517
Interest in perpetual funds held by others	–	2,050,386	2,050,386	–	2,013,211	2,013,211
Contributions receivable, net	–	122,642	122,642	–	150,498	150,498
Annuity and other split-interest agreements	–	9,741	9,741	–	11,292	11,292
Capital maintenance, infrastructure, and other donor purposes	–	84,052	84,052	–	58,039	58,039
	\$ 6,943,695	8,251,350	15,195,045	\$ 6,290,832	7,711,238	14,002,070

(14) Retirement and Deferred Compensation Plans

The University has a defined-contribution plan under the Code, Section 403(b), covering eligible employees. The University contributes an amount equal to 6% of each eligible employee's compensation to the plan as well as a supplemental contribution of 3% based on a 1.5 to 1 match of employee contributions of up to 2% of compensation. Employer contributions cliff vest after three years of service.

Emory Healthcare sponsors a retirement plan, covering most full-time employees, under which annuities are purchased with contributions made by Emory Healthcare. Benefits to eligible employees were based on a formula defined in the plan. Benefits are paid as a monthly annuity at age 65 or an eligible employee can elect a reduced benefit as early as age 55. The benefits are vested only to the extent of the annuities purchased. Benefits were frozen as of 12/31/2011. Emory Healthcare also has a defined-contribution plan under the Code, Section 403(b), covering eligible employees. Emory Healthcare contributes an amount equal to 2% of each eligible employee's compensation to the plan as well as a supplemental contribution based on a 1 to 1 match of employee contributions of up to 4% for eligible employees with less than 10 years of service and up to 5% for eligible employees with 10 or more years of service. Employer contributions cliff vest after three years of service.

TEC sponsors a defined-contribution plan under the Code, Section 403(b), The Emory Clinic, Inc. Retirement Savings Plan covering eligible employees. TEC contributes an amount equal to 6% of each eligible employee's compensation to the plan as well

as a supplemental contribution of 3% based on a 1.5 to 1 match of employee contributions of up to 2% of compensation. Employer contributions cliff vest after three years of service.

Retirement expenses for these plans totaled \$258.6 million and \$227.5 million during 2025 and 2024, respectively, and are included in fringe benefits expense in the accompanying consolidated statements of activities.

The University sponsors the Code Section 457(b) Deferred Compensation Plan primarily for the purpose of providing deferred compensation for a select group of management or highly compensated employees who are eligible for participation and elect to make salary deferrals under the Deferred Compensation Plan. These assets are fully vested and available to the participating employees at the time of termination of employment from the University. As of August 31, 2025 and 2024, respectively, the University held assets of \$309.6 million and \$270.7 million under the Retirement Plan. These assets are included in other assets, which are designated by the University to pay future salary deferral plan payments. The assets are held in separate investment funds for which the majority are classified as Level 1 in the fair value hierarchy. Associated liabilities for the obligations of \$309.6 million and \$270.7 million as of August 31, 2025 and 2024, respectively, are included in accrued liabilities for benefit obligations and professional liabilities and considered Level 2 in the fair value hierarchy.

(15) Pension Plans – Emory Healthcare

Emory Healthcare sponsors a defined-benefit pension plan (the Plan). The Plan was curtailed effective December 31, 2011. The

EMORY UNIVERSITY
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2025 AND 2024

terms of the curtailment generally provide that no further benefit accrual under the Plan is provided for service after the effective date nor will new entrants into the Plan be permitted after the effective date.

The Plan’s investment objectives related to its defined benefit plan are to protect long-term asset value by applying prudent, low-risk, high-quality investment disciplines and to enhance the values by maximizing investment returns through active security management within the Plan’s investment policy framework. Asset allocation strategies and investment management structure are designed to meet the Plan’s investment objectives.

The Plan’s expected long-term rate of return on assets is determined by reviewing the historical return of each asset category comprising the Plan’s target asset allocation.

The Joint Operating Company (JOC) assumed certain defined-benefit pension liabilities covering certain employees of the entities contributed to the JOC by Saint Joseph’s Health System SJHS (the SJHS Pension Plan). The plan was curtailed, effective December 31, 2011, and the JOC has agreed to provide for funding of the plan, generally over 10 years, beginning in fiscal

year 2015, subject to certain terms and conditions. In March 2025, Emory Healthcare acquired the noncontrolling membership interest of 49% previously held by CHE Trinity Health in the Emory/Saint Joseph’s Inc. (JOC) (note 1). Subsequent to the acquisition of the remaining membership interest, the SJHS Pension Plan was merged into the Plan.

Emory Healthcare, effective with the definitive agreement with HHSI (note 1), assumed certain defined-benefit pension liabilities covering eligible employees of HHSI under the HHSI Pension Plan. The HHSI Pension Plan had been curtailed in 2023 and merged into the Plan effective June 30, 2025.

On December 10, 2025, EHC entered into a group annuity contract covering certain participants of the Plan. Under the terms of the contract, the purchaser has assumed responsibility for paying future benefits to these participants.

The annuity buyout was executed as part of EHC’s ongoing strategy to reduce pension obligations and associated risks. The transaction resulted in the transfer of approximately \$125.0 million of plan assets to the purchaser.

The changes in the projected benefit obligations as of and for the years ended August 31 are as follows (in thousands):

	2025		2024	
	Emory Healthcare		Emory Healthcare	
Projected benefit obligation, beginning of year	\$	445,524	\$	427,798
Interest cost		21,959		23,059
Actuarial (gain) loss		(14,633)		16,237
Benefits paid		(22,882)		(21,570)
Plan combinations		89,983		–
Projected benefit obligation, end of year	\$	519,951	\$	445,524

EMORY UNIVERSITY
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2025 AND 2024

The changes in the fair value of plan assets, funded status of the plans, and the status of amounts recognized in the accompanying consolidated statements of financial position as of and for the years ended August 31 are as follows (in thousands):

	2025		2024	
	Emory Healthcare		Emory Healthcare	
Fair Value of plan assets, beginning of year	\$	408,449	\$	390,070
Actual return on plan assets		12,694		39,374
Employer contributions		2,116		575
Benefits paid		(22,882)		(21,570)
Plan combinations		92,865		–
Fair value of plan assets, end of year	\$	493,242	\$	408,449
Funded status - accrued pension cost recognized in the consolidated statements of financial position	\$	(26,709)	\$	(37,075)

The components of net periodic pension cost for the years ended August 31 are as follows (in thousands):

	2025		2024	
	Emory Healthcare		Emory Healthcare	
Interest cost	\$	21,959	\$	23,059
Expected return on assets		(22,579)		(21,064)
Amortization of prior service cost		(438)		(438)
Amortization of net loss		2,146		1,898
Net periodic pension cost	\$	1,088	\$	3,455

Net periodic pension costs are recognized as employees render the services necessary to earn the pension benefits.

EMORY UNIVERSITY
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2025 AND 2024

Weighted average assumptions used to determine benefit obligations in the accompanying consolidated statements of financial position as of August 31 are as follows:

	2025	2024
	Emory Healthcare	Emory Healthcare ⁽¹⁾
Discount rate	5.58%	5.25%
Expected long-term rate of return on plan assets	5.00	4.50

⁽¹⁾ In 2024 the discount rate and expected long-term rate of return on plan assets for the SJHS plan were 5.21% and 5.95%, respectively.

Weighted average assumptions used to determine net periodic pension cost for the years ended August 31 are as follows:

	2025	2024
	Emory Healthcare	Emory Healthcare ⁽¹⁾
Discount rate	5.25%	5.56%
Expected long-term rate of return on plan assets	5.00	4.50

⁽¹⁾ In 2024 the discount rate and expected long-term rate of return on plan assets for the SJHS plan were 5.55% and 5.95%, respectively.

The following tables summarize the plan assets, which are recorded at fair value as of August 31 as follows (in thousands):

	2025					
	Emory Healthcare	Fair Value Hierarchy			Total Fair Value	Target Allocation ⁽¹⁾
		Level 1	Level 2	NAV		
INVESTMENTS:						
Short-term investments and cash equivalents	\$ 21,126	21,126	–	–	21,126	—%
Public equity	169,995	273	169,722	–	169,995	64
Absolute return	16,249	–	–	16,249	16,249	4
Private equity/venture capital	13,675	–	–	13,675	13,675	2
Fixed income	272,197	–	272,197	–	272,197	30
Total investments	\$ 493,242	21,399	441,919	29,924	493,242	100%

EMORY UNIVERSITY
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2025 AND 2024

2024

	Emory Healthcare	Fair Value Hierarchy			NAV	Total Fair Value	Target Allocation ⁽¹⁾
		Level 1	Level 2				
INVESTMENTS:							
Short-term investments and cash equivalents	\$ 5,029	5,006	23	–	5,029	—%	
Public equity	110,981	1,427	101,353	8,201	110,981	64	
Absolute return	15,668	–	–	15,668	15,668	4	
Private equity/venture capital	15,207	–	–	15,207	15,207	2	
Fixed income	261,564	–	230,328	31,236	261,564	30	
Total investments	\$ 408,449	6,433	331,704	70,312	408,449	100%	

⁽¹⁾ While each plan has an individual target asset allocation, the percentage represents the averages for all plans assets.

Cash Flows

Emory Healthcare does not expect to contribute to the Emory Healthcare Pension Plan during fiscal year 2026.

Expected Future Benefit Payments

Emory Healthcare annual future benefit payments, excluding lump-sum settlements, are expected to range from \$32.7 million to \$37.5 million for the next five years.

Other Items

Emory Healthcare uses the straight-line method to amortize prior service cost for both plans.

(16) Postretirement Healthcare and Life Insurance Benefits

The University sponsors a postretirement life insurance and healthcare benefits plan. Participants hired after 2002 pay the full retiree-specific premium equivalent and are therefore assumed to pay the full cost of their coverage. The University and Emory Healthcare each fund a separate trust (VEBA Trust) for retiree health and life benefits. The assets of the VEBA Trust are invested primarily in equity and fixed-income securities. The University funds these benefits only to the extent of current retiree claims. The University measures its participation in the VEBA Trust at August 31 each fiscal year.

EMORY UNIVERSITY
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2025 AND 2024

The changes in the accumulated postretirement benefit obligation (APBO) as of August 31 are as follows (in thousands):

	2025			2024	
	Emory University	Emory Healthcare	Total	Total	
APBO, beginning of year	\$ 100,006	53,595	153,601	\$	144,651
Service cost	648	152	800		814
Interest cost	4,889	2,597	7,486		7,781
Actuarial loss (gains)	110	(2,126)	(2,016)		7,775
Benefits paid	(5,498)	(3,271)	(8,769)		(7,420)
APBO, end of year	\$ 100,155	50,947	151,102	\$	153,601

The discount rate to determine APBO as of August 31, 2025 and 2024 was 5.65% and 5.27%, respectively.

The changes in the fair value of plan assets, funded status of the plan, and the status of the accrued postretirement benefit obligation recognized in the accompanying consolidated statements of financial position as of and for the years ended August 31 are as follows (in thousands):

	2025			2024	
	Emory University	Emory Healthcare	Total	Total	
Fair value of plan assets, beginning of year	\$ 103,395	15,547	118,942	\$	105,472
Actual return on plan assets	3,276	1,362	4,638		15,843
Benefits paid from plan assets	–	(539)	(539)		(2,373)
Fair value of plan assets, end of year	\$ 106,671	16,370	123,041	\$	118,942
Funded status – accrued postretirement benefit cost recognized in the consolidated statements of financial position	\$ 6,516	(34,577)	(28,061)	\$	(34,659)

The components of net periodic postretirement benefit cost for the years ended August 31 are as follows (in thousands):

	2025			2024	
	Emory University	Emory Healthcare	Total	Total	
Service cost of benefits earned	\$ 648	152	800	\$	814
Interest cost on APBO	4,889	2,597	7,486		7,781
Expected return on plan assets	(6,410)	(876)	(7,286)		(6,757)
Recognized net actuarial loss	688	–	688		964
Net periodic postretirement benefit cost	\$ (185)	1,873	1,688	\$	2,802

The discount rate and expected return on plan assets used to determine net periodic postretirement benefit cost for the years ended August 31, 2025 and 2024 were 5.27% and 5.56%, respectively, and 6.20% and 6.50%, respectively.

EMORY UNIVERSITY
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2025 AND 2024

The amounts accumulated in net assets without donor restrictions follow as of August 31 (in thousands):

	2025			2024	
	Emory University	Emory Healthcare	Total	Total	Total
Net unrecognized actuarial loss	\$ (22,526)	(2,207)	(24,733)	\$	24,789
Total	\$ (22,526)	(2,207)	(24,733)	\$	24,789

In fiscal year 2026, there is no gain or loss expected to be amortized for Emory University or for Emory Healthcare from net assets without donor restrictions into net periodic postretirement benefit cost.

Plan Assets

The Investment Committee of Emory University’s Board of Trustees approves the investment guidelines and asset allocation targets for the pension benefits and postretirement benefits plans. The primary objective of the investments is to ensure the solvency of the plans over time to meet plan obligations.

The secondary objective is to meet or exceed the plans’ actuarial assumed rate of return over time without taking excess risk. The funds are diversified by asset class in accordance with established allocation targets and rebalanced as needed. Specific investments are apportioned to a combination of institutional pooled funds and mutual funds.

The following table summarizes the VEBA Trust assets for the University and Emory Healthcare as of August 31 (in thousands):

	2025					Target Allocation ⁽¹⁾
	Total Fair Value	Fair Value Hierarchy		NAV		
		Level 1	Level 2			
Fixed income	\$ 67,856	13,691	54,165	–	56%	
Public equity	33,215	–	31,266	1,949	30	
Absolute return	12,360	5,467	–	6,893	9	
Private equity/venture capital	5,095	–	–	5,095	5	
Short-term investment and cash equivalent	4,515	4,515	–	–	–	
Total investments	\$ 123,041	23,673	85,431	13,937	100%	

	2024					Target Allocation ⁽¹⁾
	Total Fair Value	Fair Value Hierarchy		NAV		
		Level 1	Level 2			
Fixed income	\$ 58,729	603	58,083	43	55%	
Public equity	41,818	–	38,362	3,456	30	
Absolute return	11,972	5,560	–	6,412	10	
Private equity/venture capital	5,661	–	–	5,661	5	
Short-term investment and cash equivalent	762	762	–	–	–	
Total investments	\$ 118,942	6,925	96,445	15,572	100%	

⁽¹⁾ While each plan has an individual target asset allocation, the percentage represents the averages for all plans assets.

EMORY UNIVERSITY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2025 AND 2024

Cash Flows

Emory University and Emory Healthcare expect to contribute \$0.0 million and \$3.2 million, respectively, to the postretirement benefit plan during fiscal year 2026.

Expected Future Benefit Payments

Annual future benefit payments are expected to range from \$5.9 million to \$6.5 million for Emory University and from \$3.2 million to \$3.6 million for Emory Healthcare for the next five years.

(17) Functional Expenses

The accompanying consolidated statements of activities present expenses by natural classification. The University also summarizes expenses by functional classification, in accordance with its mission. The University's primary program services are instruction, research, public service, and the delivery of healthcare and medical services. Expenses for academic support, institutional support, and independent operations/auxiliary enterprises are generally incurred in support of these primary program activities, with academic support being related to student financial aid. Capital and plant expenditures, costs for operation and maintenance of plant, interest on indebtedness, and depreciation and amortization are allocated using a variety of cost allocation techniques, such as square footage and time and effort.

The accompanying consolidated statements of activities include the following functional expenses for the years ended August 31 (in thousands, net of the cost allocations and recharges referenced above):

		2025				
		Instruction and Academic Support	Research and Public Service	Non-Academic Operations ⁽¹⁾	Healthcare and Medical Services ⁽²⁾	Total
Salaries	\$	520,394	480,218	365,958	3,898,879	5,265,449
Fringe benefits		138,395	135,297	79,216	906,243	1,259,151
Student financial aid		26,697	–	–	–	26,697
Other operating expenses		150,060	388,708	1,156	2,993,688	3,533,612
Interest on indebtedness		10,146	11,434	18,447	73,865	113,892
Depreciation and amortization		61,341	74,598	51,938	191,281	379,158
Total expenses	\$	907,033	1,090,255	516,715	8,063,956	10,577,959

⁽¹⁾ Non-Academic Operations includes \$277.5 million of institutional support and \$239.2 million of independent operations and auxiliary enterprises.

⁽²⁾ Healthcare and Medical Services – The portion of patient care services related to Emory Healthcare expense is \$7.6 billion. Healthcare administrative costs are \$959.9 million, included therein.

EMORY UNIVERSITY
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2025 AND 2024

2024						
		Instruction and Academic Support	Research and Public Service	Non-Academic Operations ⁽¹⁾	Healthcare and Medical Services ⁽²⁾	Total
Salaries	\$	493,873	453,234	333,865	3,391,158	4,672,130
Fringe benefits		126,704	119,777	92,303	741,865	1,080,649
Student financial aid		24,248	–	–	–	24,248
Other operating expenses		168,372	417,479	20,048	2,607,650	3,213,549
Interest on indebtedness		8,575	9,663	15,484	76,564	110,286
Depreciation and amortization		59,748	72,690	50,714	215,027	398,179
Total expenses	\$	881,520	1,072,843	512,414	7,032,264	9,499,041

⁽¹⁾ Non-Academic Operations includes \$301.1 million of institutional support and \$211.3 million of independent operations and auxiliary enterprises.

⁽²⁾ Healthcare and Medical Services – The portion of patient care services related to Emory Healthcare expense is \$6.7 billion. Healthcare administrative costs are \$759.6 million, included therein.

Costs related to the University’s operation and maintenance of property, including depreciation of property and equipment and interest on related debt, are allocated to program and supporting activities based upon information reported in the space study and debt financing records. Fundraising costs were approximately \$61.2 million and \$60.0 million in 2025 and 2024, respectively.

(18) Medical Professional and General Liability Insurance Coverage

CCIC, Emory Healthcare’s wholly owned offshore captive insurer, provides claims-made primary and some excess medical professional and general liability coverage for the University, the Hospitals, Emory Clinic, Emory Specialty Associates, and Wesley Woods Center.

As of August 31, 2025 and 2024, the University has recorded an accrual for estimated losses associated with all retained CCIC risks of approximately \$492.8 million (discounted at 3.5%) and \$382.9 million (discounted at 2.5%), respectively.

Emory has purchased layered excess and umbrella reinsurance coverage beyond the primary and buffer layers retained by CCIC, through various carriers, for a grand total of \$232.0 million per claim and in the aggregate for the full program.

The estimated liability for professional and general liability claims will be significantly affected if current and future claims differ from historical trends. While the University monitors reported claims closely and considers potential outcomes as estimated by its actuaries when determining its professional and general liability accruals, the complexity of the claims, the extended period of time to settle the claims, and the wide range of potential outcomes complicate the estimation. The

University’s management believes adequate provision has been made for the related risk.

(19) Related-Party Transactions

The Carter Center, Inc. (CCI) is a nonprofit corporation founded by former U.S. President Jimmy Carter and Rosalynn Carter, which sponsors various domestic and international programs. The Board of Trustees of CCI is comprised of between 14 and 26 members of which half are elected by the University, including the University’s president, and half, one of which shall be a lineal descendant of President and Mrs. Carter, are elected by the Carter Center class trustees. The University’s Board of Trustees has the authority to approve amendments to CCI’s articles of incorporation and bylaws. Funds held in trust for others include \$1.2 billion and \$1.1 billion, representing CCI’s investment in the University’s long-term investment portfolio as of August 31, 2025 and 2024, respectively. CCI is permitted partial withdrawals of up to 10% per year (inclusive of regular spending payouts), with 30 days’ written notice prior to a calendar quarter or fiscal year end. A full withdrawal request by CCI requires at least one year’s written notice and is subject to a multi-year distribution schedule in line with the duration of the long-term investment portfolio, as agreed upon by both CCI and the University.

Emory University and Children’s Healthcare of Atlanta, Inc. (Children’s), a Georgia nonprofit corporation, established the Emory + Children’s Pediatric Institute (the Institute) effective September 1, 2018 under a Master Affiliation Agreement (the affiliation agreement). Under the terms of the affiliation agreement, approximately 350 Emory University School of Medicine Department of Pediatrics faculty physicians and PhD researchers transferred to the Institute and became employees

EMORY UNIVERSITY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

AUGUST 31, 2025 AND 2024

thereof. The affiliation agreement restructured previous arrangements between the parties for pediatric teaching, research, and related clinical services. The ownership of the Institute is 50% Emory University and 50% Children's, with equal representation on the governing board. The funding obligations of each party are specified by the affiliation agreement, and each party funds its mission-related expenses. The University reports research and teaching expenses provided by the faculty members in salaries, fringe benefits, professional fees and purchased services, and other operating expenses in the accompanying consolidated statements of activities.

(20) Commitments and Contingencies

Purchase Commitments

Emory University and Emory Healthcare are in the process of constructing, renovating, and equipping certain facilities for which the outstanding commitments at August 31, 2025 totaled \$112.3 million and \$103.8 million, respectively.

Federal and State Regulatory Matters

Expenditures and indirect costs related to federal and state grants and contracts are subject to adjustment based upon review by the granting agencies. The amounts, if any, of expenditures which may be disallowed by the granting agencies, are not expected to have a material effect on the University's consolidated financial statements.

The University is subject to many federal and state regulations, and as a result, there may be one or more pending government investigations ongoing at any time. While the outcome of these actions is not presently determinable, it is the opinion of management that any resulting liability from these actions will not have a material adverse effect on the accompanying consolidated statements of financial position.

Current Regulatory Environment

The University receives significant funding from federal sources, including student financial aid, research grants, and other sponsored programs, as well as Medicare and Medicaid related to patient services. The University is monitoring and assessing the potential impact of proposed legislation, administration actions, and judicial decisions that may affect the higher education and health care sectors. Changes in the federal regulatory environment may impact the availability, timing and terms of federal funding and could have a material impact on the University's financial position.

Laws and regulations governing federal programs, including Medicare and Medicaid, are complex and subject to interpretation. Compliance with such laws and regulations is subject to future government review and interpretation as well as significant regulatory action, including fines, penalties, and exclusion from Federal programs. The University, through its internal processes and various compliance programs, seeks to ensure compliance with the applicable laws and regulations, and to promptly rectify instances of noncompliance with governmental program rules.

While the ultimate outcome of these matters cannot be predicted, the University believes it is taking appropriate steps to mitigate associated risks.

Other Legal Matters

Lawsuits and claims have been filed against the University in the ordinary course of business. As one of the nation's largest research universities and academic medical centers, the University has active litigation that takes several forms. The University's policy is to accrue for litigation and claims when such amounts are probable and can be reasonably estimated based on consultation with external legal counsel and Emory General Counsel. The University also has a comprehensive program of primary and excess insurance.

(21) Subsequent Events

Emory has evaluated subsequent events after the accompanying consolidated statements of financial position date of August 31, 2025 through December 12, 2025, the date the consolidated financial statements were issued. In November 2025, the University finalized the purchase of the land and buildings that were formerly known as the Egleston Children's Hospital, located on the University's campus. Consideration paid for the assets acquired was approximately \$57.5 million. Additionally, upon acquisition, the University expects to demolish the existing structure at an estimated cost of \$50.0 million and will record these additional costs as property and equipment. Other than this matter, there are no other items to disclose that would have a material impact on the University's accompanying consolidated statements of financial position.



KPMG LLP
Suite 2000
303 Peachtree Street, N.E.
Atlanta, GA 30308-3210

**Independent Auditors' Report on Internal Control Over Financial Reporting and on
Compliance and Other Matters Based on an Audit of Financial Statements Performed in
Accordance With Government Auditing Standards**

The Board of Trustees
Emory University:

We have audited, in accordance with the auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards* issued by the Comptroller General of the United States, the consolidated financial statements of Emory University and its subsidiaries (the University) which comprise the University's consolidated statement of financial position as of August 31, 2025, and the related consolidated statements of activities, and cash flows for the year then ended, and the related notes to the consolidated financial statements, and have issued our report thereon dated December 12, 2025.

Report on Internal Control Over Financial Reporting

In planning and performing our audit of the consolidated financial statements, we considered the University's internal control over financial reporting (internal control) as a basis for designing audit procedures that are appropriate in the circumstances for the purpose of expressing our opinion on the consolidated financial statements, but not for the purpose of expressing an opinion on the effectiveness of the University's internal control. Accordingly, we do not express an opinion on the effectiveness of the University's internal control.

A deficiency in internal control exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, misstatements on a timely basis. A material weakness is a deficiency, or a combination of deficiencies, in internal control, such that there is a reasonable possibility that a material misstatement of the entity's financial statements will not be prevented, or detected and corrected, on a timely basis. A significant deficiency is a deficiency, or a combination of deficiencies, in internal control that is less severe than a material weakness, yet important enough to merit attention by those charged with governance.

Our consideration of internal control was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control that might be material weaknesses or significant deficiencies. Given these limitations, during our audit we did not identify any deficiencies in internal control that we consider to be material weaknesses. However, material weaknesses or significant deficiencies may exist that were not identified.

Report on Compliance and Other Matters

As part of obtaining reasonable assurance about whether the University's consolidated financial statements are free from material misstatement, we performed tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements, noncompliance with which could have a direct and material effect on the financial statements. However, providing an opinion on compliance with those provisions was not an objective of our audit, and accordingly, we do not express such an opinion. The results of our tests disclosed no instances of noncompliance or other matters that are required to be reported under *Government Auditing Standards*.



Purpose of This Report

The purpose of this report is solely to describe the scope of our testing of internal control and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the University's internal control or on compliance. This report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the University's internal control and compliance. Accordingly, this communication is not suitable for any other purpose.

KPMG LLP

Atlanta, Georgia
December 12, 2025

**SUPPLEMENTARY SCHEDULE OF EXPENDITURES OF
FEDERAL AWARDS**

EMORY UNIVERSITY AND ITS SUBSIDIARIES
Supplementary Schedule of Expenditures of Federal Awards
Year ended August 31, 2025

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Research and Development Cluster:				
U.S. Department of Agriculture				
Agricultural Research Basic and Applied Research	58-6040-022	10.001	\$ —	7,942
Pass-through Georgia State University	59-0204-4-006	10.001	—	12,023
Total AL No. 10.001			—	19,965
Wholesale Farmers and Alternative Market Development	22-TMMSD-GA-0009	10.164	1,738	37,222
Pass-through Michigan State University	AM230300WAMSC013	10.164	6,310	16,856
Total AL No. 10.164			8,048	54,078
Sustainable Agriculture Research and Education				
Pass-through University of Georgia	20213864034724	10.215	19,351	108,334
Total AL No. 10.215			19,351	108,334
Agriculture and Food Research Initiative (AFRI)	2019-67013-29371	10.310	—	(15,408)
Agriculture and Food Research Initiative (AFRI)	20196701729642	10.310	—	(49)
Agriculture and Food Research Initiative (AFRI)	20226701336133	10.310	428	31,844
Agriculture and Food Research Initiative (AFRI)	20236701240012	10.310	—	81,178
Agriculture and Food Research Initiative (AFRI)	20246701243746	10.310	—	85,525
Agriculture and Food Research Initiative (AFRI)	20246701742441	10.310	53,651	150,622
Pass-through Mississippi State University	2021-67016-34571	10.310	—	1,185
Pass-through Texas Agricultural and Mechanical Univ	20226701536335	10.310	—	24,450
Pass-through University of Minnesota	20216702334488	10.310	56,962	107,081
Pass-through University of Pittsburgh	20206701733075	10.310	—	5,357
Pass-through Virginia Tech	20246801642391	10.310	—	11,649
Total AL No. 10.310			111,041	483,434
Partnerships for Climate-Smart Commodities				
Pass-through Rodale Institute	RI-CS04172023-100-Emory	10.937	—	(117,252)
Total AL No. 10.937			—	(117,252)
Contract				
Pass-through Florida Organic Growers	23-NOPXX-FL-0001	10.RD	—	1,844
Total AL No. 10.CTR			—	1,844
U.S. Department of Agriculture Total			138,440	550,403
U.S. Department of Defense				
Basic and Applied Scientific Research	N000142412221	12.300	—	99,244
Total AL No. 12.300			—	99,244
Military Construction, National Guard				
Pass-through Ecog-Acrin Medical Research Foundation	HT94252310572	12.400	—	130,005
Total AL No. 12.400			—	130,005
Military Medical Research And Development	HT94252310006	12.420	—	33,633
Military Medical Research And Development	HT94252310007	12.420	—	53,651
Military Medical Research And Development	HT94252310048	12.420	—	254,839
Military Medical Research And Development	HT94252310134	12.420	—	3,217

EMORY UNIVERSITY AND ITS SUBSIDIARIES
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2025

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Military Medical Research And Development	HT94252310192	12.420	\$ —	179,214
Military Medical Research And Development	HT94252310193	12.420	—	192,012
Military Medical Research And Development	HT94252310318	12.420	142,430	392,374
Military Medical Research And Development	HT94252310420	12.420	—	668,432
Military Medical Research And Development	HT94252310525	12.420	9,473	270,675
Military Medical Research And Development	HT9425-23-1-0609	12.420	—	109,547
Military Medical Research And Development	HT94252310984	12.420	—	265,766
Military Medical Research And Development	HT94252410095	12.420	—	138,445
Military Medical Research And Development	HT94252410317	12.420	—	150,064
Military Medical Research And Development	HT94252410920	12.420	—	247,800
Military Medical Research And Development	HT94252510125	12.420	—	34,563
Military Medical Research And Development	HT94252510488	12.420	—	3,427
Military Medical Research And Development	HT94252510698	12.420	—	10,472
Military Medical Research And Development	S352L5PJLMP8	12.420	—	327,612
Military Medical Research And Development	W81XWH2010118	12.420	—	426,017
Military Medical Research And Development	W81XWH2010851	12.420	204,637	481,035
Military Medical Research And Development	W81XWH2110160	12.420	2,547	27,368
Military Medical Research And Development	W81XWH2110237	12.420	9,382	133,761
Military Medical Research And Development	W81XWH2110548	12.420	—	603,096
Military Medical Research And Development	W81XWH2210073	12.420	—	(247)
Military Medical Research And Development	W81XWH2210125	12.420	—	253,379
Military Medical Research And Development	W81XWH2210236	12.420	—	(916)
Military Medical Research And Development	W81XWH2210338	12.420	36,965	72,906
Military Medical Research And Development	W81XWH2210572	12.420	38,632	115,670
Military Medical Research And Development	W81XWH2210922	12.420	—	627,241
Military Medical Research And Development	W81XWH2211040	12.420	70,312	113,293
Pass-through Columbia University	HT9425-24-1-0958	12.420	—	89,282
Pass-through Dana Farber Cancer Institute	W81HWH2110098	12.420	—	176,729
Pass-through Fred Hutchinson Research Center	HT94252311028	12.420	—	10,950
Pass-through Georgia Institute of Technology	W81XWH-20-1-0649	12.420	—	(3,845)
Pass-through Henry M Jackson Foundation	HT9425230022	12.420	—	32,556
Pass-through Public Health Institute	S352L5PJLMP8	12.420	—	252
Pass-through Rutgers The State University	HT9425-23-1-0809	12.420	—	79,854
Pass-through University of Georgia	HT94252410734	12.420	—	27,098
Pass-through University of Maryland, Baltimore	066469933	12.420	—	27,024
Pass-through University of Michigan	W81XWH2010336	12.420	—	98
Pass-through University of Pennsylvania	W81XWH2210151	12.420	—	23,499
Pass-through University of Texas Houston	HT94252510662	12.420	—	2,283
Pass-through University of Washington Saint Louis	W81XWH2210665	12.420	—	19,722
Pass-through Veterans Medical Research Foundation	HT94252310669	12.420	—	26,889
Total AL No. 12.420			<u>514,378</u>	<u>6,700,737</u>
Basic Scientific Research	W911NF-13-1-0182	12.431	—	196
Total AL No. 12.431			<u>—</u>	<u>196</u>
Basic, Applied, and Advanced Research in Science and Engineering	FA95502210259	12.630	—	134,588
Pass-through University of Maryland, Baltimore			<u>—</u>	<u>134,588</u>
Total AL No. 12.630			<u>—</u>	<u>134,588</u>

EMORY UNIVERSITY AND ITS SUBSIDIARIES
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2025

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Uniformed Services University Medical Research Projects				
Pass-through Henry M Jackson Foundation	HU000012320030	12.750	\$ —	103,913
Pass-through Henry M Jackson Foundation	HU00011920125	12.750	—	6,017
Pass-through Henry M Jackson Foundation	HU00012220063	12.750	—	6,881
Pass-through Henry M Jackson Foundation	HU0001-23-2-0037	12.750	—	2,043,199
Total AL No. 12.750			—	2,160,010
Air Force Defense Research Sciences Program	FA95501810420	12.800	625,051	703,379
Air Force Defense Research Sciences Program	FA95502310321	12.800	—	100,013
Air Force Defense Research Sciences Program	FA95502310727	12.800	68,491	206,642
Pass-through Clemson University	FA9550-23-1-0153	12.800	—	52,014
Pass-through Georgia Institute of Technology	FA9550-09-1-0162	12.800	—	(9,779)
Pass-through Rice University	FA9550-24-1-0178	12.800	—	215,000
Pass-through University of Dayton	FA8651-24-F-B013	12.800	—	229,577
Total AL No. 12.800			693,542	1,496,846
Research and Technology Development				
Pass-through Georgia Institute of Technology	HR0011-19-2-0008	12.910	—	1,966,980
Pass-through Stanford University	W911NF2320019	12.910	—	542,822
Pass-through University of Pennsylvania	N66001-14-2-4-31	12.910	—	625
Total AL No. 12.910			—	2,510,427
Contract	0011751760	12.RD	—	176,347
Contract	HR00112590020	12.RD	621,563	3,260,311
Contract	HT94252410875	12.RD	—	136,694
Contract	W81XWH22D0013	12.RD	—	74,849
Pass-through Adv Tech Intl Med Cbrn Defense Consort	2020-467	12.RD	734,063	4,348,577
Pass-through Georgia Institute of Technology	N6600122C4012	12.RD	—	(349,122)
Pass-through Grady Health System	W31P4Q-18-D-0002	12.RD	—	224,146
Pass-through Henry M Jackson Foundation	D20AC00002-11	12.RD	—	39,709
Pass-through Morehouse School of Medicine	TP210410	12.RD	—	70,760
Pass-through University of Dayton	FA8651-20-F-1024	12.RD	—	18,724
Pass-through University of Georgia	HT94252410973	12.RD	—	10,406
Pass-through University of North Carolina Chapel Hill	W81XWH22C0122	12.RD	—	327,151
Pass-through Weill Cornell Medical College	15060932	12.RD	—	(92)
Total AL No. 12.CTR			1,355,626	8,338,460
U.S. Department of Defense Total			2,563,546	21,570,513
U.S. Department of Housing and Urban Development				
Lead Technical Studies Grants	GALTS0029-24	14.902	—	61,701
Total AL No. 14.902			—	61,701
U.S. Department of Housing and Urban Development Total			—	61,701

EMORY UNIVERSITY AND ITS SUBSIDIARIES
Supplementary Schedule of Expenditures of Federal Awards
Year ended August 31, 2025

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
U.S. Department of the Interior Great Lakes Restoration	F22AC02246	15.662	\$ 68,270	108,658
Total AL No. 15.662			<u>68,270</u>	<u>108,658</u>
Cooperative Research and Training Programs – Resources of the National Park System				
Pass-through Natl Assoc Tribal Historic Preservation	P23AC0235	15.945	—	104,613
Total AL No. 15.945			<u>—</u>	<u>104,613</u>
U.S. Department of the Interior Total			<u>68,270</u>	<u>213,271</u>
U.S. Department of Justice Community-Based Violence Intervention and Prevention Initiative	15PBJA-23-GG-05206-CVIP	16.045	626,380	698,513
Total AL No. 16.045			<u>626,380</u>	<u>698,513</u>
National Institute of Justice Research, Evaluation, and Development Project Grants Pass-through George Mason University	2019-R2-CX-0005	16.560	—	72,627
Total AL No. 16.560			<u>—</u>	<u>72,627</u>
U.S. Department of Justice Total			<u>626,380</u>	<u>771,140</u>
U.S. Department of State Academic Exchange Programs – Hubert H. Humphrey Fellowship Program				
Pass-through Institute of International Education	S-ECAGD-24-CA-0003	19.010	—	64,986
Pass-through Institute of International Education	S-ECAGD-25-CA-0011	19.010	—	2,171
Total AL No. 19.010			<u>—</u>	<u>67,157</u>
Contract Pass-through Health Through Walls	HTW09202002	19.RD	—	(22,302)
Total AL No. 19.RD			<u>—</u>	<u>(22,302)</u>
U.S. Department of State Total			<u>—</u>	<u>44,855</u>
U.S. Department of Transportation Highway Research and Development Program				
Pass-through University of Michigan	693JJ31950003	20.200	—	34,429
Total AL No. 20.200			<u>—</u>	<u>34,429</u>
National Priority Safety Programs Pass-through Governors Office of Highway Safety	69A3752330000405BGAH	20.616	—	264,741
Total AL No. 20.616			<u>—</u>	<u>264,741</u>
Contract Contract	693JJ922D000025	20.RD	28,752	696,209
Pass-through University of Michigan	693JJ923F000252	20.RD	73,372	76,867
Pass-through University of Michigan	693JJ921D000021	20.RD	—	36,336
Pass-through University of Michigan	DTNH2215D00017/693JJ918F000234	20.RD	—	25,400
Total AL No. 20.CTR			<u>102,124</u>	<u>834,812</u>
U.S. Department of Transportation Total			<u>102,124</u>	<u>1,133,982</u>

EMORY UNIVERSITY AND ITS SUBSIDIARIES
Supplementary Schedule of Expenditures of Federal Awards
Year ended August 31, 2025

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
National Aeronautics and Space Administration:				
Science	80NSSC20K0309	43.001	\$ —	1,067
Science	80NSSC21K0507	43.001	54,398	216,365
Science	80NSSC22K0292	43.001	—	35,551
Science	80NSSC25K7032	43.001	—	72,880
Pass-through California Institute of Technology	1588347	43.001	—	407,775
Pass-through California Institute of Technology	80NM0018D0004	43.001	—	114,158
Pass-through National Institute of Aerospace	80NSSC21K0514	43.001	—	68,819
Pass-through Spelman College	80NSSC23K0028	43.001	—	24,477
Pass-through University of Florida	80NSSC25K7190	43.001	—	24,479
Pass-through University of Georgia	80NSSC22K1167	43.001	—	70,874
Pass-through University of Texas Houston	80NSSC24K0913	43.001	—	22,301
Total AL No. 43.001			<u>54,398</u>	<u>1,058,746</u>
Aeronautics				
Pass-through California Institute of Technology	NMO710860	43.002	—	37,615
Total AL No. 43.002			<u>—</u>	<u>37,615</u>
Exploration				
Pass-through California Institute of Technology	80NSSC21K0251	43.003	—	21,670
Total AL No. 43.003			<u>—</u>	<u>21,670</u>
Contract				
Pass-through Harvard University	1AYSAX000005-01	43.RD	—	301,226
Total AL No. 43.002			<u>—</u>	<u>301,226</u>
National Aeronautics and Space Administration Total			<u>54,398</u>	<u>1,419,257</u>
National Endowment for Humanities				
Promotion of the Arts Grants to Organizations and Individuals	1925601-38-24	45.024	—	50,000
Total AL No. 45.024			<u>—</u>	<u>50,000</u>
National Endowment for Humanities				
Promotion of the Humanities Division of Preservation and Access	PW-277494-21	45.149	350	31,802
Total AL No. 45.149			<u>350</u>	<u>31,802</u>
Promotion of the Humanities Fellowships and Stipends	FZ-292502-23	45.160	—	60,000
Total AL No. 45.160			<u>—</u>	<u>60,000</u>
Promotion of the Humanities Research	PW-296882-24	45.161	—	35,800
Promotion of the Humanities Research	RZ-292797-23	45.161	—	29,493
Pass-through University of Wisconsin-Madison	RZ-292847-24	45.161	—	4,758
Total AL No. 45.161			<u>—</u>	<u>70,051</u>
Promotion of the Humanities Office of Digital Humanities	DOI-299554-24	45.169	—	23,736
Promotion of the Humanities Office of Digital Humanities	HAA-301046-24	45.169	—	21,426
Total AL No. 45.169			<u>—</u>	<u>45,162</u>
National Endowment for the Humanities Total			<u>350</u>	<u>257,015</u>

EMORY UNIVERSITY AND ITS SUBSIDIARIES
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2025

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
National Science Foundation				
Engineering	1818476	47.041	\$ —	130
Engineering	2002815	47.041	—	(4,337)
Engineering	2005786	47.041	—	(2,322)
Engineering	2044657	47.041	—	70,286
Engineering	2231857	47.041	—	104,123
Engineering	2306371	47.041	—	157,892
Engineering	2326144	47.041	—	124,116
Engineering	2326931	47.041	—	12,036
Engineering	2333224	47.041	—	96,110
Engineering	2430423	47.041	69,811	138,543
Engineering	2448290	47.041	—	5,770
Engineering	2127509	47.041	—	2,616
Pass-through Amer Society For Engineering Education	UA-2019-0921	47.041	—	84,264
Pass-through Center for the Advancement of Science In Space	EEC-1648035	47.041	—	76,990
Pass-through Georgia Institute of Technology			—	—
Total AL No. 47.041			69,811	866,217
Mathematical And Physical Sciences	1700982	47.049	—	2,576
Mathematical And Physical Sciences	1751636	47.049	—	3,636
Mathematical And Physical Sciences	1905782	47.049	—	(876)
Mathematical And Physical Sciences	1951682	47.049	—	(90)
Mathematical And Physical Sciences	1956154	47.049	—	39
Mathematical And Physical Sciences	2010524	47.049	—	11,671
Mathematical And Physical Sciences	2012686	47.049	—	32,477
Mathematical And Physical Sciences	2014173	47.049	—	1,838
Mathematical And Physical Sciences	2015540	47.049	—	1,988
Mathematical And Physical Sciences	2026841	47.049	—	809
Mathematical And Physical Sciences	2038118	47.049	—	272,917
Mathematical And Physical Sciences	2051019	47.049	—	(483)
Mathematical And Physical Sciences	2055579	47.049	—	84,523
Mathematical And Physical Sciences	2108290	47.049	—	11,030
Mathematical And Physical Sciences	2108774	47.049	—	(3,903)
Mathematical And Physical Sciences	2113350	47.049	—	343,233
Mathematical And Physical Sciences	2143815	47.049	—	123,075
Mathematical And Physical Sciences	2146260	47.049	—	165,760
Mathematical And Physical Sciences	2152661	47.049	—	34,741
Mathematical And Physical Sciences	2205266	47.049	—	466
Mathematical And Physical Sciences	2206187	47.049	—	27,966
Mathematical And Physical Sciences	2208294	47.049	—	27,351
Mathematical And Physical Sciences	2208412	47.049	—	58,497
Mathematical And Physical Sciences	2242508	47.049	—	(275)
Mathematical And Physical Sciences	2246659	47.049	—	72,828
Mathematical And Physical Sciences	2247013	47.049	—	133,411
Mathematical And Physical Sciences	2300347	47.049	—	55,895
Mathematical And Physical Sciences	2305112	47.049	—	257,823
Mathematical And Physical Sciences	2308017	47.049	—	3,003
Mathematical And Physical Sciences	2309751	47.049	—	69,389
Mathematical And Physical Sciences	2311665	47.049	—	324,647
Mathematical And Physical Sciences	2312105	47.049	—	189,070

EMORY UNIVERSITY AND ITS SUBSIDIARIES
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2025

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Mathematical And Physical Sciences	2329296	47.049	\$ —	16,634
Mathematical And Physical Sciences	2338904	47.049	—	78,345
Mathematical And Physical Sciences	2340500	47.049	—	105,741
Mathematical And Physical Sciences	2340746	47.049	—	99,892
Mathematical And Physical Sciences	2349014	47.049	—	188,496
Mathematical And Physical Sciences	2349045	47.049	—	64,197
Mathematical And Physical Sciences	2349306	47.049	—	122,715
Mathematical And Physical Sciences	2349534	47.049	—	99,587
Mathematical And Physical Sciences	2350187	47.049	—	204,145
Mathematical And Physical Sciences	2400095	47.049	—	262,008
Mathematical And Physical Sciences	2404274	47.049	—	142,093
Mathematical And Physical Sciences	2406996	47.049	—	113,296
Mathematical And Physical Sciences	2409416	47.049	—	255,977
Mathematical And Physical Sciences	2411197	47.049	—	48,406
Mathematical And Physical Sciences	2411264	47.049	—	53,753
Mathematical And Physical Sciences	2411718	47.049	—	174,619
Mathematical And Physical Sciences	2507992	47.049	—	48
Mathematical And Physical Sciences	2539855	47.049	—	42,650
Pass-through Boston University	2327697	47.049	—	194,856
Pass-through Georgia Institute of Technology	2310741	47.049	—	38,736
Pass-through Georgia Institute of Technology	2422801	47.049	—	3,399
Pass-through Harvard University	2132338	47.049	—	8,616
Pass-through Virginia Tech	2136142	47.049	—	45,837
Total AL No. 47.049			—	4,669,078
Geosciences				
Pass-through Georgia State University	2228192	47.050	—	28,086
Pass-through University Corp For Atmospheric Research	1755088	47.050	—	(2,663)
Pass-through University of Texas Austin	2420344	47.050	—	168,737
Total AL No. 47.050			—	194,160
Computer And Information Science And Engineering	2,442,172	47.070	—	25,666
Computer And Information Science And Engineering	2103592	47.070	—	13,322
Computer And Information Science And Engineering	2106446	47.070	—	3,636
Computer And Information Science And Engineering	2124104	47.070	—	224,859
Computer And Information Science And Engineering	2125530	47.070	50,421	154,158
Computer And Information Science And Engineering	2145411	47.070	—	71,593
Computer And Information Science And Engineering	2302968	47.070	—	154,280
Computer And Information Science And Engineering	2303655	47.070	—	38,891
Computer And Information Science And Engineering	2303678	47.070	—	94,268
Computer And Information Science And Engineering	2310114	47.070	—	251,614
Computer And Information Science And Engineering	2311574	47.070	—	247,168
Computer And Information Science And Engineering	2312502	47.070	—	157,734
Computer And Information Science And Engineering	2319449	47.070	—	118,899
Computer And Information Science And Engineering	2340539	47.070	—	131,913
Computer And Information Science And Engineering	2403312	47.070	—	3,799
Computer And Information Science And Engineering	2411530	47.070	—	2,349
Computer And Information Science And Engineering	2420678	47.070	—	27,139

EMORY UNIVERSITY AND ITS SUBSIDIARIES
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2025

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Computer And Information Science And Engineering	2426997	47.070	\$ —	(5,671)
Computer And Information Science And Engineering	2429933	47.070	—	24,883
Computer And Information Science And Engineering	2437345	47.070	—	1,538
Computer And Information Science And Engineering	2504088	47.070	—	3,791
Computer And Information Science And Engineering	2506643	47.070	—	41,729
Pass-through Computing Research Association	2127309	47.070	—	(10,380)
Pass-through Duke University	ISS-2211526	47.070	—	38,909
Pass-through Georgia Institute of Technology	1915504	47.070	—	3,991
Pass-through Georgia Institute of Technology	2205152	47.070	—	96,885
Pass-through University of Tennessee Knoxville	2200140	47.070	—	903
Pass-through University of Virginia	2041952	47.070	—	63
Total AL No. 47.070			<u>50,421</u>	<u>1,917,929</u>
Biological Sciences	1755418	47.074	—	106,981
Biological Sciences	1922720	47.074	—	43,376
Biological Sciences	1927411	47.074	—	143,645
Biological Sciences	2106137	47.074	—	(11,973)
Biological Sciences	2202255	47.074	—	193,534
Biological Sciences	2209996	47.074	—	166,609
Biological Sciences	2239526	47.074	—	180,970
Biological Sciences	2243665	47.074	274,316	798,323
Biological Sciences	2310626	47.074	—	443,281
Biological Sciences	2318831	47.074	—	40,656
Biological Sciences	2329634	47.074	—	159,134
Biological Sciences	2340578	47.074	—	40,931
Biological Sciences	2418128	47.074	—	578,795
Pass-through Case Western Reserve University	DBI-2015317	47.074	—	158,902
Pass-through George Mason University	2109647	47.074	—	82,877
Pass-through University of California Riverside	2119820	47.074	—	14,849
Pass-through University of Texas Austin	2227399	47.074	—	206,804
Pass-through University of Texas Austin	2418919	47.074	—	93,102
Pass-through Virginia Tech	2421958	47.074	—	9,391
Total AL No. 47.074			<u>274,316</u>	<u>3,450,187</u>
Social, Behavioral, And Economic Sciences	1853185	47.075	—	2,002
Social, Behavioral, And Economic Sciences	1945046	47.075	—	117,206
Social, Behavioral, And Economic Sciences	1946767	47.075	—	1,405
Social, Behavioral, And Economic Sciences	1946768	47.075	—	3,465
Social, Behavioral, And Economic Sciences	2051553	47.075	—	130,253
Social, Behavioral, And Economic Sciences	2127373	47.075	—	25,483
Social, Behavioral, And Economic Sciences	2127913	47.075	—	49,996
Social, Behavioral, And Economic Sciences	2147325	47.075	—	19,451
Social, Behavioral, And Economic Sciences	2214387	47.075	—	17,391
Social, Behavioral, And Economic Sciences	2218064	47.075	—	93,573
Social, Behavioral, And Economic Sciences	2219815	47.075	—	1,986
Social, Behavioral, And Economic Sciences	2242188	47.075	—	141,869
Social, Behavioral, And Economic Sciences	2244460	47.075	—	171,687
Social, Behavioral, And Economic Sciences	2307271	47.075	227,661	395,755

EMORY UNIVERSITY AND ITS SUBSIDIARIES
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2025

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Social, Behavioral, And Economic Sciences	2314858	47.075	\$ —	1,014
Social, Behavioral, And Economic Sciences	2403479	47.075	—	168,943
Social, Behavioral, And Economic Sciences	2417535	47.075	—	61,164
Social, Behavioral, And Economic Sciences	2417905	47.075	—	66,227
Social, Behavioral, And Economic Sciences	2418389	47.075	—	139,219
Social, Behavioral, And Economic Sciences	2419527	47.075	—	84,872
Social, Behavioral, And Economic Sciences	2536378	47.075	—	33,903
Social, Behavioral, And Economic Sciences	BCS 1354088	47.075	—	300
Pass-through Case Western Reserve University	2129072	47.075	—	123,401
Pass-through Princeton University	2033912	47.075	—	19,502
Pass-through University of Illinois	2343137	47.075	—	49,363
Pass-through University of Massachusetts Boston	2321010	47.075	—	(58)
Pass-through University of Colorado	2149191	47.075	—	587
Total AL No. 47.075			227,661	1,919,959
STEM Education (formerly Education and Human Resources)	1821533	47.076	—	(2,977)
STEM Education (formerly Education and Human Resources)	1937971	47.076	—	678,829
STEM Education (formerly Education and Human Resources)	2010333	47.076	—	19,460
STEM Education (formerly Education and Human Resources)	2142262	47.076	—	1,328
STEM Education (formerly Education and Human Resources)	2405867	47.076	164,581	252,431
STEM Education (formerly Education and Human Resources)	2422606	47.076	—	112,009
STEM Education (formerly Education and Human Resources)	2439564	47.076	—	1,170,879
Total AL No. 47.076			164,581	2,231,959
Polar Programs	2450309	47.078	14,602	88,052
Total AL No. 47.078			14,602	88,052
Integrative Activities	2331578	47.083	120,416	1,296,304
Pass-through University of Washington	2403771	47.083	—	706,846
Total AL No. 47.083			120,416	2,003,150
NSF Technology, Innovation, and Partnerships	2302890	47.084	292,643	360,599
Pass-through Arizona State University	2328217	47.084	—	221,800
Pass-through University of Illinois at Chicago	2346158	47.084	—	51,752
Pass-through University of Missouri Columbia	2350104	47.084	—	331,007
Pass-through Vytal Plant Science Research	2308676	47.084	—	1,882
Total AL No. 47.084			292,643	967,040
National Science Foundation Total			1,214,451	18,307,731
U.S. Department of Veterans Affairs Contract	PO# 508D35025	64.RD	—	(33,075)
Total AL No.64.RD			—	(33,075)
U.S. Department of Veterans Affairs Total			—	(33,075)

EMORY UNIVERSITY AND ITS SUBSIDIARIES
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2025

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
U.S. Environmental Protection Agency				
Surveys, Studies, Research, Investigations, Demonstrations, and Special Purpose Activities Relating to the Clean Air Act				
Pass-through Environmental Community Action	02D45623	66.034	\$ —	28,209
Total AL No. 66.034			—	28,209
Science To Achieve Results (STAR) Research Program	84019801	66.509	—	202,617
Science To Achieve Results (STAR) Research Program	84042901	66.509	—	140,938
Science To Achieve Results (STAR) Research Program	84048501	66.509	264,362	330,826
Total AL No. 66.509			264,362	674,381
Office of Research and Development Consolidated Research/Training/Fellowships				
Pass-through North Carolina State University	84008102	66.511	—	47,670
Pass-through University of Colorado	83,234,701	66.511	—	3,537
Pass-through Virginia Tech	5314	66.511	—	98,844
Total AL No. 66.511			—	150,051
Protection of Children from Environmental Health Risks	03D28724	66.609	—	16,184
Total AL No. 66.609			—	16,184
Solid Waste Management Assistance Grants	02D01621	66.808	—	34,317
Total AL No. 66.808			—	34,317
Environmental Education Grants	02D34022	66.951	12,000	27,775
Total AL No. 66.951			12,000	27,775
Contract				
Pass-through Health Effects Institute	CR-83998101	66.RD	122,310	156,263
Total AL No. 66.CTR			122,310	156,263
U.S. Environmental Protection Agency Total			398,672	1,087,180
U.S. Department of Energy				
Office Of Science Financial Assistance Program	DE-FG02-01ER15153	81.049	—	4,274
Office Of Science Financial Assistance Program	DE-FG02-01ER15153-24	81.049	—	205,092
Office Of Science Financial Assistance Program	DEFG0207ER15906	81.049	—	669,357
Office Of Science Financial Assistance Program	DE-SC0008798	81.049	—	293
Office Of Science Financial Assistance Program	DESC0019374	81.049	629,836	997,026
Office Of Science Financial Assistance Program	DE-SC0020101	81.049	—	114,545
Office Of Science Financial Assistance Program	DE-SC0020996	81.049	—	31
Office Of Science Financial Assistance Program	DE-SC0023327	81.049	—	62,427
Office Of Science Financial Assistance Program	DE-SC0024410	81.049	12,589	20,439
Office Of Science Financial Assistance Program	DE-SC0024524	81.049	—	201,362
Office Of Science Financial Assistance Program	DE-SC0024532	81.049	—	146,774
Office Of Science Financial Assistance Program	DE-SC0025345	81.049	—	114,379
Office Of Science Financial Assistance Program	DE-SC008798	81.049	—	197,174
Office Of Science Financial Assistance Program	S352L5P-JLMP8	81.049	—	113,604
Pass-through University of Arizona	0023411	81.049	—	159,168

EMORY UNIVERSITY AND ITS SUBSIDIARIES
Supplementary Schedule of Expenditures of Federal Awards
Year ended August 31, 2025

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Pass-through University of North Carolina Chapel Hill	DE-SC0021173	81.049	\$ —	252,306
Total AL No. 81.049			<u>642,425</u>	<u>3,258,251</u>
Contract	89233218CNA000001	81.RD	—	75,742
Contract	DE-AC52-07NA27344	81.RD	—	58,608
Total AL No. 81.RD			<u>—</u>	<u>134,350</u>
U.S. Department of Energy Total			<u>642,425</u>	<u>3,392,601</u>
U.S. Department of Education				
Overseas Programs – Doctoral Dissertation Research Abroad	P022A230003	84.022	—	3,400
Total AL No. 84.022			<u>—</u>	<u>3,400</u>
Fund for the Improvement of Postsecondary Education	P116Z230070	84.116	—	180,851
Total AL No. 84.116			<u>—</u>	<u>180,851</u>
National Institute on Disability and Rehabilitation Research				
Pass-through Shepherd Center	H133N110005	84.133	—	(4,175)
Total AL No. 84.133			<u>—</u>	<u>(4,175)</u>
U.S. Department of Education Total			<u>—</u>	<u>180,076</u>
U.S. Department of Health and Human Services				
National Family Caregiver Support, Title III, Part E				
Pass-through National Alliance for Caregiving	90CGPS0002	93.052	25,902	371,280
Total AL No. 93.052			<u>25,902</u>	<u>371,280</u>
Global AIDS				
Pass-through Center for Family Health Research	1 NU2GGH002538-01-00	93.067	—	289,946
Total AL No. 93.067			<u>—</u>	<u>289,946</u>
Chronic Diseases Research, Control, and Prevention	U01DP006488	93.068	44,211	964,011
Chronic Diseases Research, Control, and Prevention	U18DP006747	93.068	196,641	677,498
Total AL No. 93.068			<u>240,852</u>	<u>1,641,509</u>
Birth Defects and Developmental Disabilities – Prevention and Surveillance	NU50DD000057	93.073	—	44,028
Birth Defects and Developmental Disabilities – Prevention and Surveillance	NU84DD000020	93.073	34,634	438,389
Pass-through Johns Hopkins University	U01DD001297	93.073	—	36,313
Total AL No. 93.073			<u>34,634</u>	<u>518,730</u>
Family Smoking Prevention and Tobacco Control Act Regulatory Research	R00DA058241	93.077	—	10,227
Pass-through Georgia State University	R01CA239308	93.077	—	71,384
Total AL No. 93.077			<u>—</u>	<u>81,611</u>
Blood Disorder Program Prevention, Surveillance, and Research				
Pass-through Georgia State University	NU58DD0000021	93.080	—	(35)
Pass-through Georgia State University	NU58DD000003	93.080	4,261	28,850
Pass-through Georgia State University	NU58DD000036	93.080	—	17,656
Pass-through Hemophilia of Georgia	NU27DD000020	93.080	—	2,575

EMORY UNIVERSITY AND ITS SUBSIDIARIES
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2025

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Pass-through Hemophilia of Georgia	NU27DD000020-05-00	93.080	\$ —	27,990
Total AL No. 93.080			<u>4,261</u>	<u>77,036</u>
Prevention of Disease, Disability, and Death through Immunization and Control of Respiratory and Related Diseases				
Pass-through Amer Geriatrics Society	NH23IP922656	93.083	—	182,369
Total AL No. 93.083			<u>—</u>	<u>182,369</u>
COVID-19 – Prevention Of Disease, Disability, And Death By Infectious Diseases	U54CK000601	93.084	477,716	1,557,943
Prevention Of Disease, Disability, And Death By Infectious Diseases	U01PS005244	93.084	493,607	1,660,672
Prevention Of Disease, Disability, And Death By Infectious Diseases	U01PS005260	93.084	63,370	245,298
Pass-through Georgia Dept of Public Health	NU50CK000626	93.084	—	625,411
Pass-through Rush University Medical Center	U54CK000607	93.084	—	23,257
Pass-through State University of New York Albany	NU38PS004650	93.084	—	38,372
Pass-through University of Iowa	U54CK000613	93.084	—	35,659
Pass-through Yale University	U01CK000572	93.084	—	36,487
Total AL No. 93.084			<u>1,034,693</u>	<u>4,223,099</u>
Advancing System Improvements for Key Issues in Women's Health				
Pass-through Boston Medical Center	ASTWH220118	93.088	—	39,524
Total AL No. 93.088			<u>—</u>	<u>39,524</u>
Food and Drug Administration Research	5R01FD003527-02 REVISED	93.103	—	(55)
Food and Drug Administration Research	R01FD005746	93.103	—	(2,066)
Pass-through Georgia Institute of Technology	P50FD004193	93.103	—	(13,347)
Pass-through Memorial Sloan Kettering Cancer Center	RD1FD007829	93.103	6,720	19,072
Pass-through Yale University	U01FD005938	93.103	—	174,627
Total AL No. 93.103			<u>6,720</u>	<u>178,231</u>
Maternal And Child Health Federal Consolidated Programs	R4250214	93.110	—	58,402
Maternal And Child Health Federal Consolidated Programs	T768446	93.110	—	8,987
Maternal And Child Health Federal Consolidated Programs	T76MC28446	93.110	65,409	395,947
Pass-through Georgia Dept of Public Health	40500-050-24244796	93.110	—	115,880
Pass-through Organization of Teratology Information S	UG4MC27861	93.110	—	97,334
Total AL No. 93.110			<u>65,409</u>	<u>676,550</u>
Environmental Health	D43ES030927	93.113	109,706	152,604
Environmental Health	F30ES036439	93.113	—	52,538
Environmental Health	F31ES036103	93.113	—	35,126
Environmental Health	F31ES036126	93.113	—	48,454
Environmental Health	F32ES034241	93.113	—	68,874
Environmental Health	K00ES033033	93.113	—	20,516
Environmental Health	K12ES033593	93.113	—	619,806
Environmental Health	K99ES036289	93.113	—	133,121
Environmental Health	KES035082A	93.113	—	145,463
Environmental Health	P20ES036110	93.113	107,190	1,442,583
Environmental Health	P2CES033430	93.113	399,162	941,944
Environmental Health	P30ES019776	93.113	56,543	1,485,602
Environmental Health	P50ES026071	93.113	—	(176)

EMORY UNIVERSITY AND ITS SUBSIDIARIES
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2025

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Environmental Health	R00ES034459	93.113	\$ —	256,121
Environmental Health	R01ES027859	93.113	—	423,211
Environmental Health	R01ES028346	93.113	465,498	543,373
Environmental Health	R01ES029212	93.113	16,132	19
Environmental Health	R01ES031980	93.113	146,636	344,152
Environmental Health	R01ES032009	93.113	301,948	681,984
Environmental Health	R01ES032140	93.113	47,575	94,045
Environmental Health	R01ES032440	93.113	—	400,460
Environmental Health	R01ES032446	93.113	—	170,401
Environmental Health	R01ES032831	93.113	143,694	360,561
Environmental Health	R01ES033241	93.113	438,354	648,238
Environmental Health	R01ES033530	93.113	695,518	1,170,282
Environmental Health	R01ES033603	93.113	—	323,454
Environmental Health	R01ES034175	93.113	232,899	636,478
Environmental Health	R01ES034708	93.113	108,551	460,170
Environmental Health	R01ES034796	93.113	—	375,765
Environmental Health	R01ES035395	93.113	610,504	999,495
Environmental Health	R01ES035738	93.113	—	675,399
Environmental Health	R01ES037289	93.113	—	39,260
Environmental Health	R03ES035184	93.113	10,858	84,341
Environmental Health	R21ES032117	93.113	—	14,319
Environmental Health	R21ES034130	93.113	11,541	29,188
Environmental Health	R21ES034139	93.113	11,588	90,979
Environmental Health	R21ES034190	93.113	—	115,829
Environmental Health	R21ES036795	93.113	—	145,359
Environmental Health	R24ES029490	93.113	—	(1,357)
Environmental Health	T32ES012870	93.113	—	440,841
Environmental Health	U24ES028507	93.113	254,491	432,901
Environmental Health	U24ES028528	93.113	21,820	406,951
Environmental Health	U24ES029490	93.113	19,658	479,557
Pass-through Alaska Community Action on Toxics	R01ES019620	93.113	—	44,684
Pass-through Arkansas Children'S Hospital Research In	R01ES036986	93.113	—	73,696
Pass-through Columbia University	R01ES030945	93.113	—	15,491
Pass-through Columbia University	U24ES036819	93.113	—	9,060
Pass-through Harvard University	R01ES035390	93.113	—	26,393
Pass-through Johns Hopkins University	R01ES035035	93.113	—	153,167
Pass-through Johns Hopkins University	R01ES035056	93.113	—	90,837
Pass-through Mount Sinai School of Medicine	R01ES033688	93.113	—	54,829
Pass-through Mount Sinai School of Medicine	R21ES035169	93.113	—	31,707
Pass-through Rutgers The State University	R01ES035766	93.113	—	20,086
Pass-through Rutgers University	R01ES032144	93.113	—	77,168
Pass-through University of Nevada	R01ES029528	93.113	—	8,432
Pass-through University of Arizona	1R01ES034690-01A1	93.113	—	41,915
Pass-through University of Arizona	R01ES032392	93.113	—	167,568
Pass-through University of Illinois at Chicago	R01ES035691	93.113	—	222,412
Pass-through University of Kentucky	R01ES032176	93.113	—	46,595
Pass-through University of Michigan	R01ES032157	93.113	—	34,177
Pass-through University of Michigan	R01ES035087	93.113	—	326,240
Pass-through University of Rochester	R21ES033750	93.113	—	5,246

EMORY UNIVERSITY AND ITS SUBSIDIARIES
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2025

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Pass-through University of Southern California	R01ES030364	93.113	\$ —	34,781
Pass-through Wayne State University	R01ES031584	93.113	—	54,942
Total AL No. 93.113			4,209,866	17,527,657
Oral Diseases And Disorders Research	R00DE026810	93.121	—	6,052
Oral Diseases And Disorders Research	R01DE028342	93.121	839	351,287
Oral Diseases And Disorders Research	R01DE028351	93.121	—	424,173
Oral Diseases And Disorders Research	R01DE028905	93.121	224,044	407,771
Oral Diseases And Disorders Research	R01DE030342	93.121	221,956	849,336
Oral Diseases And Disorders Research	R01DE031271	93.121	64,542	411,096
Oral Diseases And Disorders Research	R01DE031273	93.121	65,403	406,333
Oral Diseases And Disorders Research	R01DE032243	93.121	83,303	844,638
Oral Diseases And Disorders Research	R01DE033433	93.121	—	187,769
Oral Diseases And Disorders Research	R01DE033512	93.121	112,472	508,284
Oral Diseases And Disorders Research	R01DE033635	93.121	172,156	578,031
Oral Diseases And Disorders Research	R01DE033691	93.121	—	152,065
Oral Diseases And Disorders Research	R03DE032084	93.121	4,846	129,301
Oral Diseases And Disorders Research	R03DE033753	93.121	—	111,661
Oral Diseases And Disorders Research	R21DE034956	93.121	—	66,407
Oral Diseases And Disorders Research	R56DE031771	93.121	—	426,075
Oral Diseases And Disorders Research	R56DE033733	93.121	—	441,843
Oral Diseases And Disorders Research	R03DE030259	93.121	—	26,860
Pass-through Arizona State University	R21DE032344	93.121	—	45,017
Pass-through Baylor College of Medicine	R01DE027983	93.121	—	7,369
Pass-through Children's Hospital of Philadelphia	R01DE032332	93.121	—	28,976
Pass-through Children's Hospital of Philadelphia	R01DE032681	93.121	—	7,791
Pass-through University of Colorado	R01DE032216	93.121	—	165,604
Pass-through University of Pennsylvania	R01DE032319	93.121	—	170,600
Pass-through University of Pittsburgh			949,561	6,754,339
Total AL No. 93.121				
Health Professions Pre-graduate Scholarship Program for Indians				
Pass-through University of California Irvine	U24AT012603	93.123	—	66,753
Total AL No. 93.123			—	66,753
Nurse Anesthetist Traineeship	A2231815	93.124	—	32,231
Total AL No. 93.124			—	32,231
COVID-19 – Centers For Research And Demonstration For Health Promotion And Disease Prevention	U48DP006377	93.135	351,710	849,298
Centers for Research and Demonstration for Health Promotion and Disease Prevention	U48DP006809	93.135	59,627	834,490
Centers for Research and Demonstration for Health Promotion and Disease Prevention	U48DP006841	93.135	9,714	230,726
Centers for Research and Demonstration for Health Promotion and Disease Prevention	U48DP006877	93.135	103,669	292,917
Pass-through Morehouse School of Medicine	U48DP006411	93.135	—	19,489
Total AL No. 93.135			524,720	2,226,920
Injury Prevention And Control Research And State And Community Based Programs	R01CE003509	93.136	255,323	740,115
Injury Prevention And Control Research And State And Community Based Programs	R01CE003580	93.136	56,932	313,528
Injury Prevention And Control Research And State And Community Based Programs	R01CE003604	93.136	—	496,536
Injury Prevention And Control Research And State And Community Based Programs	R49CE003072	93.136	43,200	642,312

EMORY UNIVERSITY AND ITS SUBSIDIARIES
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2025

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Injury Prevention And Control Research And State And Community Based Programs	R49CE003553	93.136	\$ 58,612	716,563
Injury Prevention And Control Research And State And Community Based Programs	U01CE002939	93.136	—	49,307
Total AL No. 93.136			414,067	2,958,361
Community Programs to Improve Minority Health Grant Program Pass-through Georgia State University	CPIMP221348	93.137	—	51,377
Total AL No. 93.137			—	51,377
NIEHS Hazardous Waste Worker Health and Safety Training Pass-through Nova Southeastern University	U45ES019350	93.142	—	274
Total AL No. 93.142			—	274
NIEHS Superfund Hazardous Substances Basic Research and Education Pass-through Michigan State University	P42ES004911	93.143	—	65,097
Total AL No. 93.143			—	65,097
Health Program for Toxic Substances and Disease Registry Pass-through American Academy of Pediatrics	NU61TS000296	93.161	—	(4,136)
Pass-through American Academy of Pediatrics	NU61TS000296	93.161	—	1,512
Pass-through Public Health Institute	NU61TS000356	93.161	—	194,649
Total AL No. 93.161			—	192,025
Human Genome Research Pass-through Morehouse School of Medicine	R01HG012941	93.172	61,598	672,927
Pass-through University of Chicago	RM1HG012334	93.172	—	286,547
	RM1HG008935	93.172	—	74,551
Total AL No. 93.172			61,598	1,034,025
Research Related To Deafness And Communication Disorders	F31DC022802	93.173	—	32,390
Research Related To Deafness And Communication Disorders	K24DC022077	93.173	—	108,298
Research Related To Deafness And Communication Disorders	R01DC008343	93.173	—	477,108
Research Related To Deafness And Communication Disorders	R01DC013066	93.173	—	276,293
Research Related To Deafness And Communication Disorders	R01DC020749	93.173	—	529,810
Research Related To Deafness And Communication Disorders	R01DC021478	93.173	—	376,004
Research Related To Deafness And Communication Disorders	R01DC022026	93.173	—	75,019
Research Related To Deafness And Communication Disorders	R21DC019711	93.173	—	185,268
Research Related To Deafness And Communication Disorders	R21DC021029	93.173	—	176,168
Research Related To Deafness And Communication Disorders	U01DC020452	93.173	116,812	388,527
Pass-through Harvard University	R21DC019567	93.173	—	15
Pass-through Massachusetts General Hospital	P50DC015446	93.173	—	9,885
Pass-through Massachusetts General Hospital	R01DC020247	93.173	—	12,393
Pass-through University of Central Florida	R01DC009029	93.173	—	177,697
Pass-through University of Central Florida	R01DC020799	93.173	—	82,390
Pass-through Vanderbilt University	R01DC021559	93.173	—	158,036
Pass-through Vanderbilt University Medical Center	R01DC021698	93.173	—	32,046
Total AL No. 93.173			116,812	3,097,347

EMORY UNIVERSITY AND ITS SUBSIDIARIES
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2025

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
COVID-19 – Immunization Research, Demonstration, Public Information and Education Training and Clinical Skills Improvement Projects	U01IP001200	93.185	\$ 139,680	234,340
Immunization Research, Demonstration, Public Information and Education Training and Clinical Skills Improvement Projects	U01IP001200	93.185	199,441	424,366
Total AL No. 93.185			339,121	658,706
Telehealth Programs	H2ARH39957	93.211	—	91,486
Pass-through University of Arizona	U1U42527	93.211	—	102,956
Total AL No. 93.211			—	194,442
Research and Training in Complementary and Integrative Health	F31AT012140	93.213	—	47,406
Research and Training in Complementary and Integrative Health	K01AT010488	93.213	—	61,596
Research and Training in Complementary and Integrative Health	K24AT009893	93.213	—	92,540
Research and Training in Complementary and Integrative Health	R01AT011267	93.213	285,160	811,842
Research and Training in Complementary and Integrative Health	R01AT011990	93.213	466,498	808,289
Research and Training in Complementary and Integrative Health	R33AT010457	93.213	21,890	506,221
Research and Training in Complementary and Integrative Health	R33AT012421	93.213	148,259	789,395
Research and Training in Complementary and Integrative Health	R34AT012509	93.213	—	160,372
Research and Training in Complementary and Integrative Health	R61AT012421	93.213	84,326	84,779
Pass-through University of Illinois at Chicago	UH3AT011265	93.213	—	130,351
Pass-through University of Utah	R33AT012329	93.213	—	285,100
Pass-through Veterans Medical Research Foundation	U01AT010332	93.213	—	(3,900)
Total AL No. 93.213			1,006,133	3,773,991
National Research Service Awards Health Services Research Training	T32HS029585	93.225	—	303,971
Total AL No. 93.225			—	303,971
Research On Healthcare Costs, Quality And Outcomes	R01HS029677	93.226	39,682	191,595
Research On Healthcare Costs, Quality And Outcomes	R03HS027689	93.226	—	625
Research On Healthcare Costs, Quality And Outcomes	R03HS029417	93.226	11,408	55,897
Research On Healthcare Costs, Quality And Outcomes	U18HS029944	93.226	171,668	969,449
Pass-through Children's Hospital of Philadelphia	R01HS029188	93.226	—	23,943
Pass-through Medstar Health Research Institute	R18HS029291	93.226	185,067	296,953
Pass-through University of Georgia	R01HS029009	93.226	—	(98)
Pass-through University of Georgia	R21HS028485	93.226	—	584
Pass-through University of Michigan	R01HS029159	93.226	—	22,893
Total AL No. 93.226			407,825	1,561,841
National Center On Sleep Disorders Research	R01HL157954	93.233	—	1,040,179
National Center On Sleep Disorders Research	R01HL162712	93.233	—	646,588
Pass-through Beth Israel Deaconess Medical Center	R01HL161253	93.233	—	399,891
Pass-through Brigham and Womens Hospital	R01HL164462	93.233	—	42,538
Total AL No. 93.233			—	2,129,196
Mental Health Research Grants	F31MH126623	93.242	—	618
Mental Health Research Grants	F31MH132407	93.242	—	49,416
Mental Health Research Grants	F31MH133373	93.242	—	39,498
Mental Health Research Grants	F31MH135662	93.242	—	46,355
Mental Health Research Grants	F32MH132175	93.242	—	57,230
Mental Health Research Grants	F32MH134528	93.242	—	62,212

EMORY UNIVERSITY AND ITS SUBSIDIARIES
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2025

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Mental Health Research Grants	F32MH134631	93.242	\$ —	71,021
Mental Health Research Grants	F32MH135636	93.242	—	96,821
Mental Health Research Grants	F32MH139279	93.242	—	52,190
Mental Health Research Grants	K00MH139443	93.242	—	72,145
Mental Health Research Grants	K01MH121653	93.242	—	180,487
Mental Health Research Grants	K01MH126308	93.242	—	193,649
Mental Health Research Grants	K01MH133970	93.242	—	(1,195)
Mental Health Research Grants	K01MH135783	93.242	—	149,259
Mental Health Research Grants	K01MH136861	93.242	—	138,136
Mental Health Research Grants	K23MH114771	93.242	—	8,411
Mental Health Research Grants	K23MH122626	93.242	—	275,478
Mental Health Research Grants	K23MH128128	93.242	36,706	317,082
Mental Health Research Grants	K23MH130651	93.242	—	211,394
Mental Health Research Grants	P50MH100023	93.242	—	114
Mental Health Research Grants	R00MH102355	93.242	—	(187)
Mental Health Research Grants	R00MH119319	93.242	—	178,341
Mental Health Research Grants	R01MH105561	93.242	92,991	217,774
Mental Health Research Grants	R01MH108826	93.242	126,003	425,360
Mental Health Research Grants	R01MH115174	93.242	1,752	91,030
Mental Health Research Grants	R01MH115831	93.242	—	315
Mental Health Research Grants	R01MH117009	93.242	1,375	86,296
Mental Health Research Grants	R01MH117315	93.242	—	2,369
Mental Health Research Grants	R01MH118285	93.242	268,993	933,352
Mental Health Research Grants	R01MH118534	93.242	24,776	142,378
Mental Health Research Grants	R01MH118771	93.242	—	473,632
Mental Health Research Grants	R01MH118982	93.242	191,477	532,586
Mental Health Research Grants	R01MH119251	93.242	73,417	86,899
Mental Health Research Grants	R01MH120262	93.242	—	464,400
Mental Health Research Grants	R01MH121363	93.242	277,635	947,673
Mental Health Research Grants	R01MH121622	93.242	14,183	130,843
Mental Health Research Grants	R01MH121962	93.242	—	398,784
Mental Health Research Grants	R01MH122341	93.242	—	411,669
Mental Health Research Grants	R01MH123352	93.242	317,713	516,676
Mental Health Research Grants	R01MH125457	93.242	142,358	298,249
Mental Health Research Grants	R01MH125956	93.242	—	690,628
Mental Health Research Grants	R01MH126083	93.242	—	868,256
Mental Health Research Grants	R01MH126195	93.242	—	680,082
Mental Health Research Grants	R01MH126985	93.242	—	820,577
Mental Health Research Grants	R01MH128045	93.242	144,500	768,493
Mental Health Research Grants	R01MH128130	93.242	208,154	658,331
Mental Health Research Grants	R01MH128158	93.242	—	826,822
Mental Health Research Grants	R01MH128244	93.242	—	1,004,391
Mental Health Research Grants	R01MH128705	93.242	—	2,203,917
Mental Health Research Grants	R01MH128872	93.242	—	983,927
Mental Health Research Grants	R01MH129855	93.242	13,164	708,827
Mental Health Research Grants	R01MH130755	93.242	—	420,975
Mental Health Research Grants	R01MH131434	93.242	680,199	980,064
Mental Health Research Grants	R01MH131910	93.242	—	529,928
Mental Health Research Grants	R01MH132059	93.242	—	590,978

EMORY UNIVERSITY AND ITS SUBSIDIARIES
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2025

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Mental Health Research Grants	R01MH132470	93.242	\$ 114,850	738,195
Mental Health Research Grants	R01MH133259	93.242	302,978	558,479
Mental Health Research Grants	R01MH133612	93.242	—	966,325
Mental Health Research Grants	R01MH133740	93.242	—	471,129
Mental Health Research Grants	R01MH133798	93.242	29,954	722,409
Mental Health Research Grants	R01MH134267	93.242	—	750,619
Mental Health Research Grants	R01MH134972	93.242	—	434,846
Mental Health Research Grants	R01MH138893	93.242	—	128,212
Mental Health Research Grants	R01MH139780	93.242	—	2,306
Mental Health Research Grants	R01MH139822	93.242	—	89,366
Mental Health Research Grants	R01MH140180	93.242	—	39,096
Mental Health Research Grants	R03MH135363	93.242	—	79,469
Mental Health Research Grants	R03MH135518	93.242	—	68,363
Mental Health Research Grants	R13MH138043	93.242	—	20,000
Mental Health Research Grants	R21MH127404	93.242	—	(3,173)
Mental Health Research Grants	R21MH132012	93.242	—	49,444
Mental Health Research Grants	R21MH133823	93.242	—	178,437
Mental Health Research Grants	R21MH137783	93.242	7,002	81,306
Mental Health Research Grants	R21MH139049	93.242	—	147,374
Mental Health Research Grants	R21MH140191	93.242	—	28,905
Mental Health Research Grants	R25MH101079	93.242	—	189,119
Mental Health Research Grants	R33MH121625	93.242	—	754,371
Mental Health Research Grants	R33MH124200	93.242	63,110	276,424
Mental Health Research Grants	R34MH116805	93.242	65,515	45,210
Mental Health Research Grants	R34MH119007	93.242	—	6,510
Mental Health Research Grants	R34MH128048	93.242	32,531	8,112
Mental Health Research Grants	R34MH129187	93.242	7,412	197,758
Mental Health Research Grants	R34MH132497	93.242	—	152,665
Mental Health Research Grants	R34MH135806	93.242	86,773	177,544
Mental Health Research Grants	R34MH136125	93.242	—	9,928
Mental Health Research Grants	R36MH136806	93.242	—	27,439
Mental Health Research Grants	R37MH117103	93.242	—	770,274
Mental Health Research Grants	R56MH129019	93.242	4,496	1,952
Mental Health Research Grants	R61MH121625	93.242	—	(483)
Mental Health Research Grants	U01MH081988	93.242	—	166
Mental Health Research Grants	U19MH069056	93.242	—	(1,250)
Pass-through Boston University	R01MH133670	93.242	—	42,474
Pass-through Brown University	R01MH117960	93.242	—	35,991
Pass-through Carnegie Mellon University	R01MH129725	93.242	—	192,083
Pass-through Duke University	R01MH111671	93.242	—	(2,500)
Pass-through Duke University	R01MH133313	93.242	—	97,189
Pass-through Duke University	R01MH139648	93.242	—	30,362
Pass-through Georgia Institute of Technology	R61MH138966	93.242	—	84,905
Pass-through Georgia State University	R01MH130595	93.242	—	21,757
Pass-through Hartford Hospital	R01MH119815	93.242	—	26,612
Pass-through Harvard Pilgrim Health Care Institute	R21MH136855	93.242	—	13,678
Pass-through Johns Hopkins University	P30MH136919	93.242	—	241,464
Pass-through Johns Hopkins University	R01MH129656	93.242	—	276,583
Pass-through Johns Hopkins University	R01MH132150	93.242	—	480,704

EMORY UNIVERSITY AND ITS SUBSIDIARIES
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2025

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Pass-through Massachusetts General Hospital	R21MH132947	93.242	\$ —	6,548
Pass-through Md Anderson	R01MH120299	93.242	—	103,376
Pass-through Regents of the University of California	R34MH134725	93.242	—	16,910
Pass-through Research Foundation for Mental Hygiene	R01MH123660	93.242	—	(4,056)
Pass-through Rhode Island Hospital	R01MH125796	93.242	—	285,350
Pass-through Rutgers University	R01MH126449	93.242	—	245,307
Pass-through Rutgers University	R01MH134265	93.242	—	16,169
Pass-through State University of New York Stony Brook	R01MH120293	93.242	—	10,170
Pass-through University of Massachusetts	R01MH121599	93.242	—	2,411
Pass-through University of California Los Angeles	R01MH100027	93.242	—	125,643
Pass-through University of California Los Angeles	R01MH118514	93.242	—	155,483
Pass-through University of California Los Angeles	R01MH118973	93.242	—	24,808
Pass-through University of California San Diego	P50MH126231	93.242	—	3,634
Pass-through University of California San Diego	R01MH123641	93.242	—	176,448
Pass-through University of California San Diego	R01MH124590	93.242	—	99,259
Pass-through University of California San Francisco	R01MH123396	93.242	—	9,974
Pass-through University of Colorado Denver	R01MH134957	93.242	—	126,203
Pass-through University of Georgia	R01MH120092	93.242	—	98,768
Pass-through University of Georgia	R01MH124803	93.242	—	3,114
Pass-through University of Illinois at Chicago	R01MH116721	93.242	—	25,582
Pass-through University of Iowa	R01MH104363	93.242	—	(303)
Pass-through University of Louisiana at Lafayette	R01MH125395	93.242	—	566,547
Pass-through University of Maryland, Baltimore	R01MH121102	93.242	—	15,051
Pass-through University of Michigan	NS055746	93.242	—	(217)
Pass-through University of Michigan	R01MH123388	93.242	—	66,332
Pass-through University of Michigan	R01MH125857	93.242	—	56,922
Pass-through University of Michigan	R01MH126693	93.242	—	25,750
Pass-through University of Michigan	R34MH135799	93.242	—	16,011
Pass-through University of North Carolina	U01MH110925	93.242	—	1,163
Pass-through University of North Carolina Chapel Hill	R01MH134660	93.242	—	86,664
Pass-through University of Pittsburgh	R01MH115922	93.242	—	62,855
Pass-through University of Pittsburgh	R01MH118270	93.242	—	(9,409)
Pass-through University of Pittsburgh	R01MH121619	93.242	—	3,531
Pass-through University of Pittsburgh	R01MH125816	93.242	—	40,454
Pass-through University of Pittsburgh	R01MH130376	93.242	—	56,430
Pass-through University of Pittsburgh	R01MH137185	93.242	—	63,327
Pass-through University of Washington Saint Louis	R01MH123723	93.242	—	4,348
Pass-through University of Wisconsin-Madison	R01MH081884	93.242	—	1,336
Pass-through Vanderbilt University	R01MH123662	93.242	—	28,205
Pass-through Vanderbilt University Medical Center	R01MH111599	93.242	—	27,859
Pass-through Vanderbilt University Medical Center	R61MH123029	93.242	—	114,326
Pass-through Washington University	R01MH120194	93.242	—	94,009
Pass-through Washington University	R01MH125820	93.242	—	45,210
Pass-through Wayne State University	R33MH111935	93.242	—	85,383
Pass-through Yale University	R01MH125205	93.242	—	71,697
Pass-through Yale University	R34MH137756	93.242	—	5,747
Pass-through Yale University	U01MH124639	93.242	—	127,699

EMORY UNIVERSITY AND ITS SUBSIDIARIES
Supplementary Schedule of Expenditures of Federal Awards
Year ended August 31, 2025

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Pass-through Yale University	U01MH137298	93.242	\$ —	244,811
Total AL No. 93.242			<u>3,330,017</u>	<u>34,235,943</u>
Substance Abuse and Mental Health Services Projects of Regional and National Significance	H79SM081774	93.243	33,000	142,693
Pass-through Stanford University	H79SM090078	93.243	11,340	576,332
Total AL No. 93.243			<u>44,340</u>	<u>719,025</u>
Advanced Nursing Education Workforce Grant Program	T1433112	93.247	—	(45)
Advanced Nursing Education Workforce Grant Program	T9642058	93.247	—	384,100
Total AL No. 93.247			<u>—</u>	<u>384,055</u>
Occupational Safety And Health Program	R01OH011782	93.262	—	2,223
Occupational Safety And Health Program	R21OH012557	93.262	—	216,913
Total AL No. 93.262			<u>—</u>	<u>219,136</u>
HIV Demonstration, Research, Public and Professional Education Projects				
Pass-through Addis Ababa University	T84HA211245	93.266	—	(18,806)
Total AL No. 93.266			<u>—</u>	<u>(18,806)</u>
COVID-19 – Alcohol Research Programs	U01AA029345	93.273	23,188	1,409
Alcohol Research Programs	K01AA028258	93.273	—	134,290
Alcohol Research Programs	K99AA031333	93.273	—	51,700
Alcohol Research Programs	k99aa032220	93.273	—	115,033
Alcohol Research Programs	R01AA026086	93.273	—	34,290
Alcohol Research Programs	R01AA027020	93.273	—	442,933
Alcohol Research Programs	R01AA027396	93.273	—	328,229
Alcohol Research Programs	R01AA028527	93.273	—	212,727
Alcohol Research Programs	R01AA029690	93.273	—	664,579
Alcohol Research Programs	R01AA030529	93.273	182,557	594,726
Alcohol Research Programs	R01AA030893	93.273	—	333,435
Alcohol Research Programs	R21AA028606	93.273	13,621	7,043
Alcohol Research Programs	U01AA026108	93.273	320,762	526,854
Pass-through Boston Medical Center	P01AA029541	93.273	—	19,038
Pass-through Duke University	R01AA029819	93.273	—	62,457
Pass-through Georgia State University	R01AA030275	93.273	—	28,176
Pass-through Stanford University	R61AA031291	93.273	—	16,328
Pass-through University of Massachusetts	R01AA031269	93.273	—	73,455
Pass-through University of California San Diego	R01AA027785	93.273	—	31,162
Pass-through University of California San Diego	U01AA019879	93.273	—	(4,644)
Pass-through University of Colorado	R01AA031244	93.273	—	11,077
Pass-through University of Colorado	R24AA019661	93.273	—	13,156
Pass-through University of Georgia	R01AA026362	93.273	—	24,924
Pass-through Virginia Commonwealth University	R01AA030549	93.273	—	433,435
Total AL No. 93.273			<u>540,128</u>	<u>4,155,812</u>
COVID-19 – Drug Abuse and Addiction Research Programs	U01DA056000	93.279	62,047	197,607
Drug Abuse and Addiction Research Programs	DP2NS140735	93.279	—	682,682
Drug Abuse and Addiction Research Programs	F31DA059435	93.279	—	46,974

EMORY UNIVERSITY AND ITS SUBSIDIARIES
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2025

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Drug Abuse and Addiction Research Programs	F32DA061631	93.279	\$ —	73,006
Drug Abuse and Addiction Research Programs	K01DA051696	93.279	—	142,066
Drug Abuse and Addiction Research Programs	K01DA053438	93.279	—	151,574
Drug Abuse and Addiction Research Programs	K01DA053985	93.279	—	140,713
Drug Abuse and Addiction Research Programs	K23DA057415	93.279	—	201,421
Drug Abuse and Addiction Research Programs	K24AI114444	93.279	—	13
Drug Abuse and Addiction Research Programs	R01DA042742	93.279	—	(292)
Drug Abuse and Addiction Research Programs	R01DA044297	93.279	—	466,554
Drug Abuse and Addiction Research Programs	R01DA046197	93.279	—	142,895
Drug Abuse and Addiction Research Programs	R01DA049257	93.279	181,322	353,919
Drug Abuse and Addiction Research Programs	R01DA051302	93.279	300,936	699,610
Drug Abuse and Addiction Research Programs	R01DA052859	93.279	—	344,028
Drug Abuse and Addiction Research Programs	R01DA052909	93.279	74,311	739,173
Drug Abuse and Addiction Research Programs	R01DA056235	93.279	153,775	755,978
Drug Abuse and Addiction Research Programs	R01DA056436	93.279	159,418	431,483
Drug Abuse and Addiction Research Programs	R01DA056770	93.279	24,462	1,032,891
Drug Abuse and Addiction Research Programs	R01DA057599	93.279	51,369	429,642
Drug Abuse and Addiction Research Programs	R01DA058065	93.279	109,553	795,227
Drug Abuse and Addiction Research Programs	R01DA059182	93.279	50,258	611,811
Drug Abuse and Addiction Research Programs	R01DA062380	93.279	—	164,180
Drug Abuse and Addiction Research Programs	R34DA054483	93.279	64,745	130,739
Drug Abuse and Addiction Research Programs	R36DA061555	93.279	—	22,244
Drug Abuse and Addiction Research Programs	R61DA062365	93.279	21,644	381,447
Drug Abuse and Addiction Research Programs	RF1DA055667	93.279	26,776	291,619
Drug Abuse and Addiction Research Programs	RF1NS135504	93.279	147,001	1,192,207
Drug Abuse and Addiction Research Programs	T32DA050552	93.279	—	207,491
Drug Abuse and Addiction Research Programs	UG1DA055360	93.279	—	2,046,160
Drug Abuse and Addiction Research Programs	UG3DA048502	93.279	160,210	1,319,102
Drug Abuse and Addiction Research Programs	UH3DA050234	93.279	230,618	913,518
Pass-through Boston Medical Center	R01DA058367	93.279	—	16,183
Pass-through Friends Research Institute	R01DA056888	93.279	—	20,053
Pass-through Jackson Laboratory	R01DA037927	93.279	—	9,981
Pass-through Johns Hopkins University	R33DA047022	93.279	—	(359)
Pass-through Miriam Hospital	R01DA044504	93.279	—	77,519
Pass-through Miriam Hospital	R01DA056787	93.279	—	504,699
Pass-through Miriam Hospital	R25DA037190	93.279	—	945
Pass-through Northwestern University	R01DA055502	93.279	—	50,844
Pass-through RAND	P50DA046351	93.279	—	55,466
Pass-through University of California San Diego	U24DA055325	93.279	—	251,436
Pass-through University of Colorado	P50DA056408	93.279	—	22,998
Pass-through University of Colorado	R01DA049800	93.279	—	32,794
Pass-through University of Colorado Denver	P50DA056408-02	93.279	—	32,178
Pass-through University of Kentucky	R01DA049333	93.279	—	17,613
Pass-through University of Kentucky	R01DA055872	93.279	—	44,096
Pass-through University of Kentucky	U24DA058961	93.279	—	27,071
Pass-through University of Kentucky	UH3DA044798	93.279	—	64,791
Pass-through University of Miami	UG1DA013720	93.279	—	41,115
Pass-through University of Michigan	SUBK00021367	93.279	—	44,504

EMORY UNIVERSITY AND ITS SUBSIDIARIES
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2025

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Pass-through Vanderbilt University	U01DA055347	93.279	\$ —	45,978
Pass-through Wake Forest University	R01DA052214	93.279	—	41,859
Pass-through Weill Cornell Medical College	U01DA05827	93.279	—	863,800
Total AL No. 93.279			1,818,445	17,373,246
Centers for Disease Control and Prevention Investigations and Technical Assistance				
Pass-through Fdtn for Atlanta Veterans Educ and Res	2016 EIP	93.283	—	(4,063)
Pass-through Fdtn for Atlanta Veterans Educ and Res	40500-036-16130867	93.283	—	(1,162)
Pass-through Fdtn for Atlanta Veterans Educ and Res	NU50CK000485	93.283	—	15
Total AL No. 93.283			—	(5,210)
COVID-19 – Discovery And Applied Research For Technological Innovations To Improve Human Health	U54EB027690	93.286	592,783	2,660,288
Discovery And Applied Research For Technological Innovations To Improve Human Health	R01EB027147	93.286	27,399	65,367
Discovery And Applied Research For Technological Innovations To Improve Human Health	R01EB027774	93.286	136,727	367,208
Discovery And Applied Research For Technological Innovations To Improve Human Health	R01EB028350	93.286	138,563	161,579
Discovery And Applied Research For Technological Innovations To Improve Human Health	R01EB029320	93.286	138,736	91,849
Discovery And Applied Research For Technological Innovations To Improve Human Health	R01EB029857	93.286	34,341	13,042
Discovery And Applied Research For Technological Innovations To Improve Human Health	R01EB035582	93.286	140,111	396,718
Discovery And Applied Research For Technological Innovations To Improve Human Health	R13EB035467	93.286	—	7,324
Discovery And Applied Research For Technological Innovations To Improve Human Health	R13EB035921	93.286	—	10,000
Discovery And Applied Research For Technological Innovations To Improve Human Health	R13EB035927	93.286	—	13,000
Discovery And Applied Research For Technological Innovations To Improve Human Health	R21EB029622	93.286	—	28,632
Discovery And Applied Research For Technological Innovations To Improve Human Health	R21EB031545	93.286	47,937	61,937
Discovery And Applied Research For Technological Innovations To Improve Human Health	R21EB033994	93.286	—	395,113
Discovery And Applied Research For Technological Innovations To Improve Human Health	R56EB033332	93.286	—	14,824
Discovery And Applied Research For Technological Innovations To Improve Human Health	T32EB035514	93.286	—	2,585
Discovery And Applied Research For Technological Innovations To Improve Human Health	U54EB027690	93.286	458,603	1,279,662
Pass-through Beth Israel Deaconess Medical Center	R01EB030362	93.286	—	47,566
Pass-through Boston University	R01EB035429	93.286	—	139,916
Pass-through Georgia Institute of Technology	R01EB023808	93.286	—	(6,847)
Pass-through Georgia Institute of Technology	R01EB031101	93.286	—	197,477
Pass-through Georgia Institute of Technology	T32EB021962	93.286	—	23,235
Pass-through Georgia Institute of Technology	T32EB025816	93.286	—	57,773
Pass-through Massachusetts General Hospital	R01EB027122	93.286	—	15,291
Pass-through University of Maryland, Baltimore	R01EB032680	93.286	—	190,797
Total AL No. 93.286			1,715,200	6,234,336
Minority Health And Health Disparities Research	F31MD018957	93.307	—	46,036
Minority Health And Health Disparities Research	K01MD016170	93.307	35,014	142,719
Minority Health And Health Disparities Research	K01MD018637	93.307	13,392	155,910
Minority Health And Health Disparities Research	K23MD015088	93.307	—	113,214
Minority Health And Health Disparities Research	R01MD013320	93.307	89,301	310,728
Minority Health And Health Disparities Research	R01MD015204	93.307	483,617	802,644
Minority Health And Health Disparities Research	R01MD015395	93.307	—	57,111
Minority Health And Health Disparities Research	R01MD016031	93.307	—	449,331
Minority Health And Health Disparities Research	R21MD017943	93.307	—	166,673
Minority Health And Health Disparities Research	R21MD019304	93.307	—	81,602

EMORY UNIVERSITY AND ITS SUBSIDIARIES
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2025

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Pass-through African Health Research Institute	UG1MD019435	93.307	\$ —	86,444
Pass-through Columbia University	R01MD016386	93.307	—	12,202
Pass-through Columbia University	R01MD016899	93.307	—	22,742
Pass-through Florida International University	U54MD012393	93.307	—	19,683
Pass-through Medical University of South Carolina	R01MD015395	93.307	—	1,419
Pass-through New York University	R01MD018528	93.307	—	361,755
Pass-through University of Cincinnati	R25MD019150	93.307	—	10,734
Pass-through University of Michigan	R01MD016244	93.307	—	88,846
Pass-through University of Minnesota	R01MD013801	93.307	—	99,863
Pass-through University of Pennsylvania	R01MD013558	93.307	—	34,105
Total AL No. 93.307			<u>621,324</u>	<u>3,063,761</u>
COVID-19 – Trans-Nih Research Support	P30DK111024	93.310	—	5,366
COVID-19 – Trans-Nih Research Support	U01DK132737	93.310	221,371	413,773
COVID-19 – Trans-Nih Research Support	U01MD018313	93.310	44,700	238,342
Trans-Nih Research Support	DP2GM149749	93.310	7,996	616,910
Trans-Nih Research Support	DP2GM154151	93.310	—	439,906
Trans-Nih Research Support	OT2OD038065	93.310	—	41,419
Trans-Nih Research Support	R01CA271304	93.310	—	348,902
Trans-Nih Research Support	R01CA297856	93.310	—	140,229
Trans-Nih Research Support	R03HD108261	93.310	—	42,237
Trans-Nih Research Support	R25OD039834	93.310	7,713	99,298
Trans-Nih Research Support	U24DK112341	93.310	20,616	389,419
Trans-Nih Research Support	UG3OD023318	93.310	—	678,448
Trans-Nih Research Support	UH3TR002855	93.310	—	71,506
Pass-through Cerebral Palsy Foundation	UG3OD035546	93.310	—	98,509
Pass-through Massachusetts General Hospital	OT2OD032701	93.310	—	527,053
Pass-through Mount Sinai School of Medicine	DP5OD031876	93.310	—	72,131
Pass-through Pennington Biomedical Research Center	UG1OD024959	93.310	—	30,925
Pass-through Research Triangle Institute	R03HD106123	93.310	—	745
Pass-through Univ of Arkansas for Medical Services	U24OD024957	93.310	—	50,373
Pass-through University of California San Francisco	R33HD105618	93.310	—	32,784
Pass-through University of Miami	OT2OD26551	93.310	—	(4,414)
Pass-through University of Michigan	U54CA280805	93.310	—	46,672
Pass-through Vanderbilt University Medical Center	OT2OD035404	93.310	—	68,573
Pass-through Vanderbilt University Medical Center	UH3OD023282	93.310	—	(13)
Pass-through Women & Infants Hospital of Rhode Island	UH3OD023347	93.310	—	47,440
Total AL No. 93.310			<u>302,396</u>	<u>4,496,533</u>
Emerging Infections Programs				
Pass-through Georgia Dept of Public Health	NU50CK000645	93.317	117,995	8,215,436
Total AL No. 93.317			<u>117,995</u>	<u>8,215,436</u>
COVID-19 – Protecting and Improving Health Globally Building and Strengthening Public Health Impact, Systems, Capacity and Security	NU14GH001238	93.318	40,000	179,094
Protecting and Improving Health Globally Building and Strengthening Public Health Impact, Systems, Capacity and Security	NU14GH001238	93.318	—	37,637
Total AL No. 93.318			<u>40,000</u>	<u>216,731</u>

EMORY UNIVERSITY AND ITS SUBSIDIARIES
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2025

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) Pass-through Stanford University	0187.5110 ELC	93.323	\$ —	9,999
Total AL No. 93.323			—	9,999
The Healthy Brain Initiative Technical Assistance to Implement Public Health Actions related to Cognitive Health, Cognitive Impairment, and Caregiving at the State and Local Levels Pass-through Alzheimers Association	NU58DP006912	93.334	—	63,699
Total AL No. 93.334			—	63,699
National Center For Advancing Translational Sciences	KL2TR0002381	93.350	317,529	1,522,488
National Center For Advancing Translational Sciences	R03TR0004312	93.350	—	92,109
National Center For Advancing Translational Sciences	TL1TR0002382	93.350	98,937	588,093
National Center For Advancing Translational Sciences	U54TR001456	93.350	—	155
National Center For Advancing Translational Sciences	UL1TR0002378	93.350	4,440,071	9,984,120
Pass-through Rockefeller University	UL1TR001866	93.350	—	4,243
Pass-through University of Michigan	R01TR0004244	93.350	—	13,676
Pass-through University of North Carolina Chapel Hill	U01TR0003629	93.350	—	50,629
Pass-through University of North Carolina Chapel Hill	U01TR0003715	93.350	—	48,511
Pass-through University of Pittsburgh	UL1TR001857	93.350	—	(6,923)
Pass-through Wake Forest University	UG3TR0004803	93.350	—	97,760
Total AL No. 93.350			4,856,537	12,394,861
Research Infrastructure Programs	P51OD011132	93.351	44,767	25,711,491
Research Infrastructure Programs	R13OD034052	93.351	88,851	88,851
Research Infrastructure Programs	R21OD035572	93.351	—	498,229
Research Infrastructure Programs	R24OD030035	93.351	95,380	676,794
Research Infrastructure Programs	S10OD034303	93.351	—	129,319
Research Infrastructure Programs	S10OD034326	93.351	—	360,357
Research Infrastructure Programs	S10OD038233	93.351	—	1,502,652
Research Infrastructure Programs	S10OD038274	93.351	—	1,083,750
Research Infrastructure Programs	U42OD011023	93.351	—	1,468,605
Pass-through Henry M Jackson Foundation	K01OD031900	93.351	—	219,183
Total AL No. 93.351			228,998	31,739,231
Construction Support	C06OD036046	93.352	—	495,441
Construction Support	C06OD037746	93.352	—	141,230
Total AL No. 93.352			—	636,671
21st Century Cures Act – Beau Biden Cancer Moonshot Pass-through City of Hope	R37CA284040	93.353	—	69,746
Pass-through Dana Farber Cancer Institute	U24CA233243	93.353	—	68
Pass-through University of Alabama Birmingham	U01CA246567	93.353	—	103,622
Pass-through University of Florida	R37CA288560	93.353	—	6,924
Pass-through University of Michigan	U01CA254822	93.353	—	21,118
Pass-through Vanderbilt University Medical Center	U2CCA233291	93.353	—	25
Total AL No. 93.353			—	201,503

EMORY UNIVERSITY AND ITS SUBSIDIARIES
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2025

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Nurse Education, Practice Quality and Retention Grants	T1Q47312	93.359	\$ —	877,797
Nurse Education, Practice Quality and Retention Grants	UK147321	93.359	393,983	1,045,481
Nurse Education, Practice Quality and Retention Grants	US647225	93.359	—	285,634
Total AL No. 93.359			393,983	2,208,912
Biomedical Advanced Research and Development Authority (BARDA), Biodefense Medical Countermeasure Development	IDSEP190055	93.360	63,034	63,034
Total AL No. 93.360			63,034	63,034
Nursing Research	F31NR014611	93.361	—	(1,245)
Nursing Research	F31NR020575	93.361	—	39,934
Nursing Research	F31NR020847	93.361	—	44,834
Nursing Research	F31NR020848	93.361	—	59,066
Nursing Research	F31NR020988	93.361	—	43,602
Nursing Research	F31NR021000	93.361	—	36,062
Nursing Research	K01NR019651	93.361	—	103,281
Nursing Research	K23NR020037	93.361	—	8,302
Nursing Research	K23NR020208	93.361	—	84,324
Nursing Research	K23NR020356	93.361	—	145,154
Nursing Research	K23NR020631	93.361	—	191,308
Nursing Research	K24NR018866	93.361	—	70,734
Nursing Research	R01NR017939	93.361	70,790	215,634
Nursing Research	R01NR018666	93.361	48,635	298,961
Nursing Research	R01NR019083	93.361	30,772	789,484
Nursing Research	R01NR019254	93.361	74,455	640,140
Nursing Research	R01NR020154	93.361	—	477,165
Nursing Research	R01NR020188	93.361	288,013	575,954
Nursing Research	R01NR020756	93.361	147,322	491,923
Nursing Research	R01NR021664	93.361	—	609,250
Nursing Research	R25NR021324	93.361	4,600	201,051
Nursing Research	R25NR021371	93.361	—	193,823
Nursing Research	T32NR020778	93.361	—	296,081
Pass-through Cincinnati Childrens Hospital	R01NR020781	93.361	8,933	30,718
Pass-through Johns Hopkins University	R01NR020437	93.361	—	313,014
Pass-through RAND	R01NR020788	93.361	—	71,179
Pass-through State University of New York	R01NR018979	93.361	—	181,915
Total AL No. 93.361			673,520	6,211,648
21st Century Cures Act - Precision Medicine Initiative				
Pass-through University of North Carolina Chapel Hill	OT2 OD036113	93.368	—	480,764
Total AL No. 93.368			—	480,764
Advanced Research Projects Agency For Health (ARPA-H)	AY1AX000001	93.384	2,248,531	7,305,549
Advanced Research Projects Agency For Health (ARPA-H)	D25AC00140	93.384	93,220	1,854,816
Pass-through Columbia University	D24AC00345	93.384	—	2,345,268
Pass-through La Jolla Institute For Immunology	AY1AX000055	93.384	—	8,624

EMORY UNIVERSITY AND ITS SUBSIDIARIES
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2025

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Pass-through University of Pennsylvania	D24AC00253	93.384	\$ —	40,006
Total AL No. 93.384			<u>2,341,751</u>	<u>11,554,263</u>
National and State Tobacco Control Program	R01HL155711	93.387	91,096	761,966
Total AL No. 93.387			<u>91,096</u>	<u>761,966</u>
Cancer Cause And Prevention Research	F99CA294242	93.393	—	45,561
Cancer Cause And Prevention Research	OT2CA297571	93.393	—	314,952
Cancer Cause And Prevention Research	R01CA178999	93.393	—	181,739
Cancer Cause And Prevention Research	R01CA198279	93.393	—	300,800
Cancer Cause And Prevention Research	R01CA211574	93.393	99,328	125,880
Cancer Cause And Prevention Research	R01CA216579	93.393	14,441	415,899
Cancer Cause And Prevention Research	R01CA218155	93.393	—	3,028
Cancer Cause And Prevention Research	R01CA218389	93.393	6,299	36,255
Cancer Cause And Prevention Research	R01CA227918	93.393	—	(354)
Cancer Cause And Prevention Research	R01CA230268	93.393	—	40,421
Cancer Cause And Prevention Research	R01CA234538	93.393	—	249,105
Cancer Cause And Prevention Research	R01CA235721	93.393	75,624	275,418
Cancer Cause And Prevention Research	R01CA237318	93.393	703,812	1,226,793
Cancer Cause And Prevention Research	R01CA245063	93.393	11,569	448,654
Cancer Cause And Prevention Research	R01CA250110	93.393	69,288	449,611
Cancer Cause And Prevention Research	R01CA254403	93.393	—	697,249
Cancer Cause And Prevention Research	R01CA259192	93.393	—	597,629
Cancer Cause And Prevention Research	R01CA261887	93.393	139,226	355,065
Cancer Cause And Prevention Research	R01CA266574	93.393	19,543	458,802
Cancer Cause And Prevention Research	R01CA268024	93.393	528,759	929,069
Cancer Cause And Prevention Research	R01CA281873	93.393	—	190,281
Cancer Cause And Prevention Research	R01CA285198	93.393	289,062	757,012
Cancer Cause And Prevention Research	R01CA286051	93.393	228,777	522,099
Cancer Cause And Prevention Research	R01CA289761	93.393	—	377,283
Cancer Cause And Prevention Research	R03CA267456	93.393	—	4,882
Cancer Cause And Prevention Research	R03CA289843	93.393	—	3,196
Cancer Cause And Prevention Research	R21CA273773	93.393	—	65,160
Cancer Cause And Prevention Research	R37CA234119	93.393	73,912	418,795
Cancer Cause And Prevention Research	R37CA276317	93.393	407,140	838,671
Cancer Cause And Prevention Research	R37CA296075	93.393	29,897	86,705
Cancer Cause And Prevention Research	U01CA240581	93.393	22,557	355,223
Cancer Cause And Prevention Research	U01CA269181	93.393	21,600	304,061
Cancer Cause And Prevention Research	U01CA275113	93.393	301,135	585,245
Cancer Cause And Prevention Research	U01CA275120	93.393	125,939	325,020
Pass-through Baylor College of Medicine	R01CA263000	93.393	—	120,154
Pass-through Case Western Reserve University	R01CA220581	93.393	—	430,281
Pass-through Dana Farber Cancer Institute	R01CA269574	93.393	—	9,820
Pass-through Dana Farber Cancer Institute	R01CA274484	93.393	—	17,884
Pass-through Duke University	R21CA284299	93.393	—	29,636
Pass-through Duke University	R33CA274665	93.393	—	7,876
Pass-through George Washington University	R01CA278229	93.393	—	97,894
Pass-through Georgia State University	R01CA248551	93.393	—	116,058

EMORY UNIVERSITY AND ITS SUBSIDIARIES
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2025

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Pass-through Georgia State University	R01CA261887	93.393	\$ —	4,081
Pass-through M D Anderson Cancer Center	R01CA261750	93.393	—	103,725
Pass-through Mayo Clinic	R01CA248288	93.393	—	51,900
Pass-through Mayo Clinic	U01CA195568	93.393	—	140,338
Pass-through Mayo Clinic Arizona	U01CA269264	93.393	—	26,035
Pass-through Md Anderson	R01CA255322	93.393	—	225,010
Pass-through Moffitt Cancer Center	R01CA275974	93.393	—	118,273
Pass-through North Carolina State University	UG3CA265842	93.393	—	(265)
Pass-through North Carolina State University	UH3CA265842	93.393	—	624,828
Pass-through Ohio State University	R01CA266402	93.393	—	23,388
Pass-through Public Health Institute	R01CA264519	93.393	—	267,452
Pass-through Roswell Park Cancer Institute	R01CA258337	93.393	—	1,941
Pass-through Stanford University	R01CA283207	93.393	—	118,519
Pass-through State University of New York Stony Brook	R01CA235720	93.393	—	51,220
Pass-through Texas Agricultural and Mechanical Univ	R01CA257559	93.393	—	9,797
Pass-through University of Vermont	R01CA286069	93.393	—	35,565
Pass-through University of Alabama Birmingham	R01CA248439	93.393	—	5,424
Pass-through University of Alabama Birmingham	R01CA262039	93.393	—	62,978
Pass-through University of Alabama Birmingham	R21CA267124	93.393	—	98,261
Pass-through University of Arizona	R01CA264047	93.393	—	52,514
Pass-through University of California Irvine	R01CA262312	93.393	—	125,708
Pass-through University of California Irvine	R01CA272680	93.393	—	18,807
Pass-through University of Colorado Denver	R37CA246565	93.393	—	2,763
Pass-through University of Florida	R01CA268014	93.393	—	25,024
Pass-through University of Iowa	R01CA259048	93.393	—	49,550
Pass-through University of Michigan	R01CA237046	93.393	—	30,561
Pass-through University of Michigan	R01CA281976	93.393	—	167,151
Pass-through University of Michigan	R37CA251464	93.393	—	38,952
Pass-through University of Michigan	R37CA275907	93.393	—	152,512
Pass-through University of Southern California	R01CA279668	93.393	—	337,998
Pass-through University of Southern California	U01CA287036	93.393	—	183,372
Pass-through University of Southern California	U19CA214253	93.393	—	166,061
Pass-through University of Utah	R01CA237404	93.393	—	47,988
Pass-through University of Washington Saint Louis	1R01CA286120-01A1	93.393	—	91,834
Pass-through Vanderbilt University Medical Center	R01CA230352	93.393	—	47
Pass-through Vanderbilt University Medical Center	UG3CA265846	93.393	—	300,990
Total AL No. 93.393			<u>3,167,908</u>	<u>16,575,114</u>
COVID-19 – Cancer Detection And Diagnosis Research	U54CA260563	93.394	23,078	740,812
Cancer Detection And Diagnosis Research	R01CA169188	93.394	—	(12,034)
Cancer Detection And Diagnosis Research	R01CA249992	93.394	270,479	773,167
Cancer Detection And Diagnosis Research	R01CA257612	93.394	167,536	833,229
Cancer Detection And Diagnosis Research	R01CA261251	93.394	65,211	682,114
Cancer Detection And Diagnosis Research	R01CA268287	93.394	238,414	747,598
Cancer Detection And Diagnosis Research	R01CA272991	93.394	132,531	529,130
Cancer Detection And Diagnosis Research	R01CA277527	93.394	—	253,137
Cancer Detection And Diagnosis Research	R01CA281932	93.394	144,487	654,901
Cancer Detection And Diagnosis Research	R01CA283687	93.394	1,490	316,275
Cancer Detection And Diagnosis Research	R21CA256280	93.394	—	10,624

EMORY UNIVERSITY AND ITS SUBSIDIARIES
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2025

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Cancer Detection And Diagnosis Research	R21CA259935	93.394	\$ —	37,738
Cancer Detection And Diagnosis Research	R21CA286283	93.394	—	156,669
Cancer Detection And Diagnosis Research	U01CA113913	93.394	11,493	763,438
Cancer Detection And Diagnosis Research	U01CA264039	93.394	288,160	584,365
Cancer Detection And Diagnosis Research	U54CA260563	93.394	—	194,164
Pass-through Case Western Reserve University	U01CA260513	93.394	—	632
Pass-through Children's Hospital of Philadelphia	R01CA248501	93.394	—	97,602
Pass-through Dartmouth College	PO1CA190193	93.394	—	39
Pass-through Fred Hutchinson Research Center	U01CA224255	93.394	—	1,450
Pass-through Georgia Institute of Technology	R01CA273878	93.394	—	11,880
Pass-through Georgia Institute of Technology	R37CA239039	93.394	—	9,695
Pass-through Georgia Institute of Technology	R37CA289714	93.394	—	5,254
Pass-through Georgia Institute of Technology	R61CA281667	93.394	—	40,169
Pass-through La Jolla Institute For Immunology	AY1AX000055	93.394	—	253,777
Pass-through Memorial Sloan Kettering Cancer Center	U24CA264369	93.394	—	58,922
Pass-through Moffitt Cancer Center	R56CA279060	93.394	—	73,677
Pass-through Northwestern University	R01CA240639	93.394	—	40,310
Pass-through Ohio State University	R01CA237133	93.394	—	8,732
Pass-through Rhode Island Hospital	U24CA265879	93.394	—	15,399
Pass-through State Univ of New York Downstate Med Ctr	R01CA24966701A	93.394	—	12,207
Pass-through Thomas Jefferson University	R01CA236857	93.394	—	43,730
Pass-through Thomas Jefferson University	UH3CA247605	93.394	—	107,151
Pass-through University of California Davis	U01CA269191	93.394	—	55,174
Pass-through University of South Florida	R01CA240319	93.394	19,236	29,391
Pass-through University of Washington Seattle	R01CA268207	93.394	—	208,568
Pass-through University of Wisconsin-Madison	R01CA264017	93.394	—	6,469
Total AL No. 93.394			1,362,115	8,345,555
Cancer Treatment Research	P01CA257906	93.395	—	1,783,857
Cancer Treatment Research	R01CA223220	93.395	—	98,732
Cancer Treatment Research	R01CA226992	93.395	—	81,302
Cancer Treatment Research	R01CA228406	93.395	27,984	214,505
Cancer Treatment Research	R01CA238471	93.395	—	23,952
Cancer Treatment Research	R01CA245386	93.395	—	225,089
Cancer Treatment Research	R01CA255257	93.395	—	416,700
Cancer Treatment Research	R01CA257861	93.395	—	349,683
Cancer Treatment Research	R01CA262123	93.395	—	646,328
Cancer Treatment Research	R01CA267694	93.395	—	487,895
Cancer Treatment Research	R01CA276135	93.395	18,590	395,819
Cancer Treatment Research	R01CA277686	93.395	65,617	225,313
Cancer Treatment Research	R01CA281148	93.395	—	574,177
Cancer Treatment Research	R01CA284386	93.395	—	525,535
Cancer Treatment Research	R01CA285566	93.395	21,002	489,855
Cancer Treatment Research	R01CA286147	93.395	—	462,213
Cancer Treatment Research	R01CA287083	93.395	—	184,305
Cancer Treatment Research	R01CA287782	93.395	—	475,844
Cancer Treatment Research	R01CA287866	93.395	107,166	626,171
Cancer Treatment Research	R01CA288967	93.395	12,802	74,445
Cancer Treatment Research	R01CA289978	93.395	—	32,666

EMORY UNIVERSITY AND ITS SUBSIDIARIES
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2025

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Cancer Treatment Research	R01CA292466	93.395	\$ 13,456	240,439
Cancer Treatment Research	R01CA293596	93.395	143,715	336,481
Cancer Treatment Research	R01CA300792	93.395	—	176,678
Cancer Treatment Research	R01CA301614	93.395	—	254,805
Cancer Treatment Research	R03CA300834	93.395	—	4,300
Cancer Treatment Research	R03CA304028	93.395	—	4,424
Cancer Treatment Research	R21CA256456	93.395	—	(3,801)
Cancer Treatment Research	R21CA266088	93.395	16,062	71,051
Cancer Treatment Research	R21CA267612	93.395	—	68,325
Cancer Treatment Research	R21CA267914	93.395	11,573	45,142
Cancer Treatment Research	R21CA270903	93.395	6,097	94,152
Cancer Treatment Research	R21CA277103	93.395	—	57,329
Cancer Treatment Research	R21CA282579	93.395	—	74,597
Cancer Treatment Research	R21CA285254	93.395	—	116,688
Cancer Treatment Research	R21CA286273	93.395	—	111,608
Cancer Treatment Research	R37CA255459	93.395	—	412,467
Cancer Treatment Research	R50CA276010	93.395	—	156,292
Cancer Treatment Research	R50CA285492	93.395	—	178,403
Cancer Treatment Research	UG1CA233247	93.395	—	933,918
Cancer Treatment Research	UG1CA233259	93.395	593,061	676,193
Pass-through Childrens Healthcare of Atlanta	U10CA180886	93.395	—	15,006
Pass-through Childrens Healthcare of Atlanta	UM1CA228823	93.395	—	741
Pass-through Clark Atlanta University	R01CA256058	93.395	—	43,248
Pass-through Eastern Coop Oncology Group	U10CA180820	93.395	—	(538)
Pass-through Ecog-Acrin Medical Research Foundation	U10CA180820	93.395	—	39,442
Pass-through Fred Hutchinson Research Center	U01CA154967	93.395	—	(4,874)
Pass-through Frontier Science and Technology Res Fdn	E3612ECOG23	93.395	—	(626)
Pass-through Indiana University	R01CA235632	93.395	(835)	15,907
Pass-through Johns Hopkins University	UM1CA186691	93.395	—	(7,580)
Pass-through New York University	R01CA276438	93.395	—	93,985
Pass-through St Jude Childrens Research Hospital	U24CA055727	93.395	29,439	177,745
Pass-through St Jude Childrens Research Hospital	UM1CA081457	93.395	12,628	89,306
Pass-through University of Arizona	UG1CA242596	93.395	—	4,661
Pass-through University of California San Francisco	R01CA266596	93.395	—	15,173
Pass-through University of Chicago	R37CA272755	93.395	—	60,246
Pass-through University of Cincinnati	R01CA255331	93.395	—	13,028
Pass-through University of North Carolina Chapel Hill	R01CA249190	93.395	—	128,717
Pass-through University of North Carolina Chapel Hill	R01CA259077	93.395	—	111,217
Pass-through University of Tennessee Health Sciences nce Ctr	R01CA240447	93.395	—	423,819
Pass-through Washington University	R01CA258681	93.395	—	7,113
Total AL No. 93.395			1,078,357	13,629,613
Cancer Biology Research	R01CA175316	93.396	—	3,589
Cancer Biology Research	R01CA247367	93.396	58,588	424,141
Cancer Biology Research	R01CA250422	93.396	—	257,861
Cancer Biology Research	R01CA251393	93.396	100,453	752,336
Cancer Biology Research	R01CA257446	93.396	—	430,109
Cancer Biology Research	R01CA258765	93.396	38,742	618,869
Cancer Biology Research	R01CA258857	93.396	369,339	654,937

EMORY UNIVERSITY AND ITS SUBSIDIARIES
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2025

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Cancer Biology Research	R01CA266613	93.396	\$ —	415,741
Cancer Biology Research	R01CA275193	93.396	13,171	251,934
Cancer Biology Research	R01CA275199	93.396	28,491	687,115
Cancer Biology Research	R01CA275964	93.396	—	326,069
Cancer Biology Research	R01CA280069	93.396	—	536,635
Cancer Biology Research	R01CA284648	93.396	6,485	307,555
Cancer Biology Research	R01CA295722	93.396	—	268,273
Cancer Biology Research	R21CA274620	93.396	—	251
Cancer Biology Research	R21CA280584	93.396	—	237,828
Cancer Biology Research	R35CA197603	93.396	—	1,178
Cancer Biology Research	R50CA265345	93.396	—	147,804
Cancer Biology Research	UG3CA290302	93.396	514,570	700,450
Pass-through Baylor College of Medicine	R01CA271588	93.396	—	97,746
Pass-through Case Western Reserve University	R01CA266050	93.396	—	5,756
Pass-through Childrens Mercy Hospital	R01CA279065	93.396	—	49,594
Pass-through City of Hope	R37CA276517	93.396	—	6,260
Pass-through Georgia Institute of Technology	R01CA266052	93.396	—	196,266
Pass-through Georgia Institute of Technology	U01CA214354	93.396	—	(4,899)
Pass-through Georgia Institute of Technology	U01CA250040	93.396	—	170,768
Pass-through Houston Methodist Research Institute	U01CA253553	93.396	—	15,780
Pass-through Indiana University	R01CA121044	93.396	—	44,765
Pass-through University of Kentucky	R01CA278989	93.396	—	34,387
Pass-through University of North Carolina Chapel Hill	R01CA244361	93.396	—	8,013
Pass-through University of North Carolina Chapel Hill	R01CA248359	93.396	—	10,018
Pass-through University of Pennsylvania	U01CA254886	93.396	—	18,409
Total AL No. 93.396			1,129,839	7,675,538
Cancer Centers Support Grants	P30CA138292	93.397	55,409	3,734,732
Cancer Centers Support Grants	P50CA217691	93.397	13,937	866,791
Cancer Centers Support Grants	U54CA284036	93.397	369,832	708,108
Pass-through Case Western Reserve University	RES600415	93.397	—	153,926
Pass-through Case Western Reserve University	U54CA254566	93.397	—	35,724
Pass-through Cleveland Clinic Foundation	U54CA274513	93.397	—	739,904
Pass-through Mayo Clinic	P50CA116201	93.397	—	29,719
Total AL No. 93.397			439,178	6,268,904
Cancer Research Manpower	F30CA291027	93.398	—	31,940
Cancer Research Manpower	F31CA247564	93.398	—	1,335
Cancer Research Manpower	F31CA278008	93.398	—	51,584
Cancer Research Manpower	F31CA281258	93.398	—	47,787
Cancer Research Manpower	F31CA294972	93.398	—	53,678
Cancer Research Manpower	F31CA294990	93.398	—	2,399
Cancer Research Manpower	F31CA295014	93.398	—	4,798
Cancer Research Manpower	K08CA248962	93.398	—	116,919
Cancer Research Manpower	K08CA263541	93.398	—	192,002
Cancer Research Manpower	K08CA267055	93.398	—	258,248
Cancer Research Manpower	K08CA270401	93.398	—	244,856
Cancer Research Manpower	K08CA279766	93.398	—	63,686

EMORY UNIVERSITY AND ITS SUBSIDIARIES
Supplementary Schedule of Expenditures of Federal Awards
Year ended August 31, 2025

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Cancer Research Manpower	K12CA237806	93.398	\$ —	163,028
Cancer Research Manpower	K22CA266739	93.398	—	225,183
Cancer Research Manpower	R00CA252616	93.398	—	308,412
Cancer Research Manpower	R00CA277580	93.398	—	65,345
Cancer Research Manpower	R25CA265864	93.398	—	69,126
Cancer Research Manpower	R25CA281836	93.398	—	238,226
Cancer Research Manpower	T32CA272392	93.398	—	241,164
Cancer Research Manpower	T32CA275777	93.398	—	231,552
Total AL No. 93.398			—	2,611,268
Cancer Control	UG1CA275400	93.399	133,166	240,787
Cancer Control	UG1CA284884	93.399	3,233	233,665
Pass-through Nrg Oncology Foundation, Inc.	UG1CA189867	93.399	—	163,319
Total AL No. 93.399			136,399	637,771
COVID-19 - Strengthening Public Health Systems and Services through National Partnerships to Improve and Protect the Nation's Health	NU50CK000617	93.421	—	475,342
Strengthening Public Health Systems and Services through National Partnerships to Improve and Protect the Nation's Health				
Pass-through American College of Preventive Medicine	NU38O3000289	93.421	—	2,500
Pass-through American College of Preventive Medicine	NU38OT000289	93.421	—	19,458
Pass-through University of Washington	NU38OT000286	93.421	—	2,431
Pass-through University of Washington	NU38PW000036	93.421	—	35,000
Total AL No. 93.421			—	534,731
The National Cardiovascular Health Program				
Pass-through South Dakota Department of Health	NU58DP007438	93.426	—	215,475
Total AL No. 93.426			—	215,475
Networking2Save" CDC's National Network Approach to Preventing and Controlling Tobacco-related Cancers in Special Populations				
Pass-through Patient Advocate Foundation	NU58DP007621	93.431	—	43,332
Total AL No. 93.431			—	43,332
CDC Undergraduate Public Health Scholars Program (CUPS) A Public Health Experience to Expose Undergraduates Interested in Minority Health to Public Health and the Public Health Professions				
Pass-through Kennedy Krieger Institute	NU50CD300866	93.456	—	27,963
Total AL No. 93.456			—	27,963
Congressional Directives	H79FG001059	93.493	—	216,581
Total AL No. 93.493			—	216,581
COVID-19 – Affordable Care Act (ACA) Public Health Training Centers Program	T2946687	93.516	81,000	1,164,427
COVID-19 – Affordable Care Act (ACA) Public Health Training Centers Program	T5246760	93.516	—	22,866
Affordable Care Act (ACA) Public Health Training Centers Program	UB631680	93.516	251,209	1,240,000
Total AL No. 93.516			332,209	2,427,293

EMORY UNIVERSITY AND ITS SUBSIDIARIES
Supplementary Schedule of Expenditures of Federal Awards
Year ended August 31, 2025

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Children's Justice Grants to States Pass-through Georgia Department of Human Services Total AL No. 93.643	42700-040-25-118227	93.643	\$ —	86,544
			—	86,544
Child Abuse and Neglect Discretionary Activities Pass-through Research Institute at Nationwide Children's Hospital Total AL No. 93.670	UH3HL161338	93.670	—	135,858
			—	135,858
COVID-19 – Mental and Behavioral Health Education and Training Grants Mental and Behavioral Health Education and Training Grants Total AL No. 93.732	U3N45397 T6249312	93.732 93.732	— —	391,210 701,726
			—	1,092,936
Medical Assistance Program Pass-through Georgia Department of Behavioral Health Pass-through Georgia Department of Behavioral Health Total AL No. 93.778	2305GA5MAP 2505GA5MAP	93.778 93.778	— —	(106,062) 176,895
			—	70,833
Centers for Medicare and Medicaid Services (CMS) Research, Demonstrations and Evaluations Pass-through Prairie View A&M University Total AL No. 93.779	1W1CMS331887	93.779	—	17,416
			—	17,416
Paul Coverdell National Acute Stroke Program National Center for Chronic Disease Prevention and Health Promotion Pass-through Georgia Dept of Public Health Total AL No. 93.810	NU58DP006120	93.810	—	7,262
			—	7,262
Hospital Preparedness Program (HPP) Ebola Preparedness and Response Activities Hospital Preparedness Program (HPP) Ebola Preparedness and Response Activities Pass-through Georgia Dept of Public Health Pass-through Georgia Dept of Public Health Total AL No. 93.817	HITEP210054 U3REP220673 U3REP150546 U3REP150546	93.817 93.817 93.817 93.817	518,731 479,465 — —	2,209,464 1,824,637 69,825 22
			998,196	4,103,948
Health Careers Opportunity Program Health Careers Opportunity Program Total AL No. 93.822	6 D18HP290340301 D18HP32120	93.822 93.822	— 13,118	(1,287) 525,775
			13,118	524,488
COVID-19 - Public Health Response, Forecasting, and Analytic Capacities Related to Disease Outbreaks, Epidemics, and Pandemics Public Health Response, Forecasting, and Analytic Capacities Related to Disease Outbreaks, Epidemics, and Pandemics Total AL No. 93.823	NU38FT000001 NU38FT000001	93.823 93.823	503,862 —	3,454,544 988,054
			503,862	4,442,598
National Ebola Training and Education Center (NETEC) Total AL No. 93.825	U3REP150549	93.825	5,712,505	8,932,342
			5,712,505	8,932,342
Planning Grant for Healthcare and Public Health Sector Cybersecurity Information Sharing Pass-through University of Florida Total AL No. 93.835	R01NS112291	93.835	—	37,070
			—	37,070

EMORY UNIVERSITY AND ITS SUBSIDIARIES
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2025

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Cardiovascular Diseases Research	F31HL168878	93.837	\$ —	47,359
Cardiovascular Diseases Research	F31HL170697	93.837	—	49,444
Cardiovascular Diseases Research	F31HL172677	93.837	—	40,714
Cardiovascular Diseases Research	F31HL172683	93.837	—	41,708
Cardiovascular Diseases Research	F31HL176148	93.837	—	46,212
Cardiovascular Diseases Research	F32HL172499	93.837	—	60,127
Cardiovascular Diseases Research	K01HL155235	93.837	—	122,543
Cardiovascular Diseases Research	K01HL171465	93.837	—	132,082
Cardiovascular Diseases Research	K23HL143164	93.837	(665)	(718)
Cardiovascular Diseases Research	K23HL148545	93.837	9,129	177,559
Cardiovascular Diseases Research	K23HL152903	93.837	—	138,338
Cardiovascular Diseases Research	K24HL163696	93.837	—	106,916
Cardiovascular Diseases Research	K24HL171937	93.837	—	127,513
Cardiovascular Diseases Research	K24HL176324	93.837	—	45,293
Cardiovascular Diseases Research	P01HL154996	93.837	1,190,593	2,328,655
Cardiovascular Diseases Research	R00HL143211	93.837	—	333,986
Cardiovascular Diseases Research	R00HL144824	93.837	11,439	57,473
Cardiovascular Diseases Research	R00HL161355	93.837	—	295,906
Cardiovascular Diseases Research	R01HL109413	93.837	—	94,028
Cardiovascular Diseases Research	R01HL122392	93.837	143,105	457,357
Cardiovascular Diseases Research	R01HL125246	93.837	—	(196,994)
Cardiovascular Diseases Research	R01HL130471	93.837	—	(15,148)
Cardiovascular Diseases Research	R01HL135183	93.837	82,170	699,891
Cardiovascular Diseases Research	R01HL136205	93.837	—	(32,525)
Cardiovascular Diseases Research	R01HL140223	93.837	—	701,712
Cardiovascular Diseases Research	R01HL142762	93.837	—	457,965
Cardiovascular Diseases Research	R01HL143348	93.837	33,702	(871)
Cardiovascular Diseases Research	R01HL144741	93.837	—	201,194
Cardiovascular Diseases Research	R01HL150005	93.837	—	281,627
Cardiovascular Diseases Research	R01HL155537	93.837	185,145	506,781
Cardiovascular Diseases Research	R01HL155549	93.837	85,512	728,442
Cardiovascular Diseases Research	R01HL156008	93.837	—	772,009
Cardiovascular Diseases Research	R01HL157242	93.837	—	816,879
Cardiovascular Diseases Research	R01HL157311	93.837	—	930,822
Cardiovascular Diseases Research	R01HL157323	93.837	595,493	858,523
Cardiovascular Diseases Research	R01HL158141	93.837	41,253	573,142
Cardiovascular Diseases Research	R01HL158571	93.837	8,419	708,416
Cardiovascular Diseases Research	R01HL160589	93.837	—	547,839
Cardiovascular Diseases Research	R01HL160693	93.837	216,850	585,946
Cardiovascular Diseases Research	R01HL161366	93.837	183,799	643,561
Cardiovascular Diseases Research	R01HL163998	93.837	449,506	1,007,977
Cardiovascular Diseases Research	R01HL164806	93.837	—	564,542
Cardiovascular Diseases Research	R01HL165252	93.837	—	748,848
Cardiovascular Diseases Research	R01HL165940	93.837	81,487	426,723
Cardiovascular Diseases Research	R01HL166004	93.837	—	721,704
Cardiovascular Diseases Research	R01HL166233	93.837	136,615	480,503
Cardiovascular Diseases Research	R01HL166817	93.837	—	544,778
Cardiovascular Diseases Research	R01HL168383	93.837	—	583,617
Cardiovascular Diseases Research	R01HL168894	93.837	85,825	628,496

EMORY UNIVERSITY AND ITS SUBSIDIARIES
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2025

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Cardiovascular Diseases Research	R01HL169955	93.837	\$ —	836,105
Cardiovascular Diseases Research	R01HL175069	93.837	83,198	512,429
Cardiovascular Diseases Research	R21HL156184	93.837	—	8,000
Cardiovascular Diseases Research	R21HL172209	93.837	—	129,014
Cardiovascular Diseases Research	R33HL154116	93.837	—	(1,388)
Cardiovascular Diseases Research	R38HL167243	93.837	—	149,024
Cardiovascular Diseases Research	R56HL164737	93.837	1,586	92,199
Cardiovascular Diseases Research	T32HL007745	93.837	—	439,202
Cardiovascular Diseases Research	T32HL130025	93.837	—	660,431
Cardiovascular Diseases Research	T32HL166146	93.837	62,269	352,062
Cardiovascular Diseases Research	U01HL146241	93.837	142,336	4,023,930
Cardiovascular Diseases Research	U54HL141981	93.837	142,791	480,686
Cardiovascular Diseases Research	UM1HL172715	93.837	179,203	261,626
Pass-through Albert Einstein College of Medicine	R01HL159062	93.837	—	41,174
Pass-through Ann & Robert H. Lurie Children's Hospital	R01HL118491	93.837	—	16,694
Pass-through Ann & Robert H. Lurie Children's Hospital	R01HL164773	93.837	—	2,431
Pass-through Ann & Robert H. Lurie Children's Hospital	UH3HL148318	93.837	3,813	11,432
Pass-through Beth Israel Deaconess Medical Center	R01HL161697	93.837	—	16,970
Pass-through Beth Israel Deaconess Medical Center	R01HL173557	93.837	—	149,187
Pass-through Beth Israel Deaconess Medical Center	R01HL177355	93.837	—	8,151
Pass-through Case Western Reserve University	R01HL158071	93.837	—	266,725
Pass-through Cedars Sinai Medical Center	R01HL159428	93.837	—	118,205
Pass-through Cincinnati Childrens Hospital	U01HL131003	93.837	39,702	66,602
Pass-through Duke University	R01HL177003	93.837	—	96,280
Pass-through Frontier Science and Technology Res Fdn	PSAWCIEM00	93.837	—	(19,661)
Pass-through Frontier Science and Technology Res Fdn	PSAWCIEMOO	93.837	—	(23,947)
Pass-through Georgia Institute of Technology	R01HL135505	93.837	—	(4,197)
Pass-through Georgia Institute of Technology	R01HL140325	93.837	—	(218,673)
Pass-through Georgia Institute of Technology	R01HL144714	93.837	—	2,420
Pass-through Georgia State University	R01HL168465	93.837	—	48,407
Pass-through Indiana University	R01HL171631	93.837	8,598	15,413
Pass-through Johns Hopkins University	R01HL138714	93.837	—	363,532
Pass-through Mayo Clinic Arizona	R01HL167811	93.837	—	308,553
Pass-through Montana State University	R01HL163237	93.837	—	20,388
Pass-through Ohio State University	R01HL148581	93.837	—	(36)
Pass-through Research Institute at Nationwide Children's Hospital	R01HL145032	93.837	—	(61)
Pass-through Research Institute at Nationwide Children's Hospital	UG3HL166794	93.837	—	2,709
Pass-through Research Institute at Nationwide Children's Hospital	UH3HL166794	93.837	—	144,824
Pass-through Research Triangle Institute	U54HL178351	93.837	—	450,327
Pass-through State University of New York	R25HL105446	93.837	—	(4,694)
Pass-through Univ of Texas Health Sciences Ctr	R01HL160793	93.837	—	46,522
Pass-through Univ of Texas Hlth Sci Ctr At San Antoni	R21HL157810	93.837	—	(14,091)
Pass-through University of Mississippi Medical Center	R01HL175323	93.837	—	67,383
Pass-through University of Alabama Birmingham	R01HL131017	93.837	—	280,176
Pass-through University of California Berkeley	R01HL157820	93.837	—	106,485
Pass-through University of California Davis	R01HL124879	93.837	—	(1,016)
Pass-through University of California Los Angeles	R01HL160850	93.837	—	25,707
Pass-through University of Cincinnati	R01HL156779	93.837	—	87,514
Pass-through University of Cincinnati	U01HL131755	93.837	—	(663)

EMORY UNIVERSITY AND ITS SUBSIDIARIES
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2025

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Pass-through University of Georgia	R01HL173931	93.837	\$ —	62,564
Pass-through University of Miami	R01HL164405	93.837	—	139,786
Pass-through University of Pennsylvania	R01HL151277	93.837	—	77,692
Pass-through University of Pittsburgh	R01HL174652	93.837	—	190,865
Pass-through University of Texas Houston	K01HL149982	93.837	—	(1,952)
Pass-through University of Texas San Antonio	U01HL146382	93.837	—	81,852
Pass-through University of Texas Southwestern	K01HL149982	93.837	—	25,297
Pass-through University of Virginia	R01HL137112	93.837	—	286,747
Pass-through University of Washington	R01HL153136	93.837	—	19,628
Pass-through Washington University	R01HL156991	93.837	—	36,934
Pass-through Yale University	R01HL172840	93.837	—	11,148
Total AL No. 93.837			4,202,873	31,529,947
Lung Diseases Research	F31HL164049	93.838	—	27,603
Lung Diseases Research	F31HL168914	93.838	—	15,876
Lung Diseases Research	F31HL168949	93.838	—	47,477
Lung Diseases Research	F31HL176090	93.838	—	52,065
Lung Diseases Research	K23HL151897	93.838	—	46,550
Lung Diseases Research	K23HL166775	93.838	—	162,592
Lung Diseases Research	R00HL151965	93.838	—	7,144
Lung Diseases Research	R01HL094622	93.838	—	404,484
Lung Diseases Research	R01HL136414	93.838	212,870	380,174
Lung Diseases Research	R01HL139876	93.838	169,654	155,444
Lung Diseases Research	R01HL144478	93.838	112,494	94,605
Lung Diseases Research	R01HL148171	93.838	40,613	350,492
Lung Diseases Research	R01HL150658	93.838	—	512,464
Lung Diseases Research	R01HL158747	93.838	335,870	534,727
Lung Diseases Research	R01HL158979	93.838	283,155	597,855
Lung Diseases Research	R01HL159058	93.838	52,275	1,008,449
Lung Diseases Research	R01HL162171	93.838	9,658	861,291
Lung Diseases Research	R01HL166455	93.838	—	195,379
Lung Diseases Research	R01HL169373	93.838	32,886	808,615
Lung Diseases Research	R01HL171627	93.838	77,302	438,130
Lung Diseases Research	R01HL171735	93.838	130,312	638,905
Lung Diseases Research	R01HL173340	93.838	16,287	702,901
Lung Diseases Research	R01HL173500	93.838	—	343,713
Lung Diseases Research	R01HL175515	93.838	—	29,728
Lung Diseases Research	R01HL176542	93.838	603	347,222
Lung Diseases Research	R35HL150803	93.838	—	392,715
Lung Diseases Research	T32HL116271	93.838	—	(3,342)
Lung Diseases Research	U24HL171672	93.838	127,410	719,801
Pass-through Ann & Robert H. Lurie Children's Hospital	R01HL163692	93.838	—	62
Pass-through Ann & Robert H. Lurie Children's Hospital	R01HL164570	93.838	—	16,770
Pass-through Cincinnati Childrens Hospital	R34HL158586	93.838	—	31,103
Pass-through Georgia Institute of Technology	R01HL173002	93.838	—	21,270
Pass-through Georgia State University	R61HL173984	93.838	—	50,000
Pass-through Massachusetts General Hospital	OT2HL161841-01	93.838	—	209,233
Pass-through Medical College of Georgia	R01HL138410	93.838	—	(19,825)
Pass-through Morehouse School of Medicine	OT2HL158287	93.838	—	64,138

EMORY UNIVERSITY AND ITS SUBSIDIARIES
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2025

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Pass-through Mount Sinai Medical Center	R01HL164775	93.838	\$ —	31,687
Pass-through New York University	OT2HL161847-01	93.838	4,137	5,812
Pass-through NYU Grossman School of Medicine	OT2HL161847	93.838	208,940	551,081
Pass-through Purdue University	R01HL167046	93.838	—	174,921
Pass-through RTI International	1OT2HL156812-01	93.838	—	190,526
Pass-through RTI International	OT2HL156812	93.838	—	41,830
Pass-through Society of Critical Care Medicine	R01HL162954	93.838	—	3,269
Pass-through University of Arizona	UG3HL147016	93.838	—	147,894
Pass-through University of Cincinnati	R01HL170156	93.838	—	11,703
Pass-through University of Colorado	OT2HL161847-01	93.838	—	(7,697)
Pass-through University of Florida	OT2HL161847	93.838	—	41,738
Pass-through University of Georgia	R01HL163256	93.838	—	12,178
Pass-through University of Michigan	R01HL162661	93.838	—	20,649
Pass-through University of North Carolina Chapel Hill	OT2HL161847	93.838	—	256,066
Pass-through Weill Cornell Medical College	UH3HL154944	93.838	—	5,141
Total AL No. 93.838			1,814,466	11,732,608
Blood Diseases And Resources Research	F31HL158223	93.839	—	53,741
Blood Diseases And Resources Research	K08HL141635	93.839	—	20,603
Blood Diseases And Resources Research	K08HL151965	93.839	—	122,822
Blood Diseases And Resources Research	K23HL146904	93.839	25,220	162,298
Blood Diseases And Resources Research	K25HL141636	93.839	—	11,347
Blood Diseases And Resources Research	K99HL150626	93.839	—	74,731
Blood Diseases And Resources Research	K99HL156073	93.839	—	77,396
Blood Diseases And Resources Research	K99HL175098	93.839	—	96,770
Blood Diseases And Resources Research	R00HL177821	93.839	—	179,894
Blood Diseases And Resources Research	R01HL130995	93.839	—	309,057
Blood Diseases And Resources Research	R01HL140589	93.839	—	(84)
Blood Diseases And Resources Research	R01HL146668	93.839	65,395	201,551
Blood Diseases And Resources Research	R01HL152074	93.839	—	47,039
Blood Diseases And Resources Research	R01HL152131	93.839	—	29,786
Blood Diseases And Resources Research	R01HL152322	93.839	—	272,783
Blood Diseases And Resources Research	R01HL155330	93.839	939	461,374
Blood Diseases And Resources Research	R01HL159213	93.839	54,360	536,165
Blood Diseases And Resources Research	R01HL162725	93.839	—	473,504
Blood Diseases And Resources Research	R01HL163637	93.839	29,544	598,493
Blood Diseases And Resources Research	R01HL164583	93.839	131,498	444,540
Blood Diseases And Resources Research	R01HL177430	93.839	—	463,499
Blood Diseases And Resources Research	R03HL164333	93.839	—	30,639
Blood Diseases And Resources Research	R03HL174883	93.839	—	101,782
Blood Diseases And Resources Research	R03HL178876	93.839	—	16,134
Blood Diseases And Resources Research	R21HL173513	93.839	—	140,661
Blood Diseases And Resources Research	R33HL163743	93.839	—	487,849
Blood Diseases And Resources Research	R35HL145000	93.839	44,308	718,093
Blood Diseases And Resources Research	R61HL163743	93.839	—	(5,791)
Blood Diseases And Resources Research	T32HL069769	93.839	47,765	111,221
Blood Diseases And Resources Research	T32HL139443	93.839	—	293,160
Blood Diseases And Resources Research	UG1HL174446	93.839	59,939	132,311
Blood Diseases And Resources Research	UG3HL173303	93.839	72,142	401,820

EMORY UNIVERSITY AND ITS SUBSIDIARIES
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2025

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Blood Diseases And Resources Research	UH3HL148560	93.839	\$ 761,426	1,533,823
Pass-through Ann & Robert H. Lurie Children's Hospital	R01HL136480	93.839	—	(6,510)
Pass-through Boston Children's Hospital	P01HL046925	93.839	—	8,740
Pass-through Boston Children's Hospital	UH3HL157564	93.839	—	7,265
Pass-through Children'S Research Institute	R61HL167806	93.839	—	13,320
Pass-through Research Triangle Institute	R01HL166254	93.839	—	35,467
Pass-through Rice University	R01HL152314	93.839	—	(19,802)
Pass-through Rice University	R01HL169761	93.839	322	143,434
Pass-through University of Maryland	UH3HL143192	93.839	—	32,508
Pass-through University of Pittsburgh	UG3HL165839	93.839	—	28,133
Pass-through University of Virginia	P01HL169552	93.839	79,259	1,460,087
Pass-through University of Washington	UG3HL165064	93.839	—	224,385
Pass-through Vanderbilt University	U01HL156620	93.839	—	3,809
Pass-through Wake Forest University	R01HL161290	93.839	—	70,792
Pass-through Wake Forest University	R01HL165247	93.839	—	66,149
Pass-through Wake Forest University	R01HL166462	93.839	—	34,054
Total AL No. 93.839			1,372,117	10,700,842
Transplantation and Implementation Science Research for Heart, Lung, Blood Diseases, and Sleep Disorders	K23HL152368	93.840	—	86,241
Transplantation and Implementation Science Research for Heart, Lung, Blood Diseases, and Sleep Disorders	K23HL173694	93.840	75,384	269,570
Pass-through University of Maryland, Baltimore	HL163514-01	93.840	—	33,139
Pass-through University of Witwatersrand	UG3HL156388	93.840	—	322,557
Pass-through Yale University	R56HL166523	93.840	—	2,530
Total AL No. 93.840			75,384	714,037
Arthritis, Musculoskeletal And Skin Diseases Research	F31AR081697	93.846	—	45,380
Arthritis, Musculoskeletal And Skin Diseases Research	F31AR084335	93.846	—	47,477
Arthritis, Musculoskeletal And Skin Diseases Research	K23AR075888	93.846	—	176,768
Arthritis, Musculoskeletal And Skin Diseases Research	K23AR080245	93.846	—	246,034
Arthritis, Musculoskeletal And Skin Diseases Research	R01AR048615	93.846	—	162,632
Arthritis, Musculoskeletal And Skin Diseases Research	R01AR070736	93.846	—	380,472
Arthritis, Musculoskeletal And Skin Diseases Research	R01AR070898	93.846	—	(7,204)
Arthritis, Musculoskeletal And Skin Diseases Research	R01AR073874	93.846	—	720
Arthritis, Musculoskeletal And Skin Diseases Research	R01AR076153	93.846	30,122	14,644
Arthritis, Musculoskeletal And Skin Diseases Research	R01AR076427	93.846	70,404	366,440
Arthritis, Musculoskeletal And Skin Diseases Research	R01AR077926	93.846	—	30,908
Arthritis, Musculoskeletal And Skin Diseases Research	R01AR078892	93.846	187,963	305,864
Arthritis, Musculoskeletal And Skin Diseases Research	R01AR078908	93.846	54,907	373,399
Arthritis, Musculoskeletal And Skin Diseases Research	R01AR079298	93.846	95,875	641,466
Arthritis, Musculoskeletal And Skin Diseases Research	R01AR080169	93.846	—	494,581
Arthritis, Musculoskeletal And Skin Diseases Research	R01AR080750	93.846	299,955	595,684
Arthritis, Musculoskeletal And Skin Diseases Research	R21AR078463	93.846	—	10,273
Arthritis, Musculoskeletal And Skin Diseases Research	R21AR080869	93.846	—	173,332
Arthritis, Musculoskeletal And Skin Diseases Research	R56AR080718	93.846	—	83,623
Pass-through Georgia Institute of Technology	R01AR071026	93.846	—	(1,765)
Pass-through Georgia Institute of Technology	R01AR077357	93.846	—	13,075
Pass-through Georgia State University	R01AR080154	93.846	—	110,183
Pass-through Hospital for Special Surgery	R01AR071463	93.846	—	36,635
Pass-through Louisiana State University	R01AR073277	93.846	—	15,473

EMORY UNIVERSITY AND ITS SUBSIDIARIES
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2025

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Pass-through Mayo Clinic Rochester	R01AR055563	93.846	\$ —	(308)
Pass-through Medical University of South Carolina	P30AR072582	93.846	—	11,772
Pass-through Medical University of South Carolina	R21AR084039	93.846	—	18,282
Pass-through Ohio University	R01AR077248	93.846	—	14,842
Pass-through University of California Los Angeles	R01AR081794	93.846	—	35,034
Pass-through University of Florida	UC2AR082196	93.846	—	14,675
Pass-through University of Michigan	U01AR073485	93.846	—	21,401
Pass-through University of Washington	R01AR078785	93.846	—	65,820
Total AL No. 93.846			739,226	4,497,612
Diabetes, Digestive, and Kidney Diseases Extramural Research	DP1DK139804	93.847	100,272	615,816
Diabetes, Digestive, and Kidney Diseases Extramural Research	DP3DK108245	93.847	—	32
Diabetes, Digestive, and Kidney Diseases Extramural Research	F30DK134204	93.847	—	46,335
Diabetes, Digestive, and Kidney Diseases Extramural Research	F30DK139762	93.847	—	54,028
Diabetes, Digestive, and Kidney Diseases Extramural Research	F31DK126467	93.847	—	14,064
Diabetes, Digestive, and Kidney Diseases Extramural Research	F31DK134199	93.847	—	37,617
Diabetes, Digestive, and Kidney Diseases Extramural Research	F31DK135379	93.847	—	(2,262)
Diabetes, Digestive, and Kidney Diseases Extramural Research	F31DK136254	93.847	—	50,304
Diabetes, Digestive, and Kidney Diseases Extramural Research	F31DK137590	93.847	—	50,146
Diabetes, Digestive, and Kidney Diseases Extramural Research	F31DK139740	93.847	—	42,216
Diabetes, Digestive, and Kidney Diseases Extramural Research	F32DK127848	93.847	—	(2,034)
Diabetes, Digestive, and Kidney Diseases Extramural Research	F32DK137409	93.847	—	76,921
Diabetes, Digestive, and Kidney Diseases Extramural Research	K01DK133669	93.847	19,356	161,873
Diabetes, Digestive, and Kidney Diseases Extramural Research	K01DK137030	93.847	—	63,302
Diabetes, Digestive, and Kidney Diseases Extramural Research	K01DK137620	93.847	—	146,644
Diabetes, Digestive, and Kidney Diseases Extramural Research	K01DK140605	93.847	—	89,479
Diabetes, Digestive, and Kidney Diseases Extramural Research	K23DK118189	93.847	75	3,028
Diabetes, Digestive, and Kidney Diseases Extramural Research	K23DK122115	93.847	—	(70)
Diabetes, Digestive, and Kidney Diseases Extramural Research	K23DK122199	93.847	—	116,194
Diabetes, Digestive, and Kidney Diseases Extramural Research	K23DK124647	93.847	—	67,076
Diabetes, Digestive, and Kidney Diseases Extramural Research	K23DK131317	93.847	—	179,669
Diabetes, Digestive, and Kidney Diseases Extramural Research	K23DK138267	93.847	—	122,520
Diabetes, Digestive, and Kidney Diseases Extramural Research	K23MH129684	93.847	—	188,051
Diabetes, Digestive, and Kidney Diseases Extramural Research	K25DK135913	93.847	—	146,451
Diabetes, Digestive, and Kidney Diseases Extramural Research	P30DK111024	93.847	185,815	786,847
Diabetes, Digestive, and Kidney Diseases Extramural Research	P30DK125013	93.847	266,676	984,258
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK044234	93.847	—	418,725
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK080684	93.847	178,114	410,748
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK087694	93.847	—	40,684
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK114891	93.847	—	(133)
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK115213	93.847	—	610,807
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK120814	93.847	161,320	304,037
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK124821	93.847	79,990	307,663
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK125187	93.847	107,069	1,030,427
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK125246	93.847	—	826,850
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK125647	93.847	21,681	411,534
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK125701	93.847	—	5,029
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK125936	93.847	50,817	1,406
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK127083	93.847	301,620	321,069

EMORY UNIVERSITY AND ITS SUBSIDIARIES
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2025

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK128061	93.847	\$ —	395,122
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK128902	93.847	—	205,345
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK129950	93.847	—	124,739
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK131189	93.847	—	223,404
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK132653	93.847	—	366,250
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK133523	93.847	2,752	815,862
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK133605	93.847	172,394	558,479
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK133650	93.847	73,538	522,496
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK134509	93.847	12,598	839,432
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK136023	93.847	—	375,235
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK136983	93.847	—	551,169
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK138366	93.847	344,060	610,761
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK139326	93.847	—	150,833
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK139594	93.847	—	15,992
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK139632	93.847	16,626	151,048
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK139653	93.847	—	483,888
Diabetes, Digestive, and Kidney Diseases Extramural Research	R01DK140485	93.847	17,789	405,272
Diabetes, Digestive, and Kidney Diseases Extramural Research	R03DK129627	93.847	—	38,367
Diabetes, Digestive, and Kidney Diseases Extramural Research	R03DK136975	93.847	—	90,470
Diabetes, Digestive, and Kidney Diseases Extramural Research	R03DK137007	93.847	—	100,468
Diabetes, Digestive, and Kidney Diseases Extramural Research	R03DK140419	93.847	—	22,844
Diabetes, Digestive, and Kidney Diseases Extramural Research	R21DK128731	93.847	—	115,408
Diabetes, Digestive, and Kidney Diseases Extramural Research	R25DK101390	93.847	—	100,391
Diabetes, Digestive, and Kidney Diseases Extramural Research	R56DK137888	93.847	—	167,457
Diabetes, Digestive, and Kidney Diseases Extramural Research	T32DK108735	93.847	—	337,693
Diabetes, Digestive, and Kidney Diseases Extramural Research	TL1DK136047	93.847	190,044	806,738
Diabetes, Digestive, and Kidney Diseases Extramural Research	U01DK062470	93.847	303,842	205,366
Diabetes, Digestive, and Kidney Diseases Extramural Research	U01DK116099	93.847	16,502	237,634
Diabetes, Digestive, and Kidney Diseases Extramural Research	U01DK134191	93.847	118,665	630,865
Diabetes, Digestive, and Kidney Diseases Extramural Research	U01DK137269	93.847	73,896	872,047
Diabetes, Digestive, and Kidney Diseases Extramural Research	U2CDK129501	93.847	7,419	537,016
Pass-through Albert Einstein College of Medicine	P30DK111102	93.847	—	6,895
Pass-through Ann & Robert H. Lurie Children's Hospital	U01DK127995	93.847	—	(3,578)
Pass-through Baylor College of Medicine	R01DK124395	93.847	—	116,296
Pass-through Brigham and Womens Hospital	R01DK048873	93.847	—	64,698
Pass-through Brigham and Womens Hospital	R01DK056626	93.847	—	105,976
Pass-through Brigham and Womens Hospital	R01DK103046	93.847	—	101,752
Pass-through Brigham and Womens Hospital	R01DK133988	93.847	—	67,483
Pass-through Columbia University	R01DK123285	93.847	—	78,506
Pass-through Connecticut Childrens Medical Center	U01DK134356	93.847	—	425,567
Pass-through Dartmouth College	P30DK117469	93.847	—	19,581
Pass-through Drexel University	R01DK124388	93.847	—	10,596
Pass-through Duke University	R01DK118431	93.847	—	60,067
Pass-through George Washington University	U01DK098246	93.847	—	27,683
Pass-through Georgia State University	R01DK099071	93.847	—	6,217
Pass-through Georgia State University	R01DK136624	93.847	—	(5,231)
Pass-through Indiana University	R01DK136283	93.847	—	41,987
Pass-through Mount Sinai School of Medicine	U01DK119200	93.847	—	8,741
Pass-through Research Institute at Nationwide Children's Hospital	U01DK100866	93.847	—	30,442

EMORY UNIVERSITY AND ITS SUBSIDIARIES
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2025

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Pass-through Sanford Health	R01DK131020	93.847	\$ —	12,785
Pass-through Seattle Children's Research Institute	R01DK129211	93.847	—	135,947
Pass-through The Nemours Foundation	R01DK134499	93.847	—	87,100
Pass-through University of Alabama Birmingham	R01DK128457	93.847	—	9,371
Pass-through University of Alabama Birmingham	U01DK106858	93.847	—	34,610
Pass-through University of Arizona	U01DK119094	93.847	—	1,669
Pass-through University of California Los Angeles	U34DK104619	93.847	—	(2,323)
Pass-through University of California San Francisco	R01DK132271	93.847	—	257
Pass-through University of Colorado Denver	UO1DK062453	93.847	—	(21,840)
Pass-through University of Florida	R01DK133465	93.847	—	151,130
Pass-through University of Kansas Medical Center	R01DK099611	93.847	—	4,235
Pass-through University of Miami	R03DK138255	93.847	—	13,489
Pass-through University of Michigan	U01DK133090	93.847	—	57,759
Pass-through University of Pittsburgh	01DK072145	93.847	—	1,540
Pass-through University of South Florida	U01DK106993	93.847	—	145,769
Pass-through University of Virginia	R01DK131491	93.847	—	182,089
Pass-through University of Virginia	R01DK132369	93.847	—	120,214
Pass-through Vanderbilt University	R01DK110375	93.847	—	196,721
Pass-through Vanderbilt University Medical Center	U01DK137533	93.847	—	49,214
Pass-through Virginia Commonwealth University	R01DK135815	93.847	—	22,990
Pass-through Virginia Commonwealth University	U01DK061731	93.847	1,364	20,729
Pass-through Virginia Commonwealth University	U01DK062470	93.847	—	76,315
Pass-through Washington University	R21DK134104	93.847	—	22,787
Pass-through Yale University	R01DK139672	93.847	—	101,996
Total AL No. 93.847			2,824,294	22,373,673
Extramural Research Programs In The Neurosciences And Neurological Disorders	1R21NS142860	93.853	—	28,737
Extramural Research Programs In The Neurosciences And Neurological Disorders	DP2NS127291	93.853	42,720	372,704
Extramural Research Programs In The Neurosciences And Neurological Disorders	DP2NS127704	93.853	21,658	472,482
Extramural Research Programs In The Neurosciences And Neurological Disorders	F31NS117086	93.853	—	387
Extramural Research Programs In The Neurosciences And Neurological Disorders	F31NS125984	93.853	—	36,616
Extramural Research Programs In The Neurosciences And Neurological Disorders	F31NS127419	93.853	—	36,898
Extramural Research Programs In The Neurosciences And Neurological Disorders	F31NS127537	93.853	—	43,919
Extramural Research Programs In The Neurosciences And Neurological Disorders	F31NS127545	93.853	—	15,606
Extramural Research Programs In The Neurosciences And Neurological Disorders	F31NS127574	93.853	—	31,807
Extramural Research Programs In The Neurosciences And Neurological Disorders	F31NS130993	93.853	—	45,776
Extramural Research Programs In The Neurosciences And Neurological Disorders	F31NS131020	93.853	—	51,174
Extramural Research Programs In The Neurosciences And Neurological Disorders	F31NS134314	93.853	—	45,032
Extramural Research Programs In The Neurosciences And Neurological Disorders	F31NS134380	93.853	—	42,694
Extramural Research Programs In The Neurosciences And Neurological Disorders	F31NS135955	93.853	—	42,529
Extramural Research Programs In The Neurosciences And Neurological Disorders	F31NS135980	93.853	—	48,960
Extramural Research Programs In The Neurosciences And Neurological Disorders	F31NS139599	93.853	—	6,192
Extramural Research Programs In The Neurosciences And Neurological Disorders	F31NS141610	93.853	—	33,849
Extramural Research Programs In The Neurosciences And Neurological Disorders	F99NS141391	93.853	—	48,097
Extramural Research Programs In The Neurosciences And Neurological Disorders	K00NS118713	93.853	—	129,013
Extramural Research Programs In The Neurosciences And Neurological Disorders	K01NS124912	93.853	—	158,185
Extramural Research Programs In The Neurosciences And Neurological Disorders	K23NS083748	93.853	—	(11)
Extramural Research Programs In The Neurosciences And Neurological Disorders	K23NS105944	93.853	—	63
Extramural Research Programs In The Neurosciences And Neurological Disorders	K23NS119964	93.853	—	155,816

EMORY UNIVERSITY AND ITS SUBSIDIARIES
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2025

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Extramural Research Programs In The Neurosciences And Neurological Disorders	K23NS133497	93.853	\$ —	159,999
Extramural Research Programs In The Neurosciences And Neurological Disorders	P50NS123103	93.853	81,555	2,433,491
Extramural Research Programs In The Neurosciences And Neurological Disorders	R00NS119739	93.853	—	324,264
Extramural Research Programs In The Neurosciences And Neurological Disorders	R00NS129963	93.853	—	267,525
Extramural Research Programs In The Neurosciences And Neurological Disorders	R01NS045962	93.853	—	209,697
Extramural Research Programs In The Neurosciences And Neurological Disorders	R01NS047357	93.853	—	413,953
Extramural Research Programs In The Neurosciences And Neurological Disorders	R01NS065992	93.853	—	92,917
Extramural Research Programs In The Neurosciences And Neurological Disorders	R01NS083654	93.853	—	385,556
Extramural Research Programs In The Neurosciences And Neurological Disorders	R01NS084844	93.853	—	121,890
Extramural Research Programs In The Neurosciences And Neurological Disorders	R01NS088748	93.853	115,247	430,456
Extramural Research Programs In The Neurosciences And Neurological Disorders	R01NS099162	93.853	24,439	661,931
Extramural Research Programs In The Neurosciences And Neurological Disorders	R01NS102850	93.853	—	2,194
Extramural Research Programs In The Neurosciences And Neurological Disorders	R01NS105971	93.853	—	39,256
Extramural Research Programs In The Neurosciences And Neurological Disorders	R01NS106905	93.853	121,385	396,374
Extramural Research Programs In The Neurosciences And Neurological Disorders	R01NS109237	93.853	34,201	119,360
Extramural Research Programs In The Neurosciences And Neurological Disorders	R01NS109257	93.853	53,675	130,562
Extramural Research Programs In The Neurosciences And Neurological Disorders	R01NS110110	93.853	—	497,237
Extramural Research Programs In The Neurosciences And Neurological Disorders	R01NS110347	93.853	372,632	654,403
Extramural Research Programs In The Neurosciences And Neurological Disorders	R01NS111280	93.853	—	347,428
Extramural Research Programs In The Neurosciences And Neurological Disorders	R01NS111470	93.853	52,499	146,277
Extramural Research Programs In The Neurosciences And Neurological Disorders	R01NS112308	93.853	—	275,486
Extramural Research Programs In The Neurosciences And Neurological Disorders	R01NS112350	93.853	—	287,017
Extramural Research Programs In The Neurosciences And Neurological Disorders	R01NS113541	93.853	208,754	430,367
Extramural Research Programs In The Neurosciences And Neurological Disorders	R01NS113746	93.853	198,723	338,250
Extramural Research Programs In The Neurosciences And Neurological Disorders	R01NS114074	93.853	1,344	162,498
Extramural Research Programs In The Neurosciences And Neurological Disorders	R01NS114221	93.853	—	353,735
Extramural Research Programs In The Neurosciences And Neurological Disorders	R01NS114253	93.853	64,978	256,332
Extramural Research Programs In The Neurosciences And Neurological Disorders	R01NS118819	93.853	—	507,829
Extramural Research Programs In The Neurosciences And Neurological Disorders	R01NS119758	93.853	—	228,036
Extramural Research Programs In The Neurosciences And Neurological Disorders	R01NS119831	93.853	190,723	287,704
Extramural Research Programs In The Neurosciences And Neurological Disorders	R01NS120182	93.853	56,091	613,093
Extramural Research Programs In The Neurosciences And Neurological Disorders	R01NS120676	93.853	216,304	468,044
Extramural Research Programs In The Neurosciences And Neurological Disorders	R01NS123447	93.853	79,606	344,428
Extramural Research Programs In The Neurosciences And Neurological Disorders	R01NS123562	93.853	—	464,763
Extramural Research Programs In The Neurosciences And Neurological Disorders	R01NS124764	93.853	—	642,756
Extramural Research Programs In The Neurosciences And Neurological Disorders	R01NS125143	93.853	87,587	543,077
Extramural Research Programs In The Neurosciences And Neurological Disorders	R01NS125317	93.853	—	582,542
Extramural Research Programs In The Neurosciences And Neurological Disorders	R01NS125768	93.853	—	187,166
Extramural Research Programs In The Neurosciences And Neurological Disorders	R01NS126348	93.853	—	579,816
Extramural Research Programs In The Neurosciences And Neurological Disorders	R01NS126392	93.853	167,450	551,147
Extramural Research Programs In The Neurosciences And Neurological Disorders	R01NS126924	93.853	—	674,933
Extramural Research Programs In The Neurosciences And Neurological Disorders	R01NS127964	93.853	—	582,915
Extramural Research Programs In The Neurosciences And Neurological Disorders	R01NS129984	93.853	—	500,177
Extramural Research Programs In The Neurosciences And Neurological Disorders	R01NS130036	93.853	—	335,657
Extramural Research Programs In The Neurosciences And Neurological Disorders	R01NS130551	93.853	—	643,724
Extramural Research Programs In The Neurosciences And Neurological Disorders	R01NS132725	93.853	—	436,023
Extramural Research Programs In The Neurosciences And Neurological Disorders	R01NS132884	93.853	8,825	419,912
Extramural Research Programs In The Neurosciences And Neurological Disorders	R01NS133344	93.853	—	481,563
Extramural Research Programs In The Neurosciences And Neurological Disorders	R01NS133809	93.853	56,544	522,124

EMORY UNIVERSITY AND ITS SUBSIDIARIES
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2025

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Extramural Research Programs In The Neurosciences And Neurological Disorders	R01NS134941	93.853	\$ —	525,923
Extramural Research Programs In The Neurosciences And Neurological Disorders	R01NS136529	93.853	—	452,038
Extramural Research Programs In The Neurosciences And Neurological Disorders	R01NS137434	93.853	—	586,484
Extramural Research Programs In The Neurosciences And Neurological Disorders	R01NS138044	93.853	155,023	364,531
Extramural Research Programs In The Neurosciences And Neurological Disorders	R01NS138605	93.853	—	122,872
Extramural Research Programs In The Neurosciences And Neurological Disorders	R01NS138733	93.853	—	257,566
Extramural Research Programs In The Neurosciences And Neurological Disorders	R03NS127079	93.853	—	12,364
Extramural Research Programs In The Neurosciences And Neurological Disorders	R13NS139605	93.853	—	25,000
Extramural Research Programs In The Neurosciences And Neurological Disorders	R21NS091986	93.853	—	(195)
Extramural Research Programs In The Neurosciences And Neurological Disorders	R21NS116639	93.853	—	36,257
Extramural Research Programs In The Neurosciences And Neurological Disorders	R21NS119985	93.853	—	13,540
Extramural Research Programs In The Neurosciences And Neurological Disorders	R21NS122013	93.853	—	70,763
Extramural Research Programs In The Neurosciences And Neurological Disorders	R21NS123487	93.853	—	66,915
Extramural Research Programs In The Neurosciences And Neurological Disorders	R21NS125287	93.853	—	17,945
Extramural Research Programs In The Neurosciences And Neurological Disorders	R21NS125496	93.853	19,997	52,069
Extramural Research Programs In The Neurosciences And Neurological Disorders	R21NS130378	93.853	41,915	311
Extramural Research Programs In The Neurosciences And Neurological Disorders	R21NS132010	93.853	—	258,583
Extramural Research Programs In The Neurosciences And Neurological Disorders	R21NS132071	93.853	—	189,468
Extramural Research Programs In The Neurosciences And Neurological Disorders	R21NS132393	93.853	—	115,661
Extramural Research Programs In The Neurosciences And Neurological Disorders	R21NS133633	93.853	—	279,531
Extramural Research Programs In The Neurosciences And Neurological Disorders	R21NS133638	93.853	—	238,963
Extramural Research Programs In The Neurosciences And Neurological Disorders	R21NS133933	93.853	—	287,364
Extramural Research Programs In The Neurosciences And Neurological Disorders	R21NS133960	93.853	—	243,592
Extramural Research Programs In The Neurosciences And Neurological Disorders	R21NS134172	93.853	—	56,061
Extramural Research Programs In The Neurosciences And Neurological Disorders	R21NS136877	93.853	—	209,733
Extramural Research Programs In The Neurosciences And Neurological Disorders	R21NS140900	93.853	—	6,666
Extramural Research Programs In The Neurosciences And Neurological Disorders	R21NS142808	93.853	—	27,967
Extramural Research Programs In The Neurosciences And Neurological Disorders	R21NS143271	93.853	—	11,661
Extramural Research Programs In The Neurosciences And Neurological Disorders	R21NS145545	93.853	—	4,783
Extramural Research Programs In The Neurosciences And Neurological Disorders	R34NS137017	93.853	23,897	363,669
Extramural Research Programs In The Neurosciences And Neurological Disorders	R35NS111602	93.853	—	1,085,333
Extramural Research Programs In The Neurosciences And Neurological Disorders	R35NS111619	93.853	—	1,111,942
Extramural Research Programs In The Neurosciences And Neurological Disorders	R61NS130128	93.853	115,994	466,590
Extramural Research Programs In The Neurosciences And Neurological Disorders	RF1NS139325	93.853	17,489	428,581
Extramural Research Programs In The Neurosciences And Neurological Disorders	T32NS096050	93.853	—	357,277
Extramural Research Programs In The Neurosciences And Neurological Disorders	U01NS128433	93.853	—	1,677,672
Extramural Research Programs In The Neurosciences And Neurological Disorders	U24NS107234	93.853	—	399,030
Extramural Research Programs In The Neurosciences And Neurological Disorders	U24NS126936	93.853	355,246	933,402
Extramural Research Programs In The Neurosciences And Neurological Disorders	U24NS133949	93.853	674,675	930,755
Extramural Research Programs In The Neurosciences And Neurological Disorders	U54NS116025	93.853	239,737	689,606
Extramural Research Programs In The Neurosciences And Neurological Disorders	UH3NS127386	93.853	—	399,017
Pass-through Albert Einstein College of Medicine	R01NS083085	93.853	—	336,731
Pass-through Boston Children's Hospital	R61NS130215	93.853	—	21,422
Pass-through Brigham and Womens Hospital	R01HL165975	93.853	—	82,729
Pass-through Children's Hospital of Philadelphia	U01NS106845	93.853	4,239	21,873
Pass-through Children's Hospital of Philadelphia	U54NS115052	93.853	32,969	57,516
Pass-through Columbia University	R01NS110826	93.853	—	41,764
Pass-through Columbia University	R01NS131606	93.853	—	58,031
Pass-through Cornell University	R01NS121544	93.853	—	103,255

EMORY UNIVERSITY AND ITS SUBSIDIARIES
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2025

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Pass-through Duke University	R01NS130832	93.853	\$ —	68,004
Pass-through George Washington University	R01NS124477	93.853	—	147,654
Pass-through George Washington University	R01NS126090	93.853	—	596,442
Pass-through Georgia Institute of Technology	R01NS115994	93.853	—	323,643
Pass-through Georgia Institute of Technology	R01NS117613	93.853	—	3,261
Pass-through Georgia Institute of Technology	R01NS126183	93.853	—	280,535
Pass-through Indiana University	R01NS119683	93.853	—	136,830
Pass-through Jackson Laboratory	RF1NS139948	93.853	—	420,104
Pass-through Johns Hopkins University	R01NS111283	93.853	—	56,984
Pass-through Mayo Clinic	P01NS084974	93.853	—	704,092
Pass-through Mayo Clinic	R01NS132330	93.853	—	258,174
Pass-through Medical University of South Carolina	R01NS110347	93.853	—	(14,490)
Pass-through Morehouse School of Medicine	R01NS112422	93.853	—	202,257
Pass-through Mount Sinai School of Medicine	UH3NS103550	93.853	—	(274)
Pass-through Oklahoma Medical Research Foundation	R01NS135830	93.853	—	10,791
Pass-through Pennsylvania State University	R01NS113912	93.853	—	4,780
Pass-through Public Health Institute	RF1NS130713	93.853	—	284,767
Pass-through Research Institute at Nationwide Children's Hospital	R01NS133037	93.853	—	23,027
Pass-through Rush University Medical Center	R01NS125294	93.853	—	56,119
Pass-through St Jude Childrens Research Hospital	R61CA280978	93.853	(26,030)	(25,462)
Pass-through Stanford University	U01NS038455	93.853	—	(12,404)
Pass-through Stanford University	U01NS114042	93.853	—	52,098
Pass-through Texas Agricultural and Mechanical Univ	R01NS118731	93.853	—	89,116
Pass-through Texas Agricultural and Mechanical Univ	R01NS133338	93.853	—	86,814
Pass-through University of Georgia Research Fdtn	R01NS131659	93.853	—	4,185
Pass-through University of Oregon	R01NS134772	93.853	—	19,859
Pass-through University of California Los Angeles	RF1NS130691	93.853	—	68,745
Pass-through University of California San Diego	R01NS124585	93.853	—	230,765
Pass-through University of Chicago	U01NS131797	93.853	—	31,054
Pass-through University of Cincinnati	U01NS120910	93.853	—	15,116
Pass-through University of Florida	U01NS124613	93.853	—	69,619
Pass-through University of Georgia	R01NS130210	93.853	—	96,858
Pass-through University of Georgia	R01NS131273	93.853	—	80,574
Pass-through University of Michigan	K12NS137516	93.853	—	23,846
Pass-through University of Michigan	U01NS08803401	93.853	—	(61)
Pass-through University of North Carolina Chapel Hill	R01NS125073	93.853	—	11,352
Pass-through University of Pennsylvania	R01NS116504	93.853	—	37,885
Pass-through University of Pennsylvania	U01NS113198	93.853	—	53,846
Pass-through University of South Carolina	R01NS117821	93.853	—	80,060
Pass-through University of Southern California	U01NS056256	93.853	—	(50)
Pass-through University of Texas Austin	R21NS133605	93.853	—	11,737
Pass-through University of Texas Medical Branch	UG3NS128397	93.853	—	12,480
Pass-through Virginia Commonwealth University	U24NS100673	93.853	—	31,415
Pass-through Weill Cornell Medical College	R01NS093002	93.853	—	24,688
Pass-through Weill Cornell Medical College	R01NS115963	93.853	—	15,505
Total AL No. 93.853			3,912,091	41,155,360
COVID-19 – Allergy, Immunology And Transplantation Research	P51OD011132	93.855	—	(4,217)
COVID-19 – Allergy, Immunology And Transplantation Research	R01AI143875	93.855	—	12,870

EMORY UNIVERSITY AND ITS SUBSIDIARIES
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2025

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
COVID-19 – Allergy, Immunology And Transplantation Research	R01AI148378	93.855	\$ —	(9,139)
COVID-19 – Allergy, Immunology And Transplantation Research	R01AI161570	93.855	(151,299)	(151,339)
COVID-19 – Allergy, Immunology And Transplantation Research	U19AI110483	93.855	—	(63,075)
COVID-19 – Allergy, Immunology And Transplantation Research	U19AI171403	93.855	8,305,850	12,372,155
COVID-19 – Allergy, Immunology And Transplantation Research	UM1AI148576	93.855	—	42,647
COVID-19 – Allergy, Immunology And Transplantation Research	UM1AI148684	93.855	8,436,043	11,587,015
Allergy, Immunology And Transplantation Research	75D30124P19882	93.855	—	209,766
Allergy, Immunology And Transplantation Research	F31AI167527	93.855	—	46,281
Allergy, Immunology And Transplantation Research	F31AI172335	93.855	—	37,371
Allergy, Immunology And Transplantation Research	F31AI172377	93.855	—	9,653
Allergy, Immunology And Transplantation Research	F31AI172618	93.855	—	47,765
Allergy, Immunology And Transplantation Research	F31AI174951	93.855	—	48,839
Allergy, Immunology And Transplantation Research	F31AI176717	93.855	—	22,836
Allergy, Immunology And Transplantation Research	F31AI179103	93.855	—	50,832
Allergy, Immunology And Transplantation Research	F31AI179158	93.855	—	38,249
Allergy, Immunology And Transplantation Research	F31AI179207	93.855	—	42,807
Allergy, Immunology And Transplantation Research	F31AI179424	93.855	—	48,173
Allergy, Immunology And Transplantation Research	F31AI179463	93.855	—	43,852
Allergy, Immunology And Transplantation Research	F31AI183823	93.855	—	49,041
Allergy, Immunology And Transplantation Research	F31AI184167	93.855	—	30,110
Allergy, Immunology And Transplantation Research	F31AI186480	93.855	—	48,749
Allergy, Immunology And Transplantation Research	F31AI186518	93.855	—	36,674
Allergy, Immunology And Transplantation Research	F31AI186550	93.855	—	46,001
Allergy, Immunology And Transplantation Research	F31AI189070	93.855	—	24,021
Allergy, Immunology And Transplantation Research	F31AI194923	93.855	—	4,500
Allergy, Immunology And Transplantation Research	F32AI189066	93.855	—	50,555
Allergy, Immunology And Transplantation Research	K01AI166093	93.855	—	126,770
Allergy, Immunology And Transplantation Research	K08AI166837	93.855	—	131,135
Allergy, Immunology And Transplantation Research	K08AI178093	93.855	—	176,223
Allergy, Immunology And Transplantation Research	K08AI180431	93.855	—	183,578
Allergy, Immunology And Transplantation Research	K23AI143479	93.855	—	75,664
Allergy, Immunology And Transplantation Research	K23AI144036	93.855	—	92,687
Allergy, Immunology And Transplantation Research	K23AI144040	93.855	—	123,705
Allergy, Immunology And Transplantation Research	K23AI175676	93.855	—	158,993
Allergy, Immunology And Transplantation Research	K23AI177081	93.855	—	180,199
Allergy, Immunology And Transplantation Research	K23AI177087	93.855	—	130,014
Allergy, Immunology And Transplantation Research	K24AI114444	93.855	—	65,412
Allergy, Immunology And Transplantation Research	K24AI165099	93.855	—	102,585
Allergy, Immunology And Transplantation Research	P01AI125180	93.855	440,886	2,848,756
Allergy, Immunology And Transplantation Research	P01AI178376	93.855	519,805	1,831,746
Allergy, Immunology And Transplantation Research	P01AI186819	93.855	—	171,777
Allergy, Immunology And Transplantation Research	P30AI050409	93.855	1,038,173	4,693,527
Allergy, Immunology And Transplantation Research	P30AI168386	93.855	59,948	1,090,761
Allergy, Immunology And Transplantation Research	R00AI151891	93.855	—	97,447
Allergy, Immunology And Transplantation Research	R00AI169473	93.855	—	151,018
Allergy, Immunology And Transplantation Research	R01AI021150	93.855	117,462	429,452
Allergy, Immunology And Transplantation Research	R01AI030048	93.855	—	(24,570)
Allergy, Immunology And Transplantation Research	R01AI053668	93.855	—	(107)
Allergy, Immunology And Transplantation Research	R01AI064060	93.855	—	242

EMORY UNIVERSITY AND ITS SUBSIDIARIES
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2025

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Allergy, Immunology And Transplantation Research	R01AI072435	93.855	\$ —	663,647
Allergy, Immunology And Transplantation Research	R01AI088025	93.855	3,068	552,350
Allergy, Immunology And Transplantation Research	R01AI1072435	93.855	—	(22,478)
Allergy, Immunology And Transplantation Research	R01AI107960	93.855	321,621	849,554
Allergy, Immunology And Transplantation Research	R01AI110680	93.855	—	1,971
Allergy, Immunology And Transplantation Research	R01AI112787	93.855	78,292	1,059,050
Allergy, Immunology And Transplantation Research	R01AI113021	93.855	39,775	434,500
Allergy, Immunology And Transplantation Research	R01AI116933	93.855	—	428,253
Allergy, Immunology And Transplantation Research	R01AI120860	93.855	219,906	505,339
Allergy, Immunology And Transplantation Research	R01AI123383	93.855	—	455,697
Allergy, Immunology And Transplantation Research	R01AI125064	93.855	—	1,000,034
Allergy, Immunology And Transplantation Research	R01AI127799	93.855	—	190,149
Allergy, Immunology And Transplantation Research	R01AI129862	93.855	22,875	517,735
Allergy, Immunology And Transplantation Research	R01AI130163	93.855	(80)	26,198
Allergy, Immunology And Transplantation Research	R01AI132833	93.855	—	700,581
Allergy, Immunology And Transplantation Research	R01AI133706	93.855	—	(3,513)
Allergy, Immunology And Transplantation Research	R01AI136533	93.855	—	109,112
Allergy, Immunology And Transplantation Research	R01AI136581	93.855	—	322,023
Allergy, Immunology And Transplantation Research	R01AI137127	93.855	—	96,484
Allergy, Immunology And Transplantation Research	R01AI138646	93.855	—	1,393
Allergy, Immunology And Transplantation Research	R01AI139406	93.855	50,397	274,042
Allergy, Immunology And Transplantation Research	R01AI139761	93.855	—	53,027
Allergy, Immunology And Transplantation Research	R01AI141327	93.855	—	580,402
Allergy, Immunology And Transplantation Research	R01AI143875	93.855	—	30,695
Allergy, Immunology And Transplantation Research	R01AI144067	93.855	—	445,730
Allergy, Immunology And Transplantation Research	R01AI145231	93.855	—	349,919
Allergy, Immunology And Transplantation Research	R01AI145640	93.855	57,728	369,095
Allergy, Immunology And Transplantation Research	R01AI146017	93.855	—	4,806
Allergy, Immunology And Transplantation Research	R01AI146260	93.855	—	318,338
Allergy, Immunology And Transplantation Research	R01AI147609	93.855	44,545	339,334
Allergy, Immunology And Transplantation Research	R01AI147890	93.855	—	1,057
Allergy, Immunology And Transplantation Research	R01AI148377	93.855	—	478,687
Allergy, Immunology And Transplantation Research	R01AI148378	93.855	—	(42,741)
Allergy, Immunology And Transplantation Research	R01AI148382	93.855	159,366	(5,119)
Allergy, Immunology And Transplantation Research	R01AI148471	93.855	53,272	71,619
Allergy, Immunology And Transplantation Research	R01AI148661	93.855	134,693	663,116
Allergy, Immunology And Transplantation Research	R01AI149297	93.855	76,729	228,181
Allergy, Immunology And Transplantation Research	R01AI149486	93.855	—	444,454
Allergy, Immunology And Transplantation Research	R01AI149527	93.855	—	11,892
Allergy, Immunology And Transplantation Research	R01AI149724	93.855	—	66,334
Allergy, Immunology And Transplantation Research	R01AI150453	93.855	—	647,981
Allergy, Immunology And Transplantation Research	R01AI150774	93.855	122,987	266,762
Allergy, Immunology And Transplantation Research	R01AI152516	93.855	—	155,429
Allergy, Immunology And Transplantation Research	R01AI152766	93.855	—	714,058
Allergy, Immunology And Transplantation Research	R01AI153071	93.855	—	346,287
Allergy, Immunology And Transplantation Research	R01AI153102	93.855	—	349,795
Allergy, Immunology And Transplantation Research	R01AI153152	93.855	304,270	821,422
Allergy, Immunology And Transplantation Research	R01AI154894	93.855	167,263	380,721
Allergy, Immunology And Transplantation Research	R01AI155007	93.855	788,000	1,013,201

EMORY UNIVERSITY AND ITS SUBSIDIARIES
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2025

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Allergy, Immunology And Transplantation Research	R01AI155023	93.855	\$ 108,815	748,994
Allergy, Immunology And Transplantation Research	R01AI156052	93.855	—	522,265
Allergy, Immunology And Transplantation Research	R01AI158484	93.855	167,974	1,217,003
Allergy, Immunology And Transplantation Research	R01AI161570	93.855	288,238	672,557
Allergy, Immunology And Transplantation Research	R01AI162267	93.855	—	1,131,766
Allergy, Immunology And Transplantation Research	R01AI162633	93.855	—	422,378
Allergy, Immunology And Transplantation Research	R01AI164716	93.855	—	942,891
Allergy, Immunology And Transplantation Research	R01AI165368	93.855	408,111	859,823
Allergy, Immunology And Transplantation Research	R01AI165644	93.855	—	251,182
Allergy, Immunology And Transplantation Research	R01AI166305	93.855	973,224	1,459,836
Allergy, Immunology And Transplantation Research	R01AI166988	93.855	596,486	1,009,315
Allergy, Immunology And Transplantation Research	R01AI167356	93.855	218,827	849,755
Allergy, Immunology And Transplantation Research	R01AI167724	93.855	—	990,470
Allergy, Immunology And Transplantation Research	R01AI172254	93.855	—	623,229
Allergy, Immunology And Transplantation Research	R01AI172452	93.855	—	360,694
Allergy, Immunology And Transplantation Research	R01AI172740	93.855	83,014	1,058,028
Allergy, Immunology And Transplantation Research	R01AI173229	93.855	781,196	1,167,240
Allergy, Immunology And Transplantation Research	R01AI173244	93.855	—	2,314
Allergy, Immunology And Transplantation Research	R01AI173252	93.855	—	578,963
Allergy, Immunology And Transplantation Research	R01AI173946	93.855	462,156	698,291
Allergy, Immunology And Transplantation Research	R01AI174933	93.855	—	954,251
Allergy, Immunology And Transplantation Research	R01AI175428	93.855	152,349	700,772
Allergy, Immunology And Transplantation Research	R01AI176545	93.855	704,773	1,003,768
Allergy, Immunology And Transplantation Research	R01AI176952	93.855	97,545	910,331
Allergy, Immunology And Transplantation Research	R01AI177696	93.855	—	742,508
Allergy, Immunology And Transplantation Research	R01AI179476	93.855	247,935	751,541
Allergy, Immunology And Transplantation Research	R01AI179686	93.855	220,406	897,395
Allergy, Immunology And Transplantation Research	R01AI179782	93.855	255,518	601,669
Allergy, Immunology And Transplantation Research	R01AI180089	93.855	—	629,462
Allergy, Immunology And Transplantation Research	R01AI180093	93.855	—	536,863
Allergy, Immunology And Transplantation Research	R01AI181682	93.855	84,951	512,690
Allergy, Immunology And Transplantation Research	R01AI181710	93.855	14,797	710,925
Allergy, Immunology And Transplantation Research	R01AI181799	93.855	206,903	846,150
Allergy, Immunology And Transplantation Research	R01AI182244	93.855	111,615	789,391
Allergy, Immunology And Transplantation Research	R01AI182276	93.855	—	66,425
Allergy, Immunology And Transplantation Research	R01AI182314	93.855	—	21,287
Allergy, Immunology And Transplantation Research	R01AI183455	93.855	—	959,617
Allergy, Immunology And Transplantation Research	R01AI185140	93.855	343,929	623,403
Allergy, Immunology And Transplantation Research	R01AI185192	93.855	61,108	564,254
Allergy, Immunology And Transplantation Research	R01AI185849	93.855	—	469,134
Allergy, Immunology And Transplantation Research	R01AI186330	93.855	—	694,492
Allergy, Immunology And Transplantation Research	R01AI186371	93.855	214,841	415,625
Allergy, Immunology And Transplantation Research	R01AI187162	93.855	—	105,928
Allergy, Immunology And Transplantation Research	R01AI188896	93.855	—	562,843
Allergy, Immunology And Transplantation Research	R01AI189249	93.855	—	337,819
Allergy, Immunology And Transplantation Research	R01AI189829	93.855	—	134,922
Allergy, Immunology And Transplantation Research	R01AI190198	93.855	—	25,669
Allergy, Immunology And Transplantation Research	R01AI190202	93.855	—	228,094
Allergy, Immunology And Transplantation Research	R01AI190367	93.855	—	151,234

EMORY UNIVERSITY AND ITS SUBSIDIARIES
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2025

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Allergy, Immunology And Transplantation Research	R01AI192319	93.855	\$ —	32,234
Allergy, Immunology And Transplantation Research	R01AI192330	93.855	—	34,227
Allergy, Immunology And Transplantation Research	R01AI47839	93.855	1,271	54,532
Allergy, Immunology And Transplantation Research	R13AI188976	93.855	—	5,000
Allergy, Immunology And Transplantation Research	R13AI189261	93.855	—	30,000
Allergy, Immunology And Transplantation Research	R21AI122192	93.855	—	3,410
Allergy, Immunology And Transplantation Research	R21AI152031	93.855	—	204,765
Allergy, Immunology And Transplantation Research	R21AI154232	93.855	—	52
Allergy, Immunology And Transplantation Research	R21AI155221	93.855	—	15,783
Allergy, Immunology And Transplantation Research	R21AI161521	93.855	—	16,512
Allergy, Immunology And Transplantation Research	R21AI164733	93.855	—	4,241
Allergy, Immunology And Transplantation Research	R21AI167032	93.855	—	124
Allergy, Immunology And Transplantation Research	R21AI167418	93.855	141,784	265,490
Allergy, Immunology And Transplantation Research	R21AI171501	93.855	—	27,922
Allergy, Immunology And Transplantation Research	R21AI173471	93.855	80,807	224,687
Allergy, Immunology And Transplantation Research	R21AI174000	93.855	110,762	164,308
Allergy, Immunology And Transplantation Research	R21AI175846	93.855	—	128,225
Allergy, Immunology And Transplantation Research	R21AI175869	93.855	—	47,914
Allergy, Immunology And Transplantation Research	R21AI176458	93.855	96,364	172,464
Allergy, Immunology And Transplantation Research	R21AI176683	93.855	160,517	188,047
Allergy, Immunology And Transplantation Research	R21AI176944	93.855	—	201,994
Allergy, Immunology And Transplantation Research	R21AI176946	93.855	—	164,566
Allergy, Immunology And Transplantation Research	R21AI178324	93.855	—	164,350
Allergy, Immunology And Transplantation Research	R21AI178702	93.855	34,021	213,205
Allergy, Immunology And Transplantation Research	R21AI180610	93.855	—	283,015
Allergy, Immunology And Transplantation Research	R21AI180913	93.855	—	116,193
Allergy, Immunology And Transplantation Research	R21AI180928	93.855	8,932	142,398
Allergy, Immunology And Transplantation Research	R21AI186218	93.855	—	312,303
Allergy, Immunology And Transplantation Research	R21AI186306	93.855	—	310,683
Allergy, Immunology And Transplantation Research	R21AI186628	93.855	106,245	239,223
Allergy, Immunology And Transplantation Research	R21AI188271	93.855	—	424
Allergy, Immunology And Transplantation Research	R21AI189247	93.855	19,774	67,384
Allergy, Immunology And Transplantation Research	R21AI191116	93.855	—	14,314
Allergy, Immunology And Transplantation Research	R21AI192086	93.855	—	18,753
Allergy, Immunology And Transplantation Research	R24AI162317	93.855	501,482	966,055
Allergy, Immunology And Transplantation Research	R25AI147391	93.855	—	390,299
Allergy, Immunology And Transplantation Research	R25AI175048	93.855	—	257,549
Allergy, Immunology And Transplantation Research	R37AI066998	93.855	—	264
Allergy, Immunology And Transplantation Research	R37AI076119	93.855	37,099	442,283
Allergy, Immunology And Transplantation Research	R37AI141258	93.855	2,795	1,187,151
Allergy, Immunology And Transplantation Research	R37AI150556	93.855	84,290	702,745
Allergy, Immunology And Transplantation Research	R37AI157862	93.855	—	282,186
Allergy, Immunology And Transplantation Research	R38AI140299	93.855	—	339,428
Allergy, Immunology And Transplantation Research	R56AI167702	93.855	—	383,386
Allergy, Immunology And Transplantation Research	R56AI177703	93.855	—	640,735
Allergy, Immunology And Transplantation Research	R56AI182395	93.855	131,102	453,196
Allergy, Immunology And Transplantation Research	R56AI187162	93.855	22,632	306,620
Allergy, Immunology And Transplantation Research	R56AI189254	93.855	—	91,250
Allergy, Immunology And Transplantation Research	T32AI070081	93.855	—	196,984

EMORY UNIVERSITY AND ITS SUBSIDIARIES
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2025

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Allergy, Immunology And Transplantation Research	T32AI074492	93.855	\$ —	407,280
Allergy, Immunology And Transplantation Research	T32AI106699	93.855	—	217,259
Allergy, Immunology And Transplantation Research	T32AI138952	93.855	—	291,134
Allergy, Immunology And Transplantation Research	T32AI157855	93.855	—	499,192
Allergy, Immunology And Transplantation Research	U01AI103408	93.855	—	(442)
Allergy, Immunology And Transplantation Research	U01AI131295	93.855	593,799	847,289
Allergy, Immunology And Transplantation Research	U01AI138909	93.855	—	614,000
Allergy, Immunology And Transplantation Research	U01AI141993	93.855	136,377	637,470
Allergy, Immunology And Transplantation Research	U01AI148069	93.855	121,764	450,385
Allergy, Immunology And Transplantation Research	U01AI150747	93.855	422,043	859,827
Allergy, Immunology And Transplantation Research	U01AI187057	93.855	189,063	460,620
Allergy, Immunology And Transplantation Research	U19AI057266	93.855	844,516	2,198,890
Allergy, Immunology And Transplantation Research	U19AI110483	93.855	1,538,816	3,465,520
Allergy, Immunology And Transplantation Research	U19AI11121	93.855	—	(135)
Allergy, Immunology And Transplantation Research	U19AI158080	93.855	789,976	2,502,384
Allergy, Immunology And Transplantation Research	U19AI159819	93.855	299,953	1,719,469
Allergy, Immunology And Transplantation Research	U24AI120134	93.855	131,963	954,619
Allergy, Immunology And Transplantation Research	UG3AI176853	93.855	—	1,633,938
Allergy, Immunology And Transplantation Research	UM1AI069418	93.855	1,118,815	3,697,560
Allergy, Immunology And Transplantation Research	UM1AI124436	93.855	—	(403,464)
Allergy, Immunology And Transplantation Research	UM1AI148576	93.855	—	2,256,936
Allergy, Immunology And Transplantation Research	UM1AI164562	93.855	1,864,461	4,422,583
Allergy, Immunology And Transplantation Research	UM1AI169662	93.855	1,765,001	7,844,215
Pass-through Albert Einstein College of Medicine	R01AI184416	93.855	—	48,218
Pass-through Albert Einstein College of Medicine	R01HL149921	93.855	—	102,590
Pass-through Benaroya Research Institute	UM1AI109565	93.855	—	303,763
Pass-through Beth Israel Deaconess Medical Center	UM1AI124377	93.855	—	(3,533)
Pass-through Boston Children's Hospital	R24AI162637	93.855	—	14,602
Pass-through Boston Children's Hospital	U24AI152179	93.855	—	50,692
Pass-through Case Western Reserve University	R01AI072219	93.855	—	82,423
Pass-through Case Western Reserve University	R37AI141258	93.855	—	(9,100)
Pass-through Cincinnati Children's Hospital	R01AI176519	93.855	—	355,343
Pass-through Cincinnati Children's Hospital	U01AI144673	93.855	—	692,064
Pass-through Columbia University	R01AI169938	93.855	—	244,080
Pass-through Duke Clinical Research Institute	UM1AI104681	93.855	—	(5,485)
Pass-through Duke University	SUM1AI104681-12	93.855	—	34,956
Pass-through Duke University	R01AI143457	93.855	—	31,193
Pass-through Duke University	R01AI175411	93.855	—	17,150
Pass-through Duke University	UM1AI104681	93.855	—	62,242
Pass-through FHI 360 Llc	P018001927	93.855	183,650	183,650
Pass-through FHI 360 Llc	UM1 AI068619	93.855	—	604,550
Pass-through FHI 360 Llc	UM1AI068619	93.855	98,852	104,111
Pass-through Florida State University	R01AI173084	93.855	—	120,281
Pass-through Fred Hutchinson Research Center	UM1AI068614	93.855	—	730,719
Pass-through Fred Hutchinson Research Center	UM1AI068635	93.855	—	41,524
Pass-through George Washington University	R01AI186786	93.855	—	9,501
Pass-through Georgia Institute of Technology	R01AI153116	93.855	—	205,185
Pass-through Georgia Institute of Technology	R01AI181282	93.855	—	27,572
Pass-through Georgia Institute of Technology	R01AI186314	93.855	—	4,069

EMORY UNIVERSITY AND ITS SUBSIDIARIES
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2025

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Pass-through Georgia Institute of Technology	R01AI68408	93.855	\$ —	299,460
Pass-through Georgia Institute of Technology	R56AI184449	93.855	—	91,974
Pass-through Georgia State University	R01AI141222	93.855	—	34
Pass-through Georgia State University	R01AI153400	93.855	—	157,122
Pass-through Georgia State University	R01AI154656	93.855	—	42,990
Pass-through Harvard Pilgrim Health Care Institute	R01A174862	93.855	—	36,799
Pass-through Harvard University	P01AI056299	93.855	—	162,292
Pass-through Immune Tolerance Network	UM1AI109565	93.855	—	277,362
Pass-through Indiana University	R21AI185419	93.855	—	20,236
Pass-through J. Craig Venter Institute	R01AI170111	93.855	—	127,959
Pass-through Johns Hopkins University	R01AI172092	93.855	—	31,131
Pass-through Johns Hopkins University	U01AI069918	93.855	—	84,183
Pass-through Johns Hopkins University	U01AI138897	93.855	—	5,216
Pass-through Johns Hopkins University	UM1 A1068632	93.855	—	19,223
Pass-through Johns Hopkins University	UM1AI068632	93.855	—	33,727
Pass-through Johns Hopkins University	UM1AI164566	93.855	—	1,735,660
Pass-through Johns Hopkins University	UM1AI182034	93.855	—	36,642
Pass-through La Jolla Institute For Allergy	R37AI125068	93.855	—	141,863
Pass-through La Jolla Institute For Allergy	U01AI167892	93.855	—	44,146
Pass-through La Jolla Institute For Immunology	R61AI183471	93.855	—	314,220
Pass-through La Jolla Institute For Immunology	U01AI167892	93.855	—	22,460
Pass-through Massachusetts General Hospital	R01AI176533	93.855	—	585,958
Pass-through Massachusetts General Hospital	R37AI106878	93.855	—	23,938
Pass-through Massachusetts Institute of Technology	R33AI161297	93.855	—	367,913
Pass-through Massachusetts Institute of Technology	R61AI161297	93.855	—	61
Pass-through Md Anderson	R01CA110709	93.855	—	(1,834)
Pass-through Medical University of South Carolina	U01AI125159	93.855	—	(45,806)
Pass-through Medical University of South Carolina	U01AI184159	93.855	—	335,659
Pass-through Memorial Sloan Kettering Cancer Center	R01AI087644	93.855	—	54,931
Pass-through Mercer University	R15AI176177	93.855	—	138,932
Pass-through Mount Sinai School of Medicine	P01AI097092	93.855	—	7,635
Pass-through Mount Sinai School of Medicine	U19AI135972	93.855	—	303,935
Pass-through New York University	U01AI174997	93.855	—	4,667
Pass-through Pennsylvania State University	R01AI158706	93.855	—	(16,101)
Pass-through Regents of the University of California	UM1AI068636	93.855	—	5,397
Pass-through Research Institute at Nationwide Children's Hospital	R01AI096882	93.855	—	104,268
Pass-through Research Institute at Nationwide Children's Hospital	R01AI151175	93.855	—	54,294
Pass-through Research Institute at Nationwide Children's Hospital	R01AI175800	93.855	—	182,004
Pass-through Research Institute at Nationwide Children's Hospital	R01AI183877	93.855	—	254,518
Pass-through Rutgers The State University	R01AI175555	93.855	—	12,582
Pass-through Rutgers University	R21AI171755	93.855	—	(541)
Pass-through Scripps Research Institute	P01AI157299	93.855	—	376,052
Pass-through Scripps Research Institute	R01AI145629	93.855	—	219,013
Pass-through Scripps Research Institute	R01AI168232	93.855	—	200,880
Pass-through Scripps Research Institute	R01AI177265	93.855	—	70,684
Pass-through Scripps Research Institute	UM1 AI144462	93.855	—	200,435
Pass-through Scripps Research Institute	UM1AI144462	93.855	—	1,561,038
Pass-through Scripps Research Institute	UM1AI164561	93.855	—	2,645,776
Pass-through Seattle Childrens Hospital	R01AI165351	93.855	—	10,046

EMORY UNIVERSITY AND ITS SUBSIDIARIES
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2025

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Pass-through Seattle Childrens Hospital	U54AI170855	93.855	\$ —	183,807
Pass-through Seattle Children's Research Institute	U54AI170855	93.855	—	963,883
Pass-through Seattle Children's Research Institute	U54AI70855	93.855	—	55,264
Pass-through St Jude Childrens Research Hospital	U01AI144616	93.855	—	390,601
Pass-through Stanford University	U19AI159840	93.855	—	95,558
Pass-through Stanford University	U19AI167903	93.855	—	102,866
Pass-through Stanford University	U19AI171421	93.855	—	536,508
Pass-through Temple University	R01AI178849	93.855	—	152,001
Pass-through Texas Biomedical Research Institute	R56AI184089	93.855	—	50,739
Pass-through University of Massachusetts Lowell	R33AI140472	93.855	—	27,706
Pass-through University of Alabama Birmingham	R01AI153365	93.855	—	119,469
Pass-through University of Alabama Birmingham	U19AI109962	93.855	—	2,990
Pass-through University of Calgary	R01AI165327	93.855	407	38,347
Pass-through University of California Berkeley	U01AI151788	93.855	—	43,456
Pass-through University of California Davis	P01AI181044	93.855	—	767
Pass-through University of California Irvine	R01AI152161	93.855	—	193,793
Pass-through University of California Irvine	R01AI175312	93.855	—	19,782
Pass-through University of California Los Angeles	UM1AI068636	93.855	—	2,862
Pass-through University of California Los Angeles	UM1AI106701	93.855	—	346,751
Pass-through University of California San Diego	P30AI036214	93.855	—	36,528
Pass-through University of California San Diego	R21AI171385	93.855	—	115,536
Pass-through University of California San Francisco	R01AI143464	93.855	—	169,467
Pass-through University of California San Francisco	R01AI151075	93.855	—	281,792
Pass-through University of California San Francisco	R01AI158527	93.855	—	380,484
Pass-through University of California San Francisco	R01AI165706	93.855	—	103,055
Pass-through University of California San Francisco	R01AI175614	93.855	—	114,546
Pass-through University of California San Francisco	R01AI181732	93.855	—	23,081
Pass-through University of California San Francisco	R01AI184205	93.855	—	3,349
Pass-through University of California San Francisco	R25AI154589	93.855	—	11,569
Pass-through University of California San Francisco	U01AI131296	93.855	—	7,378
Pass-through University of California San Francisco	U01AI163090	93.855	—	41,130
Pass-through University of Colorado Denver	R01AI162665	93.855	—	197,557
Pass-through University of Georgia	R01AI148667	93.855	—	42,295
Pass-through University of Georgia	R61AI187112	93.855	—	39,240
Pass-through University of Iowa	R33AI169659	93.855	—	17,149
Pass-through University of Kentucky	R01AI141889	93.855	—	23
Pass-through University of Maryland, Baltimore	P01AI124912	93.855	—	(117,315)
Pass-through University of Michigan	U54AI170660	93.855	—	60,088
Pass-through University of Minnesota	U19AI174966	93.855	—	1,232,768
Pass-through University of Missouri Columbia	R21AI167742	93.855	—	(18,973)
Pass-through University of North Carolina Chapel Hill	R01AI136990	93.855	—	(3,558)
Pass-through University of North Carolina Chapel Hill	R01AI153007	93.855	—	56,737
Pass-through University of North Carolina Chapel Hill	UM1AI164567	93.855	—	1,351,493
Pass-through University of Pennsylvania	R01AI139188	93.855	—	2,987
Pass-through University of Pennsylvania	R01AI158452-01A1	93.855	—	92,228
Pass-through University of Pennsylvania	R01AI179666	93.855	—	637,894
Pass-through University of Pennsylvania	U01AI169767	93.855	—	70,475
Pass-through University of Pittsburgh	R01AI187016	93.855	—	51,376
Pass-through University of South Florida	R01AI153830	93.855	—	68,998

EMORY UNIVERSITY AND ITS SUBSIDIARIES
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2025

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Pass-through University of Texas Austin	R01AI158706	93.855	\$ —	88,244
Pass-through University of Texas Medical Branch	R01AI143653	93.855	—	2,477
Pass-through University of Texas Medical Branch	R01AI187192	93.855	—	3,039
Pass-through University of Texas Medical Branch	U19AI171413	93.855	—	390,277
Pass-through University of Texas Southwestern	R01AI161399	93.855	—	100,823
Pass-through University of Utah	R01AI169835	93.855	—	74,305
Pass-through University of Utah	R37AI150479	93.855	—	142,757
Pass-through University of Virginia	R01AI154242	93.855	—	30,533
Pass-through University of Virginia	R01AI170093	93.855	—	38,881
Pass-through University of Washington	R01AI142647	93.855	—	75,233
Pass-through University of Washington	R01AI174979	93.855	—	3,700
Pass-through University of Washington	R01AI181634	93.855	—	131,494
Pass-through University of Washington	R21AI183907	93.855	—	19,373
Pass-through University of Washington	U01AI163090	93.855	—	14,681
Pass-through University of Wisconsin-Madison	R01AI108415	93.855	—	83,763
Pass-through University of Wisconsin-Madison	R01AI148707	93.855	—	66,888
Pass-through Vanderbilt University	U19AI095227	93.855	—	(3,354)
Pass-through Vanderbilt University Medical Center	R01AI170172	93.855	—	25,533
Pass-through Vanderbilt University Medical Center	U01AI154659	93.855	—	37,504
Pass-through Vanderbilt University Medical Center	U01AI167799	93.855	—	28,523
Pass-through Vanderbilt University Medical Center	U01AI67789	93.855	—	32,472
Pass-through Vanderbilt University Medical Center	U19AI095227	93.855	—	2,913
Pass-through Washington State University	U01AI151799	93.855	—	120,366
Pass-through Washington University	U19AI157797	93.855	—	22,405
Pass-through Wistar Institute	U19AI109646	93.855	—	(327)
Pass-through Yale University	R01AI112970	93.855	—	65,280
Total AL No. 93.855			39,855,619	157,815,170
Biomedical Research and Research Training	F31GM143891	93.859	—	9,680
Biomedical Research and Research Training	F31GM153153	93.859	—	46,828
Biomedical Research and Research Training	F31GM157874	93.859	—	19,446
Biomedical Research and Research Training	F32GM153152	93.859	—	74,400
Biomedical Research and Research Training	K12GM000680	93.859	33,062	1,074,193
Biomedical Research and Research Training	K23GM137182	93.859	—	78,610
Biomedical Research and Research Training	K23GM144867	93.859	—	293,255
Biomedical Research and Research Training	K99GM143517	93.859	—	1,365
Biomedical Research and Research Training	K99GM157498	93.859	—	77,293
Biomedical Research and Research Training	R01GM093278	93.859	—	238,651
Biomedical Research and Research Training	R01GM099142	93.859	—	126,949
Biomedical Research and Research Training	R01GM100151	93.859	—	(949)
Biomedical Research and Research Training	R01GM116991	93.859	—	808
Biomedical Research and Research Training	R01GM124472	93.859	—	1,150
Biomedical Research and Research Training	R01GM129495	93.859	—	2,151
Biomedical Research and Research Training	R01GM130950	93.859	—	388,723
Biomedical Research and Research Training	R01GM136880	93.859	—	4,084
Biomedical Research and Research Training	R01GM137011	93.859	—	186,015
Biomedical Research and Research Training	R01GM138544	93.859	—	359,220
Biomedical Research and Research Training	R01GM139842	93.859	125,427	293,325
Biomedical Research and Research Training	R01GM140632	93.859	189,975	364,288

EMORY UNIVERSITY AND ITS SUBSIDIARIES
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2025

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Biomedical Research and Research Training	R01GM141074	93.859	\$ —	289,871
Biomedical Research and Research Training	R01GM142113	93.859	—	263,187
Biomedical Research and Research Training	R01GM144563	93.859	—	209,042
Biomedical Research and Research Training	R01GM144729	93.859	—	388,335
Biomedical Research and Research Training	R01GM148075	93.859	42,920	687,076
Biomedical Research and Research Training	R01GM151093	93.859	—	197,426
Biomedical Research and Research Training	R01GM152543	93.859	47,688	185,051
Biomedical Research and Research Training	R21GM127971	93.859	—	79
Biomedical Research and Research Training	R21GM148931	93.859	39,259	139,585
Biomedical Research and Research Training	R25GM125598	93.859	—	68,871
Biomedical Research and Research Training	R25GM146271	93.859	—	169,395
Biomedical Research and Research Training	R25GM154377	93.859	6,664	184,820
Biomedical Research and Research Training	R25GM156529	93.859	—	22,719
Biomedical Research and Research Training	R35GM119426	93.859	—	465,252
Biomedical Research and Research Training	R35GM122568	93.859	—	475,657
Biomedical Research and Research Training	R35GM122591	93.859	—	748,689
Biomedical Research and Research Training	R35GM128570	93.859	—	431,840
Biomedical Research and Research Training	R35GM133509	93.859	—	(79)
Biomedical Research and Research Training	R35GM133719	93.859	—	(1,917)
Biomedical Research and Research Training	R35GM136407	93.859	—	355,763
Biomedical Research and Research Training	R35GM138123	93.859	—	277,272
Biomedical Research and Research Training	R35GM138313	93.859	18,036	341,481
Biomedical Research and Research Training	R35GM139408	93.859	—	517,279
Biomedical Research and Research Training	R35GM142503	93.859	—	302,130
Biomedical Research and Research Training	R35GM142724	93.859	—	707,944
Biomedical Research and Research Training	R35GM143050	93.859	—	442,201
Biomedical Research and Research Training	R35GM147557	93.859	—	478,885
Biomedical Research and Research Training	R35GM147558	93.859	—	488,137
Biomedical Research and Research Training	R35GM148217	93.859	—	662,130
Biomedical Research and Research Training	R35GM148416	93.859	—	475,095
Biomedical Research and Research Training	R35GM149296	93.859	31,398	33,714
Biomedical Research and Research Training	R35GM150587	93.859	—	435,838
Biomedical Research and Research Training	R35GM150760	93.859	—	582,739
Biomedical Research and Research Training	R35GM150920	93.859	—	420,447
Biomedical Research and Research Training	R35GM151220	93.859	—	395,916
Biomedical Research and Research Training	R35GM153472	93.859	64,635	671,164
Biomedical Research and Research Training	R35GM155032	93.859	—	365,999
Biomedical Research and Research Training	R35GM155357	93.859	—	396,949
Biomedical Research and Research Training	R35GM156629	93.859	—	103,069
Biomedical Research and Research Training	R35GM156739	93.859	—	226,944
Biomedical Research and Research Training	R35GM158221	93.859	—	52,425
Biomedical Research and Research Training	R35GM158404	93.859	—	60,946
Biomedical Research and Research Training	RM1GM145394	93.859	211,880	1,557,632
Biomedical Research and Research Training	T32GM095442	93.859	—	324,641
Biomedical Research and Research Training	T32GM135060	93.859	—	362,073
Biomedical Research and Research Training	T32GM142617	93.859	—	1,433,688
Biomedical Research and Research Training	T32GM145445	93.859	—	452,739
Biomedical Research and Research Training	T32GM148391	93.859	—	515,640
Biomedical Research and Research Training	T32GM149422	93.859	—	513,958

EMORY UNIVERSITY AND ITS SUBSIDIARIES
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2025

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Biomedical Research and Research Training	T32GM152344	93.859	\$ —	305,562
Biomedical Research and Research Training	T34GM149511	93.859	—	290,260
Pass-through Brown University	R01GM141392	93.859	—	166,160
Pass-through Cincinnati Childrens Hospital	R21GM151703	93.859	—	(48)
Pass-through Delaware State University	UC2GM157743	93.859	—	35,417
Pass-through Georgia Institute of Technology	R01AI148740	93.859	—	86,905
Pass-through Georgia Institute of Technology	R35GM147437	93.859	—	57,270
Pass-through Georgia Institute of Technology	R35GM150689	93.859	—	51,534
Pass-through Johns Hopkins University	R01GM147162	93.859	—	87,278
Pass-through North Carolina State University	R25GM130528	93.859	—	17,039
Pass-through Northwestern University	R01GM121359	93.859	—	16,009
Pass-through Ohio State University	R01GM130135	93.859	—	90,933
Pass-through Pennsylvania State University	R01GM121650	93.859	—	(17,890)
Pass-through Seattle Children's Research Institute	U54AI150472	93.859	—	263
Pass-through Texas Agricultural and Mechanical Univ	R01AI145640	93.859	—	65,317
Pass-through University of Texas Austin	7R01GM121650-07	93.859	—	297,341
Total AL No. 93.859			810,944	24,068,572
Child Health And Human Development Extramural Research	75N94022P00789	93.865	—	28,797
Child Health And Human Development Extramural Research	F31HD107968	93.865	—	378
Child Health And Human Development Extramural Research	F31HD108974	93.865	—	46,214
Child Health And Human Development Extramural Research	F31HD111310	93.865	—	15,606
Child Health And Human Development Extramural Research	F31HD112113	93.865	—	47,601
Child Health And Human Development Extramural Research	F31HD116541	93.865	—	50,762
Child Health And Human Development Extramural Research	F31HD116544	93.865	—	19,887
Child Health And Human Development Extramural Research	F31HD118798	93.865	—	27,995
Child Health And Human Development Extramural Research	F32HD100176	93.865	—	(667)
Child Health And Human Development Extramural Research	F32HD108927	93.865	—	80,733
Child Health And Human Development Extramural Research	F32HD112128	93.865	—	63,531
Child Health And Human Development Extramural Research	F32HD112173	93.865	—	67,641
Child Health And Human Development Extramural Research	HHSN2752008000024C	93.865	—	(519,010)
Child Health And Human Development Extramural Research	K01HD100588	93.865	—	26,492
Child Health And Human Development Extramural Research	K01HD107294	93.865	—	57,804
Child Health And Human Development Extramural Research	K12HD072245	93.865	—	413,537
Child Health And Human Development Extramural Research	K12HD085850	93.865	—	490,138
Child Health And Human Development Extramural Research	P01HD112217	93.865	—	1,819,272
Child Health And Human Development Extramural Research	P50HD104458	93.865	699,962	1,532,533
Child Health And Human Development Extramural Research	R00HD096322	93.865	—	118,032
Child Health And Human Development Extramural Research	R00HD103912	93.865	—	211,384
Child Health And Human Development Extramural Research	R00HD104896	93.865	—	202,795
Child Health And Human Development Extramural Research	R00HD104991	93.865	—	204,101
Child Health And Human Development Extramural Research	R00HD105984	93.865	—	362,746
Child Health And Human Development Extramural Research	R01HD046922	93.865	—	567,373
Child Health And Human Development Extramural Research	R01HD081120	93.865	122,875	703,259
Child Health And Human Development Extramural Research	R01HD082373	93.865	—	418,255
Child Health And Human Development Extramural Research	R01HD090642	93.865	412,911	741,713
Child Health And Human Development Extramural Research	R01HD093706	93.865	—	4,486
Child Health And Human Development Extramural Research	R01HD094716	93.865	—	78,048
Child Health And Human Development Extramural Research	R01HD095741	93.865	—	115,167

EMORY UNIVERSITY AND ITS SUBSIDIARIES
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2025

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Child Health And Human Development Extramural Research	R01HD095975	93.865	\$ —	467,048
Child Health And Human Development Extramural Research	R01HD097175	93.865	67,141	114,214
Child Health And Human Development Extramural Research	R01HD099480	93.865	—	1,415
Child Health And Human Development Extramural Research	R01HD101600	93.865	232,952	412,642
Child Health And Human Development Extramural Research	R01HD102534	93.865	272,665	559,998
Child Health And Human Development Extramural Research	R01HD107002	93.865	47,350	114,587
Child Health And Human Development Extramural Research	R01HD108310	93.865	556,048	716,526
Child Health And Human Development Extramural Research	R01HD109005	93.865	79,644	171,465
Child Health And Human Development Extramural Research	R01HD109126	93.865	24,392	689,409
Child Health And Human Development Extramural Research	R01HD110480	93.865	160,090	681,519
Child Health And Human Development Extramural Research	R01HD114116	93.865	115,802	609,319
Child Health And Human Development Extramural Research	R01HD114862	93.865	—	283,297
Child Health And Human Development Extramural Research	R01HD115644	93.865	12,916	327,794
Child Health And Human Development Extramural Research	R01HD115881	93.865	—	356,451
Child Health And Human Development Extramural Research	R21HD107409	93.865	22,029	135,870
Child Health And Human Development Extramural Research	R21HD109652	93.865	20,638	265,645
Child Health And Human Development Extramural Research	R21HD109723	93.865	108,049	183,285
Child Health And Human Development Extramural Research	R21HD110847	93.865	—	62,615
Child Health And Human Development Extramural Research	R21HD111635	93.865	—	142,387
Child Health And Human Development Extramural Research	R21HD116165	93.865	—	82,882
Child Health And Human Development Extramural Research	R21HD116484	93.865	—	34,024
Child Health And Human Development Extramural Research	R21HD117191	93.865	—	40,906
Child Health And Human Development Extramural Research	R33HD099745	93.865	107,622	314,774
Child Health And Human Development Extramural Research	R56HD113703	93.865	—	130,353
Child Health And Human Development Extramural Research	R61HD117325	93.865	—	263,267
Child Health And Human Development Extramural Research	UG1HD027851	93.865	—	297,229
Pass-through Baylor College of Medicine	P5DH104463	93.865	—	467,871
Pass-through Boston Medical Center	R01HD109005	93.865	—	25,861
Pass-through Bradley Hospital	R01HD095837	93.865	—	5,012
Pass-through Brown University	R01HD108048	93.865	—	19,391
Pass-through Case Western Reserve University	R01HD092351	93.865	—	12,312
Pass-through Childrens Hospital of Los Angeles	R01HD101641	93.865	—	25,024
Pass-through Childrens Hospital of Los Angeles	R21HD107983	93.865	—	19,393
Pass-through Children's Hospital of Philadelphia	R01HD101528	93.865	—	50,683
Pass-through City University of New York	R01HD102429	93.865	—	165,964
Pass-through Drexel University	R01HD110140	93.865	—	79,399
Pass-through Florida State University	UM2HD111102	93.865	—	39,363
Pass-through Georgia Institute of Technology	P2CHD086844	93.865	—	10,800
Pass-through Georgia State University	R01HD107016	93.865	—	55,356
Pass-through Harvard University	R01HD102342	93.865	—	55,890
Pass-through Michigan State University	R01HD096033	93.865	—	567
Pass-through Morehouse School of Medicine	U54HD113292-01	93.865	36,668	793,152
Pass-through Northwestern University	K12HD073945	93.865	—	(60)
Pass-through Northwestern University	R01HD099344	93.865	—	6,458
Pass-through Phoenix Children'S Hospital	R01HD088528	93.865	—	(82,259)
Pass-through Population Council	P50HD106793	93.865	—	107,633
Pass-through Rush University Medical Center	R01HD107522	93.865	—	154,728
Pass-through Stellenbosch University	R01HD102050	93.865	—	182,501
Pass-through Tulane University	R01HD111444	93.865	—	35,902
Pass-through Univ of Massachusetts Medical School	R01HD109293	93.865	—	37,863

EMORY UNIVERSITY AND ITS SUBSIDIARIES
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2025

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Pass-through University of California Davis	R01HD102571	93.865	\$ —	85,081
Pass-through University of California San Francisco	P01HD106414	93.865	—	128,291
Pass-through University of Connecticut	R01HD106617	93.865	—	42,970
Pass-through University of Kansas Medical Center	R01HD112446	93.865	—	137,983
Pass-through University of Miami	R01HD101352	93.865	—	845,496
Pass-through University of Michigan	R01HD097107	93.865	—	171,106
Pass-through University of Michigan	R21HD11811	93.865	—	13,524
Pass-through University of Minnesota	R01HD103634	93.865	—	31,436
Pass-through University of North Carolina Chapel Hill	U24HD089880	93.865	—	334
Pass-through University of Pennsylvania	R01HD111643	93.865	—	193,702
Pass-through University of Pennsylvania	U24HD113146	93.865	—	21,384
Pass-through University of Pittsburgh	P2CHD101895	93.865	—	129
Pass-through University of Pittsburgh	R01HD102313	93.865	—	110,000
Pass-through University of South Carolina	R01HD110844	93.865	—	151,112
Pass-through University of Washington	P01 HD107669	93.865	—	134,137
Pass-through Vanderbilt University Medical Center	P50HD106446	93.865	—	103,442
Pass-through Vanderbilt University Medical Center	R01HD107695	93.865	—	21,302
Pass-through Wake Forest University	R01HD099231	93.865	—	297,855
Pass-through Wayne State University	R01HD099178	93.865	—	158,440
Pass-through Weill Cornell Medical College	K12HD000850	93.865	—	116,663
Pass-through Women & Infants Hospital of Rhode Island	R01HD084515	93.865	—	626,507
Total AL No. 93.865			3,099,754	21,115,222
Aging Research	F31AG076332	93.866	—	38,062
Aging Research	F31AG079597	93.866	—	33,564
Aging Research	F31AG079670	93.866	—	40,970
Aging Research	F31AG081046	93.866	—	45,257
Aging Research	F31AG081129	93.866	—	60,966
Aging Research	F31AG086006	93.866	—	42,773
Aging Research	F32AG081135	93.866	—	72,744
Aging Research	F32AG090054	93.866	—	58,669
Aging Research	K01AG078497	93.866	—	44,684
Aging Research	K08AG068604	93.866	—	140,202
Aging Research	K22AG088144	93.866	—	114,484
Aging Research	K23AG065505	93.866	—	95,066
Aging Research	K23AG066931	93.866	—	195,095
Aging Research	K23AG070378	93.866	—	216,068
Aging Research	K23AG073516	93.866	—	220,500
Aging Research	K23AG076977	93.866	—	158,212
Aging Research	K23AG084415	93.866	—	142,665
Aging Research	K23AG084851	93.866	—	223,364
Aging Research	P30AG064200	93.866	141,764	719,920
Aging Research	P30AG066511	93.866	14,446	2,080,125
Aging Research	P50AG025688	93.866	—	(4,620)
Aging Research	R01AG049752	93.866	—	(374,800)
Aging Research	R01AG058704	93.866	205,489	618,511
Aging Research	R01AG062515	93.866	—	504,404
Aging Research	R01AG062577	93.866	—	123,324

EMORY UNIVERSITY AND ITS SUBSIDIARIES
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2025

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Aging Research	R01AG062581	93.866	\$ —	258,559
Aging Research	R01AG062691	93.866	—	256,308
Aging Research	R01AG064464	93.866	—	16,864
Aging Research	R01AG065177	93.866	—	187,524
Aging Research	R01AG065611	93.866	247,279	541,849
Aging Research	R01AG066203	93.866	40,067	231,396
Aging Research	R01AG066956	93.866	604,390	898,910
Aging Research	R01AG067736	93.866	—	623,998
Aging Research	R01AG068247	93.866	—	271,087
Aging Research	R01AG069114	93.866	53,668	881,429
Aging Research	R01AG069253	93.866	—	192,477
Aging Research	R01AG070060	93.866	—	487,956
Aging Research	R01AG070704	93.866	33,582	1,349,831
Aging Research	R01AG070937	93.866	37,679	7,286,858
Aging Research	R01AG072603	93.866	93,404	740,608
Aging Research	R01AG072756	93.866	—	617,033
Aging Research	R01AG074019	93.866	79,175	339,955
Aging Research	R01AG074357	93.866	156,664	698,660
Aging Research	R01AG075444	93.866	27,989	299,380
Aging Research	R01AG075827	93.866	—	(16,398)
Aging Research	R01AG075963	93.866	211,638	944,833
Aging Research	R01AG076373	93.866	—	641,561
Aging Research	R01AG078248	93.866	—	676,876
Aging Research	R01AG078937	93.866	—	940,119
Aging Research	R01AG079170	93.866	—	395,936
Aging Research	R01AG079199	93.866	—	2,079
Aging Research	R01AG079269	93.866	—	1,936
Aging Research	R01AG079836	93.866	155,176	781,640
Aging Research	R01AG079956	93.866	—	170,615
Aging Research	R01AG079990	93.866	478,353	575,651
Aging Research	R01AG081282	93.866	—	65,613
Aging Research	R01AG082300	93.866	98,845	396,222
Aging Research	R01AG082833	93.866	51,220	809,567
Aging Research	R01AG083084	93.866	—	555,943
Aging Research	R01AG083154	93.866	41,600	655,809
Aging Research	R01AG083477	93.866	362,906	554,892
Aging Research	R01AG085557	93.866	—	1,117,695
Aging Research	R01AG085587	93.866	—	450,610
Aging Research	R01AG087190	93.866	—	238,712
Aging Research	R01AG087216	93.866	35,207	520,093
Aging Research	R01AG087250	93.866	—	813,503
Aging Research	R01AG087296	93.866	183,266	342,938
Aging Research	R01AG089497	93.866	—	394,385
Aging Research	R01AG089703	93.866	—	19,183
Aging Research	R01AG089759	93.866	870,860	3,860,590
Aging Research	R01AG089806	93.866	—	395,574
Aging Research	R01AG094161	93.866	—	5,955
Aging Research	R01AS072309	93.866	24,156	300,923
Aging Research	R03AG087436	93.866	—	192,048

EMORY UNIVERSITY AND ITS SUBSIDIARIES
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2025

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Aging Research	R03AG087482	93.866	\$ —	157,078
Aging Research	R21AG055995	93.866	—	(7,305)
Aging Research	R21AG074218	93.866	—	(6,721)
Aging Research	R21AG078058	93.866	—	105,000
Aging Research	R21AG080247	93.866	—	204,034
Aging Research	R21AG080262	93.866	—	120,275
Aging Research	R21AG082333	93.866	—	115,439
Aging Research	R21AG083366	93.866	48,787	244,529
Aging Research	R21AG083414	93.866	34,351	159,527
Aging Research	R21AG084231	93.866	—	242,233
Aging Research	R24AG066599	93.866	209,714	445,259
Aging Research	R36AG088283	93.866	—	46,489
Aging Research	R56AG074886	93.866	—	199,691
Aging Research	R56AG083167	93.866	335,906	591,618
Aging Research	R56AG083845	93.866	—	385,384
Aging Research	R56AG085250	93.866	—	130,037
Aging Research	R56AG086417	93.866	—	386,777
Aging Research	R61AG080606	93.866	—	285,809
Aging Research	RAG065282A	93.866	121,512	750,488
Aging Research	RF1AG064942	93.866	—	81,767
Aging Research	RF1AG065282	93.866	37,807	38,833
Aging Research	RF1AG069253	93.866	—	671,574
Aging Research	RF1AG071170	93.866	—	678,216
Aging Research	RF1AG073428	93.866	4,150	62,089
Aging Research	RF1AG079199	93.866	101,805	690,216
Aging Research	RF1AG079256	93.866	148,042	578,281
Aging Research	RF1AG079269	93.866	386,146	804,549
Aging Research	RF1AG079318	93.866	—	722,306
Aging Research	RF1AG081401	93.866	—	642,939
Aging Research	T32AG087922	93.866	—	253,928
Aging Research	U01AG061357	93.866	—	139,979
Aging Research	U01AG088113	93.866	21,594	929,416
Aging Research	U01AG088425	93.866	93,143	1,629,600
Aging Research	U24AG077110	93.866	217,431	374,572
Aging Research	U54AG062334	93.866	185,852	424,954
Aging Research	U54AG065187	93.866	5,023,722	8,564,057
Pass-through Beth Israel Deaconess Medical Center	R01AG068141	93.866	—	58,657
Pass-through Case Western Reserve University	R01AG067607	93.866	—	34,390
Pass-through Case Western Reserve University	R01AG077554	93.866	—	16,811
Pass-through Columbia University	R01AG062624	93.866	—	1,741
Pass-through Dian Fossey Gorilla Fund	R01AG087961	93.866	—	190,078
Pass-through Georgia Institute of Technology	R01AG082039	93.866	—	217,553
Pass-through Georgia State University	R01AG080093	93.866	—	9,205
Pass-through Indiana University	U54AG054345	93.866	—	298,013
Pass-through Johns Hopkins University	UG3AG090673	93.866	—	5,922
Pass-through M D Anderson Cancer Center	R01AG067419	93.866	—	108,443
Pass-through M D Anderson Cancer Center	R01AG071174	93.866	—	64,726
Pass-through Mayo Clinic Florida	R01AG089380	93.866	—	20,713
Pass-through Mclean Hospital	R01AG061100	93.866	—	76,599

EMORY UNIVERSITY AND ITS SUBSIDIARIES
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2025

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Pass-through Medical University of South Carolina	R01AG046543	93.866	\$ —	(11,120)
Pass-through Northwestern University	U19AG073153	93.866	—	(91)
Pass-through NYU Grossman School of Medicine	R33AG058926	93.866	—	26,460
Pass-through Ohio State University	R01AG084676	93.866	—	22,885
Pass-through Oregon Health and Science University	R01AG067546	93.866	—	28,468
Pass-through Stanford University	5P30AG059307	93.866	—	19,897
Pass-through State University of New York Stony Brook	R01AG067590	93.866	—	61,121
Pass-through Tulane University	R01AG077497	93.866	—	18,645
Pass-through Univ of Texas Health Sciences Ctr	R33AG078523	93.866	—	48,270
Pass-through University of Nevada	R01AG083177	93.866	—	77,756
Pass-through University of Oregon	R01AR078375	93.866	—	30,451
Pass-through University of Toledo	R01AG083628	93.866	—	135,798
Pass-through University of Alabama Birmingham	R01AG061800	93.866	—	13,801
Pass-through University of Arizona	U19AG065169	93.866	—	702,331
Pass-through University of California Berkeley	R01AG077001	93.866	—	15,828
Pass-through University of California Davis	R01AG062517	93.866	—	295,718
Pass-through University of California San Diego	R01AG062387	93.866	—	11,073
Pass-through University of California San Diego	U19G010483	93.866	—	1,209
Pass-through University of California San Francisco	R01AG061179	93.866	—	17,805
Pass-through University of Chicago	U19AG073153	93.866	—	157,265
Pass-through University of Florida	R01AG064786	93.866	—	32,832
Pass-through University of Florida	R01AG074569	93.866	—	476,289
Pass-through University of Florida	RF1AG064914	93.866	—	(5,960)
Pass-through University of Florida	RF1AG074569	93.866	—	54,841
Pass-through University of Georgia	R21AG070765	93.866	—	115,371
Pass-through University of Georgia	U01AG074960	93.866	—	10,266
Pass-through University of Illinois at Chicago	R21HD112862	93.866	—	16,006
Pass-through University of Michigan	U24AG077012	93.866	—	15,793
Pass-through University of Minnesota	RF1AG079100	93.866	—	11,961
Pass-through University of Minnesota	U54AG089300	93.866	—	143,171
Pass-through University of Nebraska Medical Center	R01AG069609	93.866	—	215,258
Pass-through University of New Mexico	R01AG049395	93.866	—	166,623
Pass-through University of North Carolina Greensboro	R01AG058919	93.866	—	75,075
Pass-through University of North Carolina Greensboro	R21AR084039	93.866	—	91,512
Pass-through University of Pennsylvania	R01AG069401	93.866	—	3,155
Pass-through University of Pennsylvania	U01AG088658	93.866	—	307,573
Pass-through University of Pittsburgh	R01AG074971	93.866	—	333,466
Pass-through University of Pittsburgh	U19AG074866-01A1	93.866	—	250,441
Pass-through University of Southern California	R01AG065482	93.866	—	4,511
Pass-through University of Southern California	R01AG079967	93.866	—	56,419
Pass-through University of Southern California	U24AG057437	93.866	—	330,238
Pass-through University of Texas Medical Branch	R01AG088215	93.866	—	216,453
Pass-through University of Texas Southwestern	R01AG085279	93.866	—	320,636
Pass-through University of Washington	U01AG016976	93.866	—	(95,254)
Pass-through University of Washington	U24AG072122	93.866	—	125,559
Pass-through University of Washington Saint Louis	RAG056639A	93.866	—	1,118
Pass-through University of Wisconsin-Madison	R01AG070883	93.866	—	111,574
Pass-through University of Wisconsin-Madison	RF1AG074608	93.866	—	9,771
Pass-through Vanderbilt University	R01AG069900	93.866	—	190,405

EMORY UNIVERSITY AND ITS SUBSIDIARIES
Supplementary Schedule of Expenditures of Federal Awards
Year ended August 31, 2025

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Pass-through Vanderbilt University	R01AG089717	93.866	\$ —	208,850
Pass-through Vanderbilt University Medical Center	R01AG085873	93.866	—	891,515
Pass-through Virginia Commonwealth University	R01AG082251	93.866	—	43,206
Pass-through Wake Forest University	R01AG075959	93.866	—	8,163
Pass-through Washington University	R01AG067505	93.866	—	39
Pass-through Washington University	U19AG032438	93.866	—	299
Pass-through Washington University	U19AG071754	93.866	—	305,033
Pass-through Yale University	R01AG075820-04	93.866	—	162,696
Total AL No. 93.866			11,218,785	68,420,236
Vision Research	F30EY035173	93.867	—	53,183
Vision Research	F31EY033691	93.867	—	30,852
Vision Research	F32EY035573	93.867	—	64,932
Vision Research	P30EY006360	93.867	—	661,881
Vision Research	R00EY029010	93.867	—	244,689
Vision Research	R01EY016435	93.867	—	58,825
Vision Research	R01EY029724	93.867	—	32,154
Vision Research	R01EY030871	93.867	162,780	765,402
Vision Research	R01EY031042	93.867	—	510,484
Vision Research	R01EY033361	93.867	606,125	791,462
Vision Research	R01EY037296	93.867	—	25,153
Vision Research	R21EY035136	93.867	—	151,295
Vision Research	R21EY035468	93.867	39,141	256,874
Vision Research	T32EY007092	93.867	47,779	100,551
Pass-through Cincinnati Childrens Hospital	R01EY032752	93.867	—	125,864
Pass-through George Mason University	R21EY032152	93.867	—	3,914
Pass-through Jaeb Center For Health Research	U10EY11751	93.867	—	6,026
Pass-through Jaeb Center For Health Research	UG1EY011751	93.867	—	57
Pass-through Johns Hopkins University	UG1EY028091	93.867	—	4,567
Pass-through Oakland University	R01EY033808	93.867	—	46,977
Pass-through Pennsylvania State University	U10EY023533-03	93.867	—	4,166
Pass-through University of Houston	R01EY032508	93.867	—	65,894
Pass-through University of Nebraska Medical Center	R01EY029594	93.867	—	50,805
Pass-through University of North Texas	R01EY030967	93.867	—	30,658
Total AL No. 93.867			855,825	4,086,665
Autism Collaboration, Accountability, Research, Education, and Support (CARES) Act of 2014	R41MC52981	93.877	16,282	28,315
Total AL No. 93.877			16,282	28,315
Medical Library Assistance	R01LM013864	93.879	31,793	397,718
Pass-through Kapiolani Med Ctr For Women and Children	R21LM013818	93.879	—	1,022
Pass-through Loyola University Chicago	R25LM014555	93.879	—	6,160
Pass-through Northeastern University	R01LM014191	93.879	46,868	136,863
Pass-through Yale University	R01LM013712	93.879	—	152,754
Total AL No. 93.879			78,661	694,517

EMORY UNIVERSITY AND ITS SUBSIDIARIES
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2025

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
National Bioterrorism Hospital Preparedness Program Pass-through Baylor College of Medicine	U3REP220671	93.889	\$ —	161,274
Total AL No. 93.889			—	161,274
Cancer Prevention and Control Programs for State, Territorial, and Tribal Organizations Pass-through Georgia Dept of Public Health	40500-036-22223686	93.898	—	668,872
Total AL No. 93.898			—	668,872
Rural Health Care Services Outreach, Rural Health Network Development and Small Health Care Provider Quality Improvement	G28RH46273	93.912	243,056	482,343
Total AL No. 93.912			243,056	482,343
HIV Prevention Activities Non-Governmental Organization Based	NU62PS924790	93.939	7,396,609	10,031,020
Total AL No. 93.939			7,396,609	10,031,020
HIV Demonstration, Research, Public And Professional Education Projects Pass-through Ann & Robert H. Lurie Children's Hospital	U01PS005270	93.941	—	133,945
Total AL No. 93.941			—	133,945
Epidemiologic Research Studies of Acquired Immunodeficiency Syndrome (AIDS) and Human Immunodeficiency Virus (HIV) Infection in Selected	U01PS005279	93.943	—	292,898
Epidemiologic Research Studies of Acquired Immunodeficiency Syndrome (AIDS) and Human Immunodeficiency Virus (HIV) Infection in Selected	U01PS005282	93.943	—	287,283
Total AL No. 93.943			—	580,181
Assistance Programs For Chronic Disease Prevention And Control Pass-through Tulane University	NU58DP007745	93.945	537,282	4,382,709
Pass-through University of Florida	U18DP006523	93.945	—	23,433
	U18DP006512	93.945	—	30,692
Total AL No. 93.945			537,282	4,436,834
Block Grants for Prevention and Treatment of Substance Abuse Pass-through Georgia Department of Behavioral Health	44100-905-CMA0000414	93.959	—	250,000
Total AL No. 93.959			—	250,000
PPHF Geriatric Education Centers	U1Q33070	93.969	127,141	81,698
PPHF Geriatric Education Centers	U1Q53036	93.969	208,279	889,964
Total AL No. 93.969			335,420	971,662
Cooperative Agreements for Diabetes Control Programs	NU58DP007422	93.988	4,398,764	11,129,233
Pass-through Amer Assoc of Diabetes Educators	NU58DP007378	93.988	—	209,319
Pass-through Kentucky Department for Public Health	NU58DP007369	93.988	—	81,472
Total AL No. 93.988			4,398,764	11,420,024
International Research and Research Training	D43TW007124	93.989	50,064	362,628
International Research and Research Training	D43TW009127	93.989	52,739	371,302
International Research and Research Training	D43TW010934	93.989	35,245	341,064
International Research and Research Training	D43TW011404	93.989	44,165	29,118
International Research and Research Training	D43TW012188	93.989	87,872	247,720
International Research and Research Training	D43TW012459	93.989	17,438	251,171
International Research and Research Training	R21TW012010	93.989	22,120	28,637

EMORY UNIVERSITY AND ITS SUBSIDIARIES
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2025

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
International Research and Research Training	U2RTW010114	93.989	\$ 273,157	370,508
Pass-through Addis Ababa University	R25TW011214	93.989	—	(80)
Pass-through Aga Khan University	D43TW010905	93.989	—	19,667
Pass-through Brown University	R01TW012677	93.989	—	21,343
Pass-through Duke University	D43TW012457	93.989	—	1,778
Pass-through University of North Carolina Chapel Hill	R01TW012676	93.989	—	21,343
Pass-through University of Virginia	R01TW012183	93.989	—	42,231
Total AL No. 93.989			582,800	2,108,430
Contract	200-2017-92309	93.RD	—	(1,508)
Contract	75A50124C00039	93.RD	128,673	258,980
Contract	75D30120C09811	93.RD	—	11
Contract	75D30121D10817	93.RD	—	4,645
Contract	75D30122C14198	93.RD	53,348	59,826
Contract	75D30122C14484	93.RD	—	57,287
Contract	75D30123C16053	93.RD	—	78,628
Contract	75D30123C16926	93.RD	—	633,004
Contract	75D301-23-C-17180	93.RD	—	27,422
Contract	75D30123C18295	93.RD	—	99,247
Contract	75D30123P17058	93.RD	19,740	21,910
Contract	75D30123P17062	93.RD	—	235,003
Contract	75D30123P17233	93.RD	—	(3,786)
Contract	75D30123P17392	93.RD	—	(1,980)
Contract	75D30124P19061	93.RD	—	114,538
Contract	75D3012D18248	93.RD	—	297,541
Contract	75N91023P00827	93.RD	—	20,002
Contract	75N91024P00717	93.RD	—	21,654
Contract	75N92022D00015	93.RD	2,451,228	11,723,655
Contract	75N92022F00003	93.RD	—	880,618
Contract	75N92022F00004	93.RD	262,979	700,694
Contract	75N92024P00148	93.RD	—	77,660
Contract	75N93019C00058	93.RD	—	(50,159)
Contract	75N93020D00005	93.RD	—	3,432,149
Contract	75N93021C00017	93.RD	1,200,843	4,995,930
Contract	75N93025C00014	93.RD	—	122,020
Contract	75N94020D00009	93.RD	—	69,238
Contract	75N94025P00062	93.RD	—	39,526
Contract	75R60123C00010	93.RD	—	100,624
Contract	HHNS272201300006C	93.RD	—	(5,243)
Contract	HHS258201800013C	93.RD	—	9,201
Contract	HHSN261201800003I	93.RD	—	3,053,457
Contract	HHSN268201700205A	93.RD	—	4,019
Contract	HHSN272201300018	93.RD	—	(431)
Contract	HHSN2722013000181	93.RD	—	598
Contract	HHSN272201300018I	93.RD	1,307,136	1,760,478
Contract	HHSN272201400004C	93.RD	—	(1,370)
Contract	HHSN275201500001I	93.RD	—	294,378
Contract	HHSN312201500004P	93.RD	—	(19)

EMORY UNIVERSITY AND ITS SUBSIDIARIES
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2025

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Pass-through Access to Advanced Health Institute	75N93019C00059	93.RD	\$ —	40,816
Pass-through Ann & Robert H. Lurie Children's Hospital	75D30122C15605	93.RD	12,018	11,117
Pass-through Boston Children's Hospital	75N95023D00001	93.RD	—	314,157
Pass-through Childrens Healthcare of Atlanta	75D30122F15322	93.RD	—	7,053
Pass-through Eastern Coop Oncology Group	PSAWCIEM00	93.RD	—	(3,172)
Pass-through Fred Hutchinson Research Center	23X077F1	93.RD	—	7,267
Pass-through Frontier Science and Technology Res Fdtn	E2408: BVR VS. BR	93.RD	—	(3,479)
Pass-through Frontier Science and Technology Res Fdtn	PSAWCIEM00	93.RD	—	(3,749)
Pass-through Georgia Institute of Technology	75F40120C00207	93.RD	—	1,481
Pass-through Georgia Institute of Technology	75F40122C00146	93.RD	—	338,518
Pass-through Georgia Institute of Technology	RF00280-SUB00312	93.RD	—	185,353
Pass-through Georgia Research Alliance	GRA.VL14.C11	93.RD	—	(76)
Pass-through Massachusetts General Hospital	OT2NS136938	93.RD	—	(7,235)
Pass-through Mount Sinai School of Medicine	75N93019C00046	93.RD	—	497,946
Pass-through Mount Sinai School of Medicine	75N93019C00051	93.RD	—	1,886,526
Pass-through Mount Sinai School of Medicine	75N9301R00028	93.RD	—	271,892
Pass-through Stanford University	75N93022C00052	93.RD	—	102,497
Pass-through Univ of Arkansas for Medical Services	75N91019D00024	93.RD	—	26,520
Pass-through University of North Texas Health Sci Ctr	10T20D032581-01	93.RD	—	505,067
Pass-through University of Alabama Birmingham	HHSN272201100034C	93.RD	—	(10,303)
Pass-through University of California San Diego	705805	93.RD	—	2,128
Pass-through University of Chicago	75N92020D00018/75N92020F00001	93.RD	—	22,501
Pass-through University of Chicago	75N93024C00023	93.RD	—	84,053
Pass-through University of Maryland	75N90022C00013	93.RD	—	652,002
Pass-through University of North Carolina Chapel Hill	75N93022C00024	93.RD	—	108,673
Pass-through University of Pennsylvania	75N93021C00015	93.RD	—	412,433
Pass-through University of Pittsburgh	HHSN272201100041C	93.RD	—	(42,179)
Pass-through University of Washington	HHSN272201800008C	93.RD	—	413,827
Pass-through Vanderbilt University Medical Center	75D30122C14944	93.RD	—	499,376
Total AL No. 93.CTR			<u>5,435,965</u>	<u>35,450,457</u>
U.S. Department of Health and Human Services Total			<u>131,300,841</u>	<u>740,813,238</u>
U.S. Department of Homeland Security				
Centers for Homeland Security				
Pass-through Arizona State University	17STQAC00001	97.061	—	128,317
Pass-through George Mason University	17STCIN00001	97.061	—	160,598
Total AL No. 97.061			<u>—</u>	<u>288,915</u>
U.S. Department of Homeland Security Total			<u>—</u>	<u>288,915</u>
U.S. Agency for International Development				
US Aid Foreign Assistance For Programs Overseas				
Pass-through FHI 360 Llc	7200AA20CA00016	98.001	—	14,305
Pass-through Int'l Aids Vaccine Initiative	AID-OAA-A-16-00032	98.001	—	148,261
Pass-through Technoserve	7200AA22LE00002	98.001	—	287,888
Pass-through Tufts University	720BHA22GR00312	98.001	—	39,788
Total AL No. 98.001			<u>—</u>	<u>490,242</u>

EMORY UNIVERSITY AND ITS SUBSIDIARIES
 Supplementary Schedule of Expenditures of Federal Awards
 Year ended August 31, 2025

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Contract				
Pass-through Intl Aids Vaccine Initiative	86,458	98.RD	\$ —	43,165
Total AL No. 98.002			—	43,165
U.S. Agency for International Development Total			—	533,407
Total Research and Development Cluster			<u>137,109,897</u>	<u>790,592,210</u>
Student Financial Assistance Cluster (notes 2 through 5)				
U.S. Department of Education				
Federal Work-Study Program		84.033	—	1,726,692
Federal Supplemental Educational Opportunity Grants		84.007	—	1,526,852
Federal Pell Grant Program		84.063	—	11,178,955
Federal Direct Loan Program		84.268	—	76,284,260
Federal Direct PLUS Loan Program		84.268	—	100,874,868
Federal Perkins Loan (FPL)		84.038	—	1,368,847
Total U.S. Department of Education			<u>—</u>	<u>192,960,474</u>
U.S. Department of Health and Human Services				
Nursing Faculty Loan Program (NFLP)		93.264	—	2,043,637
Health Professions Student Loans, Including Primary Care Loans and Loans for Disadvantaged Students (HPSL)		93.342	—	699,843
Nursing Student Loans (NSL)		93.364	—	851,853
Total U.S. Department of Health and Human Services			<u>—</u>	<u>3,595,333</u>
Total Student Financial Assistance Cluster			<u>—</u>	<u>196,555,807</u>
U.S. Department of Agriculture				
State Administrative Matching Grants for the Supplemental Nutrition Assistance Program				
Pass-through Georgia Department of Human Services	202424Q390345	10.561	43,388	123,225
Total AL No. 10.561			<u>43,388</u>	<u>123,225</u>
U.S. Department of Agriculture Total			<u>43,388</u>	<u>123,225</u>
U.S. Department of Commerce				
Cluster Grants	ED20HDQ0200045	11.020	(25,643)	(25,643)
Total AL No. 11.020			<u>(25,643)</u>	<u>(25,643)</u>
U.S. Department of Commerce Total			<u>(25,643)</u>	<u>(25,643)</u>
U.S. Department of Housing and Urban Development				
Housing Opportunities for Persons with AIDS				
Pass-through Aid Atlanta	GA-H230201	14.241	—	6,678
Total AL No. 14.241			<u>—</u>	<u>6,678</u>
U.S. Department of Housing and Urban Development Total			<u>—</u>	<u>6,678</u>

EMORY UNIVERSITY AND ITS SUBSIDIARIES
Supplementary Schedule of Expenditures of Federal Awards
Year ended August 31, 2025

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
U.S. Department of Justice				
Community-Based Violence Intervention and Prevention Initiative				
Pass-through Dekalb County	15PBJA22GG04712CVIP	16.045	\$ 108,677	185,711
Total AL No. 16.045			<u>108,677</u>	<u>185,711</u>
Delinquency Prevention Program				
Pass-through Coalition for Juvenile Justice	15PJDP23GK05303TITL	16.548	—	4,650
Total AL No. 16.548			<u>—</u>	<u>4,650</u>
U.S. Department of Justice Total			<u>108,677</u>	<u>190,361</u>
U.S. Department of State				
Public Diplomacy Programs	SET10023GR0070	19.040	10,434	44,229
Total AL No. 19.040			<u>10,434</u>	<u>44,229</u>
AEECA/ESF PD Programs	SRB10023GR0085	19.900	24,766	31,430
Total AL No. 19.900			<u>24,766</u>	<u>31,430</u>
U.S. Department of State Total			<u>35,200</u>	<u>75,659</u>
U.S. Department of Treasury				
COVID-19 - Coronavirus State and Local Fiscal Recovery Funds				
Pass-through De Kalb County	SLFRP002	21.027	—	8,471,428
Total AL No. 21.027			<u>—</u>	<u>8,471,428</u>
U.S. Department of Treasury Total			<u>—</u>	<u>8,471,428</u>
National Endowment for Humanities				
Promotion of the Arts Grants to Organizations and Individuals	1886761-42-21	45.024	—	51,215
Total AL No. 45.024			<u>—</u>	<u>51,215</u>
Promotion of the Humanities Division of Preservation and Access	PW-285174-22	45.149	—	2,918
Total AL No. 45.149			<u>—</u>	<u>2,918</u>
National Endowment for Humanities Total			<u>—</u>	<u>54,133</u>
U.S. Department of Veterans Affairs				
Legal Services for Veterans Grants	GA-256-LSV-191-22	64.056	—	25,280
Total AL No. 64.056			<u>—</u>	<u>25,280</u>
Contract	36C24720C0163	64.CTR	—	33
Contract	36C24722C0090	64.CTR	—	(28,870)
Contract	36C24724C0037	64.CTR	—	932,359
Contract	36C24E21D0032	64.CTR	—	4,671
Total AL No. 64.CTR			<u>—</u>	<u>908,193</u>
U.S. Department of Veterans Affairs Total			<u>—</u>	<u>933,473</u>

EMORY UNIVERSITY AND ITS SUBSIDIARIES
Supplementary Schedule of Expenditures of Federal Awards
Year ended August 31, 2025

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
U.S. Department of Health and Human Services National Family Caregiver Support, Title III, Part E Pass-through Atlanta Regional Commission	2301GAOASS	93.052	\$ —	18,756
Total AL No. 93.052			—	18,756
Birth Defects and Developmental Disabilities - Prevention and Surveillance	NU01DD000059	93.073	—	503,901
Total AL No. 93.073			—	503,901
Prevention of Disease, Disability, and Death by Infectious Diseases	NU38PS004653	93.084	204,724	729,611
Total AL No. 93.084			204,724	729,611
Maternal And Child Health Federal Consolidated Programs	UC153079	93.110	—	550,566
Pass-through Hemophilia of Georgia	5 H30MC24046713700	93.110	—	43,196
Total AL No. 93.110			—	593,762
Emergency Medical Services for Children	U0349671	93.127	143,846	465,715
Total AL No. 93.127			143,846	465,715
HIV-Related Training and Technical Assistance	U1032104	93.145	—	118,421
Pass-through University of Washington			—	118,421
Total AL No. 93.145			—	118,421
State Capacity Building	6 NU61TS000354	93.240	15,499	212,523
Pass-through Georgia Dept of Public Health			15,499	212,523
Total AL No. 93.240			15,499	212,523
Substance Abuse and Mental Health Services Projects of Regional and National Significance	H79SM090509	93.243	—	89,458
Total AL No. 93.243			—	89,458
Centers for Disease Control and Prevention Investigations and Technical Assistance	62810	93.283	—	(698)
Pass-through Georgia Dept of Public Health	NU58DP006828	93.283	—	49,203
Pass-through Georgia Dept of Public Health			—	48,505
Total AL No. 93.283			—	48,505
COVID-19 – Protecting and Improving Health Globally Building and Strengthening Public Health Impact, Systems, Capacity and Security	NU14GH001238	93.318	73,966	428,629
Protecting and Improving Health Globally Building and Strengthening Public Health Impact, Systems, Capacity and Security	NU2HJG000002	93.318	57,507	408,979
Total AL No. 93.318			131,473	837,608
The Healthy Brain Initiative Technical Assistance to Implement Public Health Actions related to Cognitive Health, Cognitive Impairment, and Caregiving at the State and Local Levels	NU58DP006744	93.334	—	289,305
Pass-through Alzheimers Association			—	289,305
Total AL No. 93.334			—	289,305
Public Health Emergency Response Cooperative Agreement for Emergency Response Public Health Crisis Response	6 NU90TP922182-01-01	93.354	20,610	20,610
Pass-through Kentucky Hospital Association			20,610	20,610

EMORY UNIVERSITY AND ITS SUBSIDIARIES
Supplementary Schedule of Expenditures of Federal Awards
Year ended August 31, 2025

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Pass-through Kentucky Hospital Association	NU90TP922182	93.354	\$ 51,992	105,798
Total AL No. 93.354			<u>72,602</u>	<u>126,408</u>
Sickle Cell Treatment Demonstration Program				
Pass-through University of Alabama Birmingham	U1EMCA42461	93.365	—	57,177
Total AL No. 93.365			<u>—</u>	<u>57,177</u>
COVID-19 – Strengthening Public Health Systems and Services through National Partnerships to Improve and Protect the Nation’s Health	NU50CK000617	93.421	23,248	(163,211)
Strengthening Public Health Systems and Services through National Partnerships to Improve and Protect the Nation’s Health	NU38PW000008	93.421	—	921,565
Strengthening Public Health Systems and Services through National Partnerships to Improve and Protect the Nation’s Health	NU50CK000612	93.421	—	693,002
Pass-through Amer College of Preventive Medicine	NU38OT000289	93.421	41,664	45,529
Pass-through Natl Assoc of Chronic Disease Directors	6 NU38PW000036	93.421	—	39,916
Pass-through Natl Assoc of Chronic Disease Directors	6-NU38OT000286-01	93.421	—	20
Total AL No. 93.421			<u>64,912</u>	<u>1,536,821</u>
The Innovative Cardiovascular Health Program				
Pass-through Kentucky Department for Public Health	NU58DP006612	93.435	—	(3,600)
Pass-through Utah Department of Health	NU58DP006609	93.435	—	2,982
Total AL No. 93.435			<u>—</u>	<u>(618)</u>
Congressional Directives	GE153305	93.493	—	533,937
Total AL No. 93.493			<u>—</u>	<u>533,937</u>
Community-Based Child Abuse Prevention Grants				
Pass-through Georgia Department of Human Services	42700-040-0000106749	93.590	—	(53,865)
Pass-through Georgia Department of Human Services	42700-040-0000112920-01	93.590	7,738	17,323
Total AL No. 93.590			<u>7,738</u>	<u>(36,542)</u>
Children’s Justice Grants to States				
Pass-through Georgia Department of Human Services	2201GACJA1	93.643	—	1,966
Total AL No. 93.643			<u>—</u>	<u>1,966</u>
Evidence-Based Falls Prevention Programs Financed Solely by Prevention and Public Health Funds (PPHF)				
Pass-through Natl Council on Aging	S352L5PJLMP8	93.761	—	8,794
Total AL No. 93.761			<u>—</u>	<u>8,794</u>
COVID-19 - National Ebola Training and Education Center (NETEC)	NU38CK000481	93.825	—	(97,466)
National Ebola Training and Education Center (NETEC)	NU38CK000481	93.825	—	19,346
Total AL No. 93.825			<u>—</u>	<u>(78,120)</u>
Improving Epilepsy Programs, Services, and Outcomes through National Partnerships	NU58DP007543	93.850	—	460,672
Total AL No. 93.850			<u>—</u>	<u>460,672</u>
HIV Emergency Relief Project Grants				
Pass-through Fulton County	HA89HA00007-32	93.914	—	2,442,745
Total AL No. 93.914			<u>—</u>	<u>2,442,745</u>

EMORY UNIVERSITY AND ITS SUBSIDIARIES
Supplementary Schedule of Expenditures of Federal Awards
Year ended August 31, 2025

Program title/federal grantor/pass-through entity	Award number	AL number	Passed through to subrecipients	Federal expenditures
Grants To Provide Outpatient Early Intervention Services With Respect To HIV Disease	H7607848	93.918	\$ —	2,034,338
Total AL No. 93.918			—	2,034,338
HIV Prevention Activities Non-Governmental Organization Based				
Pass-through Georgia Department of Behavioral Health	B08TI087031	93.939	—	215,298
Total AL No. 93.939			—	215,298
Centers for Disease Control and Prevention Collaboration with Academia to Strengthen Public Health				
Pass-through De Beaumont Foundation	NE11OE000067-01-00	93.967	—	15,440
Total AL No. 93.967			—	15,440
Sexually Transmitted Diseases (STD) Provider Education Grants				
Pass-through University of Washington	NU62PS924588	93.978	—	53,082
Total AL No. 93.978			—	53,082
Cooperative Agreements for Diabetes Control Programs				
Pass-through Nebraska Department of Health and Human	NU58DP007346	93.988	—	5,000
Total AL No. 93.988			—	5,000
Contract	200200302949	93.CTR	—	(27,953)
Contract	75D30120C07672	93.CTR	—	1,281,170
Contract	75D30123D18248	93.CTR	—	383,123
Contract	75D30124F00003	93.CTR	—	68,473
Contract	HHSD2002017M95146B	93.CTR	—	(1,633)
Pass-through Georgia Department of Community Health	2017001	93.CTR	—	(1,436)
Pass-through Georgia Dept of Public Health	40500-036-18161798	93.CTR	—	(505)
Pass-through North Central Health District	NU58DP007606	93.CTR	—	84,710
Total AL No. 93.CTR			—	1,785,949
U.S. Department of Health and Human Services Total			640,794	13,069,912
U.S. Department of Homeland Security				
Homeland Security Grant Program				
Pass-through Georgia Emergency Mgmt Homeland Security	EMW-2021-SS-00080	97.067	—	50,000
Total AL No. 97.067			—	50,000
U.S. Department of Homeland Security Total			—	50,000
U.S. Agency for International Development				
USAID Foreign Assistance for Programs Overseas				
Pass-through Technoserve	72062424LA00001	98.001	—	59,072
Total AL No. 98.001			—	59,072
U.S. Agency for International Development Total			—	59,072
Total Non-Research and Development Programs			802,416	23,008,298
Total Student Financial Assistance Cluster and Non-Research and Development Programs			802,416	219,564,105
Total Expenditures of Federal Awards			\$ 137,912,313	1,010,156,315

See accompanying notes to Supplementary Schedule of Expenditures of Federal Awards and Schedule of Cash Receipts and Expenditures of State of Georgia Awards.

**SUPPLEMENTARY SCHEDULE OF CASH RECEIPTS AND
EXPENDITURES OF STATE OF GEORGIA AWARDS**

EMORY UNIVERSITY AND ITS SUBSIDIARIES

Supplementary Schedule of Cash Receipts and Expenditures of State of Georgia Awards

Year ended August 31, 2025

State of Georgia contract number	State of Georgia Agency	Program title	Cash receipts	Expenditures
15PBJA22GG04712CVIP 2017001	DeKalb County Georgia Department of Community Health	DeKalb County Community-Based Violence Intervention Plan Evaluation Services for the Planning for Healthy Babies Family Planning Waiver Program	\$ 210,405 2,564,550	185,711 (1,241)
2201GACJA1	Georgia Department of Human Services	Summer Child Advocacy Program	54,416	1,966
2301GAOASS	Atlanta Regional Commission	Fuqua Center and Atlanta Regional Commission DHS Consultant Contract	56,268	18,756
2305GA5MAP	Georgia Department of Behavioral Health	2023-2024 Emory Neurodevelopmental Exposure Clinic	90,250	(106,062)
2505GA5MAP	Georgia Department of Behavioral Health	2024-2025 Emory Neurodevelopmental Exposure Clinic	270,750	176,895
40500-036-18161798	Georgia Dept of Public Health	Georgia Coverdell Acute Stroke Registry	(505)	(505)
40500-036-22223686	Georgia Dept of Public Health	Operation of the Statewide Georgia Comprehensive Cancer Registry	593,002	553,974
40500-036-22223686	Georgia Dept of Public Health	Operation of the Statewide Georgia Comprehensive Cancer Registry	116,346	114,897
40500-050-24244796	Georgia Dept of Public Health	State Newborn Screening System Priorities Program	145,000	115,880
42700-040-0000112920-01	Georgia Department of Human Services	CENTER FOR FAMILY RESILIENCE	70,242	17,323
42700-040-25-118227	Georgia Department of Human Services	Summer Child Advocacy Program 2025	4,070	86,544
44100-905-CMA0000414	Georgia Department of Behavioral Health	2023-2024 Fetal Alcohol and Drug Screening project: MSACD	61,297	250,000
6 NU61TS000354	Georgia Dept of Public Health	Brunswick community exposure reduction activities	79,385	120,486
6 NU61TS000354	Georgia Dept of Public Health	Brunswick community exposure reduction activities	91,689	92,037
62810	Georgia Dept of Public Health	GEORGIA COVERDELL ACUTE STROKE REGISTRY	(698)	(698)
69A3752330000405BGAH	Governors Office of Highway Safety	2024 Statewide Seatbelt Survey	201,636	29,445
69A3752330000405BGAH	Governors Office of Highway Safety	2024 Statewide Seatbelt Survey	161,962	235,296
B08TI087031	Georgia Department of Behavioral Health	2024-2025 Fetal Alcohol and Drug Screening project: MSACD	144,558	215,298
EMW-2021-SS-00080	Georgia Emergency Mgmt Homeland Security	Explosive Ordinance Detection K-9 and Upfitted Vehicle	50,000	50,000
HA89HA00007-32	Fulton County	Ryan White HIV/AIDS Treatment	3,053,805	2,700,565
HA89HA00007-32	Fulton County	Ryan White HIV/AIDS Treatment	826,743	435,253
NU50CK000626	Georgia Dept of Public Health	Emory University Genomic Surveillance subaward for US Public Health Pathogens Genomics Centers of Excellence	286,347	(138,016)
NU50CK000645	Georgia Dept of Public Health	EIP	3,425,201	1,084,827
NU50CK000645	Georgia Dept of Public Health	EIP	1,418,290	967,343
NU50CK000645	Georgia Dept of Public Health	EIP	149,757	82,720
NU50CK000645	Georgia Dept of Public Health	EIP	123,951	53,068
NU50CK000645	Georgia Dept of Public Health	EIP	71,518	71,518
NU50CK000645	Georgia Dept of Public Health	EIP	582,319	582,319
NU50CK000645	Georgia Dept of Public Health	EIP	8,262,232	3,337,272
NU50CK000645	Georgia Dept of Public Health	EIP	2,512,669	1,010,220
NU50CK000645	Georgia Dept of Public Health	EIP	378,847	149,499
NU50CK000645	Georgia Dept of Public Health	EIP	133,285	64,927
NU50CK000645	Georgia Dept of Public Health	EIP	1,234,959	485,669
NU50CK000645	Georgia Dept of Public Health	EIP	514,881	166,308
NU50CK000645	Georgia Dept of Public Health	EIP	399,366	159,746
NU58DP006828	Georgia Dept of Public Health	BreatheEasy Recognition Program	65,000	49,203
NU58DP007606	North Central Health District	REACH	18,410	25,315
NU58DP007606	North Central Health District	REACH Year 2	48,450	59,394
U3REP150546	Georgia Dept of Public Health	HPP SON Carryover Authorization	420,058	—
			<u>\$ 28,890,711</u>	<u>13,503,152</u>

See accompanying notes to Supplementary Schedule of Expenditures of Federal Awards and Schedule of Cash Receipts and Expenditures of State of Georgia Awards.

EMORY UNIVERSITY AND ITS SUBSIDIARIES

Notes to Supplementary Schedules of Expenditures of Federal Awards and Cash Receipts and Expenditures of State of Georgia Awards

Year ended August 31, 2025

(1) Summary of Significant Accounting Policies

The accompanying supplementary schedule of expenditures of federal awards (the Schedule) includes the federal grant activity of Emory University and its subsidiaries (the University) and is presented on the accrual basis of accounting. The Schedule presents all grants, contracts, and similar agreements entered into directly between agencies and departments of the federal government and subawards to the University from nonfederal organizations pursuant to federal grants, contracts, and similar agreements. The Schedule also presents awards passed through from the University to other nonfederal subrecipient organizations. The information in the Schedule is presented in accordance with the requirements of Title 2 U.S. Code of Federal Regulations Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance). Therefore, some amounts presented in the Schedule may differ from amounts presented in, or used in the preparation of, the consolidated financial statements.

The accompanying supplementary schedule of cash receipts and expenditures of State of Georgia awards includes expenditures incurred by the University and grant revenues received from State of Georgia agencies under various state contracts.

Negative balances represent programs with unfunded expenditures prior to normal closeout procedures, which were subsequently transferred to unrestricted cost centers.

(2) Basis of Accounting

Expenditures for federal student financial assistance programs are recognized as incurred and include grants to students under the Federal Pell Grant and Federal Supplemental Educational Opportunity Grant Programs, student earnings under the Federal Work Study Program, and administrative cost allowances, where applicable. Expenditures for loans related to the Federal Direct Student Loan Programs (FDSLP) are reported in the Schedule when disbursed.

New loans made during the fiscal year and loans from previous fiscal years for which the University has continuing compliance requirements to adhere to are reported in the Schedule. Expenditures for other federal awards are recognized as incurred using the cost accounting principles contained in Uniform Guidance. Under these cost principles, certain types of expenses are not allowable or are limited as to reimbursement.

(3) Federal Loan Programs

Most federal financial assistance is in the form of cash awards. However, there are a number of federal programs that do not involve cash transactions with the University. These noncash transactions in which the University obtains other assistance are the FDSLP and revolving loan programs, such as the Federal Perkins Loan Program.

EMORY UNIVERSITY AND ITS SUBSIDIARIES

Notes to Supplementary Schedules of Expenditures of Federal Awards and
Cash Receipts and Expenditures of State of Georgia Awards

Year ended August 31, 2025

The loans advanced and related expenditures are as follows for the various student loan programs:

	<u>AL #</u>	<u>Amount</u>
Federal Direct Student Loan Programs:		
Student loans advanced:		
Subsidized Stafford Loan Program	84.268	\$ 1,564,790
Unsubsidized Stafford Loan Program	84.268	<u>74,719,470</u>
Total Direct Stafford Loan Program		76,284,260
Federal Direct PLUS Loan Program	84.268	<u>100,874,868</u>
Total Federal Direct Student Loan Programs		\$ <u><u>177,159,128</u></u>

The Federal Perkins Loan (FPL) program, Nurse Faculty Loan Program (NFLP), Health Professions Student Loans (HPSL) program, and Nursing Student Loans (NSL) program are administered directly by the University, and balances and transactions relating to these programs are included in the University's consolidated financial statements. The amounts presented on the Schedule include the FPL, NFLP, HPSL, and NSL outstanding as of August 31, 2023 plus any loans issued in the current year and administrative charge, as applicable. FPL, NFLP, HPSL, and NSL outstanding at August 31, 2025 totaled \$938,006, \$2,016,857, \$608,261, and \$706,148, respectively. NFLP, HPSL, and NSL issued \$1,286,199, \$248,134, and \$141,962 in new loans during the year ended August 31, 2025. No FPL were issued in the current year.

The University is responsible for the performance of certain administrative duties with respect to the FDSLPL. It is not practicable to determine the balance of loans outstanding to students and former students of the University under this program as of August 31, 2025. These loans are not included in the University's consolidated financial statements.

(4) Matching

Under the Federal Supplemental Educational Opportunity Grant Program, the University matched \$381,713 in funds awarded to students for the year ended August 31, 2025 in addition to the federal share of expenditures included in the Schedule.

Under the Federal Work Study Program, the University matched \$469,302 in total compensation to students for the year ended August 31, 2025 in addition to the federal share of expenditures included in the Schedule.

EMORY UNIVERSITY AND ITS SUBSIDIARIES

Notes to Supplementary Schedules of Expenditures of Federal Awards and
Cash Receipts and Expenditures of State of Georgia Awards

Year ended August 31, 2025

(5) Administrative Cost Allowance

The University recorded an administrative cost allowance of \$147,046 for the year ended August 31, 2025. This amount is included in the Schedule as federal expenditures under the Federal Work Study Program.

(6) Indirect Costs

For the year ended August 31, 2025, the University elected to not use the de minimis indirect cost rate permitted by the Uniform Guidance.

UNIFORM GUIDANCE REPORTS



KPMG LLP
Suite 2000
303 Peachtree Street, N.E.
Atlanta, GA 30308-3210

Independent Auditors' Report on Compliance for the Major Federal Program; Report on Internal Control Over Compliance; and Report on Supplementary Schedules of Expenditures of Federal Awards Required by the Uniform Guidance and Cash Receipts and Expenditures of State of Georgia Awards

The Board of Trustees
Emory University:

Report on Compliance for Each Major Federal Program

Opinion on the Major Federal Program

We have audited Emory University and its subsidiaries' (the University) compliance with the types of compliance requirements identified as subject to audit in the *OMB Compliance Supplement* that could have a direct and material effect on the University's major federal program for the year ended August 31, 2025. The University's major federal program is identified in the summary of auditors' results section of the accompanying schedule of findings and questioned costs.

In our opinion, the University complied, in all material respects, with the compliance requirements referred to above that could have a direct and material effect on its major federal program for the year ended August 31, 2025.

Basis for Opinion on the Major Federal Program

We conducted our audit of compliance in accordance with auditing standards generally accepted in the United States of America (GAAS); the standards applicable to financial audits contained in *Government Auditing Standards* issued by the Comptroller General of the United States; and the audit requirements of Title 2 U.S. Code of Federal Regulations Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance). Our responsibilities under those standards and the Uniform Guidance are further described in the Auditors' Responsibilities for the Audit of Compliance section of our report.

We are required to be independent of the University and to meet our other ethical responsibilities, in accordance with relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion on compliance for the major federal program. Our audit does not provide a legal determination of the University's compliance with the compliance requirements referred to above.

Responsibilities of Management for Compliance

Management is responsible for compliance with the requirements referred to above and for the design, implementation, and maintenance of effective internal control over compliance with the requirements of laws, statutes, regulations, rules and provisions of contracts or grant agreements applicable to the University's federal program.

Auditors' Responsibilities for the Audit of Compliance

Our objectives are to obtain reasonable assurance about whether material noncompliance with the compliance requirements referred to above occurred, whether due to fraud or error, and express an opinion on the University's compliance based on our audit. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with GAAS,



Government Auditing Standards, and the Uniform Guidance will always detect material noncompliance when it exists. The risk of not detecting material noncompliance resulting from fraud is higher than for that resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Noncompliance with the compliance requirements referred to above is considered material if there is a substantial likelihood that, individually or in the aggregate, it would influence the judgment made by a reasonable user of the report on compliance about the University's compliance with the requirements of the major federal program as a whole.

In performing an audit in accordance with GAAS, *Government Auditing Standards*, and the Uniform Guidance, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material noncompliance, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the University's compliance with the compliance requirements referred to above and performing such other procedures as we considered necessary in the circumstances.
- Obtain an understanding of the University's internal control over compliance relevant to the audit in order to design audit procedures that are appropriate in the circumstances and to test and report on internal control over compliance in accordance with the Uniform Guidance, but not for the purpose of expressing an opinion on the effectiveness of the University's internal control over compliance. Accordingly, no such opinion is expressed.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and any significant deficiencies and material weaknesses in internal control over compliance that we identified during the audit.

Report on Internal Control Over Compliance

A deficiency in internal control over compliance exists when the design or operation of a control over compliance does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, noncompliance with a type of compliance requirement of a federal program on a timely basis. A material weakness in internal control over compliance is a deficiency, or a combination of deficiencies, in internal control over compliance, such that there is a reasonable possibility that material noncompliance with a type of compliance requirement of a federal program will not be prevented, or detected and corrected, on a timely basis. A significant deficiency in internal control over compliance is a deficiency, or a combination of deficiencies, in internal control over compliance with a type of compliance requirement of a federal program that is less severe than a material weakness in internal control over compliance, yet important enough to merit attention by those charged with governance.

Our consideration of internal control over compliance was for the limited purpose described in the Auditors' Responsibilities for the Audit of Compliance section above and was not designed to identify all deficiencies in internal control over compliance that might be material weaknesses or significant deficiencies in internal control over compliance. Given these limitations, during our audit we did not identify any deficiencies in internal control over compliance that we consider to be material weaknesses, as defined above. However, material weaknesses or significant deficiencies in internal control over compliance may exist that were not identified.

Our audit was not designed for the purpose of expressing an opinion on the effectiveness of internal control over compliance. Accordingly, no such opinion is expressed.

The purpose of this report on internal control over compliance is solely to describe the scope of our testing of internal control over compliance and the results of that testing based on the requirements of the Uniform Guidance. Accordingly, this report is not suitable for any other purpose.



Report on Supplementary Schedules of Expenditures of Federal Awards Required by the Uniform Guidance and Cash Receipts and Expenditures of State of Georgia Awards

We have audited the consolidated financial statements of the University as of and for the year ended August 31, 2025, and have issued our report thereon dated December 12, 2025 which contained an unmodified opinion on those consolidated financial statements. Our audit was performed for the purpose of forming an opinion on the consolidated financial statements as a whole. The accompanying schedules of expenditures of federal awards and cash receipts and expenditures of State of Georgia awards are presented for purposes of additional analysis as required by the Uniform Guidance and is not a required part of the consolidated financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the consolidated financial statements. The information has been subjected to the auditing procedures applied in the audit of the consolidated financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the consolidated financial statements or to the consolidated financial statements themselves, and other additional procedures in accordance with GAAS. In our opinion, the schedules of expenditures of federal awards and cash receipts and expenditures of State of Georgia awards are fairly stated in all material respects in relation to the consolidated financial statements as a whole.

KPMG LLP

Atlanta, Georgia
April 30, 2026

EMORY UNIVERSITY AND ITS SUBSIDIARIES

Schedule of Findings and Questioned Costs

Year ended August 31, 2025

(1) Summary of Auditors' Results

- (a) The type of auditors' report issued on whether the consolidated financial statements were prepared in accordance with U.S. generally accepted accounting principles: **Unmodified**
- (b) Internal control deficiencies over financial reporting disclosed by the audit of the consolidated financial statements:
 - Material weaknesses: **No**
 - Significant deficiencies: **None reported**
- (c) Noncompliance material to the consolidated financial statements: **No**
- (d) Internal control deficiencies over major program disclosed by the audit:
 - Material weaknesses: **No**
 - Significant deficiencies: **None reported**
- (e) Type of auditors' report issued on compliance for major program: **Unmodified**
- (f) Any audit findings, which are required to be reported under Section 2 CFR 200.516(a) of Uniform Guidance: **No**
- (g) Major program:
 - **Research and Development Cluster** – various AL numbers
- (h) Dollar threshold used to distinguish between Type A and Type B programs: **\$3,030,469**
- (i) Auditee qualified as a low-risk auditee: **Yes**

(2) Findings Relating to the Consolidated Financial Statements Reported in Accordance with *Government Auditing Standards*

None

(3) Findings and Questioned Costs Relating to Federal Awards

None



Summary Schedule of Prior Audit Findings

Federal Program: Federal Direct Student Loans
ALN No. 84.268
Federal Agency: U.S. Department of Education
Federal Award Year: September 1, 2023 to August 31, 2024

Management Response and Corrective Action Plan:

The finding was primarily caused by an unforeseen staff shortage. This led to one person being the preparer and reviewer with no segregation of duties. Although the differences were identified, they were not documented on the reconciliation form.

To resolve this finding, the Office of Financial Aid (OFA) has hired new employees and implemented a new process. The Financial Operations Team is now fully staffed with two senior accountants and one senior director. As part of our ongoing efforts to strengthen internal controls and ensure the integrity of our processes, we have implemented a segregation of duties framework. This approach will help us clearly define roles and responsibilities, ensuring that critical tasks are divided among different individuals. By doing so, we will meet compliance requirements, reduce errors, and promote accountability within our office. One senior accountant will prepare the monthly reconciliation by the 10th of the following month. The senior director will review the monthly reconciliation by the 15th of the following month. In the absence of the initial preparer/reviewer, the executive director of OFA will take on the reviewer role.

We understand that proper documentation is crucial for clarity, tracking, and future troubleshooting. The differences/discrepancies that are identified in the reconciliation process will be accounted for through proper documentation on the reconciliation form, which will be reviewed/investigated by a second reviewer.

The Financial Operations Team within the OFA will continue to create timely and accurate monthly Federal Direct Student Loan reconciliations that compare OPUS (Emory), General Ledger (Emory), Student Account Statement-SAS (U.S. Department of Education), and G5 (U.S. Department of Education).

Status

Following the monthly ledger close on or around the 7th of each month, the Senior Accountant completes the initial reconciliation within 3-5 business days. The Senior Director of Financial Operations (SDOFO) reviews the reconciliation within 5 business days of its completion. As part of this review, the SDOFO shares the reconciliation with the Senior Director of Systems (SDOS). Both senior directors collaborate to confirm the reasons for any variances and make any necessary corrections or notations.



EMORY
UNIVERSITY

Office of Financial Aid

The Senior Accountant and the SDOFO are responsible for finalizing and signing off on the monthly reconciliation by the 15th of each month. If the 15th falls on a weekend or recognized university holiday, the sign-off is completed on the next business day.

All completed reconciliations are stored on the Financial Operations shared drive, within the folder corresponding to the relevant month.

Fully corrected.

Responsible Department:

Office of Financial Aid

John B. Leach, Associate Vice Provost for Enrollment and University Financial Aid

Suite 300 Boisfeuillet Jones Center

200 Dowman Drive

Atlanta, Georgia 30322